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Abstract 
Early separation experiences predispose people to depression and depressive episodes 
are triggered by experiences of social loss. The normal separation response entails a 'protest' 
phase followed by a 'despair' phase. The affective neuroscience paradigm of Jaak Panksepp 
identifies two basic emotion systems as being centrally involved in this normal separation 
response, namely, PANIC/GRIEF and SEEKING, and it conceptualises the despair phase of 
the cascade as the normal prototype for depression. In affective terms, major depression is 
seen as a disorder characterised by an overactive PANIC/GRIEF system and an underactive 
SEEKING system. There is considerable pre-clinical research that underwrites this 
conclusion, but the evidence in humans is limited. The general aim of this thesis was to 
investigate the claim that the feelings associated with depression represent an abnormal 
variant of the normal mammalian separation response in human subjects. The PANIC/GRIEF 
and SEEKING systems were artificially stimulated and dampened in a sample of healthy 
volunteers (N=16) via the administration of opioid and dopamine antagonists and agonists. 
This was an exploratory study, with a double-blind, placebo-controlled, repeated-measures 
design. The effects of the medications on SEEKING, PANIC/GRIEF, positive and negative 
affect and mood were investigated using both quantitative and qualitative measures. 
The results provided suggestive rather than strongly confirmatory evidence for the 
central hypotheses of this study. Naltrexone (a mu-opioid antagonist) did not increase 
PANIC/GRIEF and negative affect as predicted but there was some evidence that it led to the 
worsening of mood, a significant reduction in positive affect and feelings of social and affective 
disconnection. Morphine (a mu-opioid agonist) reduced PANIC/GRIEF as predicted, but 
contrary to predictions, positive affect was reduced. There was some evidence to show that 
Morphine led to an increase in the expression of feelings of contentment, relaxation, happiness 
and reduced concern. Haloperidol (a dopamine antagonist) reduced SEEKING as predicted but 
did not increase negative affect as expected. There was some evidence to show that it led to a 
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worsening of mood and positive affect and produced depressive affects such as low drive, low 
energy, loss of motivation and interest. Madopar (a dopamine agonist) did not increase 
SEEKING or improve mood as predicted, but there was some evidence that it generated 
positive affects and reduced the sadness associated with experiences of loss. On Haloperidol, 
participants with lower ‘despair’ had significantly reduced SEEKING and positive affect and 
higher depression scores, compared to participants with higher ‘despair’. On Madopar, 
participants with lower ‘despair’ experienced a greater improvement in positive affect and 
mood, compared to those with higher ‘despair’. On Morphine, measures of avoidant attachment 
rather than anxious attachment were comparatively more effective in differentiating between 
Low and High ‘protest’, and that those with higher ‘protest’ experienced comparatively more 
PANIC GRIEF, negative and depressive affect. These results provide some ‘proof of concept’ 
for the conceptualization of depression as pathological ‘despair’ and that depression feels bad 
because a dampened SEEKING system and a stimulated PANIC/GRIEF system produce the 
type of feelings that are characteristic of depression. The results also draw attention to factors 





There are long-standing claims that suggest that early separation experiences 
predispose people to depression, and that depressive episodes are triggered by experiences of 
social loss (Bowlby, 1969, 1973, 1980; Freud, 1917; Heim & Nemeroff, 1999). John 
Bowlby’s classical (1969) description of the normal separation response (assuming a pre- 
existing attachment bond) entails, first, a 'protest' phase, then, a 'despair' phase. In the first 
phase of this prototypical situation, the human child (like all mammals) emits distress 
vocalizations and searches for the mother; then, in the second phase, it gives up the search 
and becomes quiescent (quasi-hibernates). Research conducted within the ‘affective 
neuroscience’ paradigm of Jaak Panksepp (Panksepp, 1998) identifies two basic emotion 
systems as being centrally involved in this normal separation response, namely, 
PANIC/GRIEF1 and SEEKING2 (Panksepp & Watt, 2011a). At a ‘primary-process’ 
(unconditioned) level, the PANIC/GRIEF system regulates social attachments by generating 
negative affects following social separation and the SEEKING system generates a hedonic 
state of anticipatory expectation, promoting exploratory behaviour and, in the context of 
social separation, seeking reunification (Panksepp, 2003). The ‘protest’ phase is thus 
associated with aroused dopamine-mediated SEEKING, followed by the ‘despair’ phase, 
which is associated with kappa opioid mediated shutting down of this dopaminergic 




1 Panksepp uses this term as well as PANIC, SEPARATION-DISTRESS and SADNESS at 
different times to refer to the same system. The term PANIC/GRIEF is the one he uses most 
consistently, especially in his later writings. I will therefore follow this usage. Readers should 
be contextually aware, however, that at some points in this study, I am specifically focusing 
on the ‘panic’ component of this bi-phasic system. 
2 The terms are capitalized in order to avoid confusion with the vernacular use of the same 
words and also to denote that they refer to core emotion systems that have been identified at a 
neural level. 
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These brain mechanisms of the separation-distress cascade have been investigated 
mainly in animal models. The protest phase is mediated by the activity of µ (mu)-opioids. 
There is substantial empirical support for the role of the opioid systems in the physiological 
regulation of hedonic experiences in animals and humans (Berridge, Robison & Aldrige, 
2009). Also, empirically established in animal models (but less well known) is the 
mechanism by which the protest phase converts to despair (Panksepp & Watt, 2011a). A 
strong candidate for the brain mechanisms of despair is blockade of mesocorticolimbic D2- 
type activity through kappa opioid (dynorphin) inhibition of medial forebrain dopamine. 
Stress induces the release of dynorphin, which in turn activates kappa opioid receptors and 
down-regulates dopamine levels. Thus, prolonged social loss, as reflected by a highly 
activated PANIC system, diminishes SEEKING. 
The assumption here is that the despair phase of the mammalian separation distress 
cascade is the normal prototype for depression, conceptualised as too easily provoked or 
excessively prolonged 'despair'. In affective terms, this translates to an understanding of 
major depression as a disorder characterised by an overactive PANIC/GRIEF system and 
underactive SEEKING system (Coenen, Schlaepfer, Maedler, & Panksepp, 2011; Panksepp, 
2004). There is a substantial body of experimental work in animal models of depression 
which points to this conclusion (see Panksepp & Watt, 2011b for review), but the evidence in 
humans is limited. This is important, for the reason that animal models are just that: models. 
Animals lack the possibility of reporting subjective states of ‘despair’; that is, feelings of 
sadness, grief, etc. These states must be inferred in animal models. 
In short, what is lacking in the human depression literature is an understanding of the 
neural mechanisms of ‘why depression feels bad’ (Solms & Panksepp, 2010). All depressed 
patients experience psychological distress. Most of the current lines of investigation into 
depression draw attention to factors of potential causal significance, but they do not provide 
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insight as to why depression feels as it does. Therefore, the aim of this thesis is to determine 
whether depression ‘feels bad’ because the brain mechanisms for SEEKING and 
PANIC/GRIEF generate the specific feelings which are typical of depression, such as mental 
pain, sadness, pessimism, hopelessness, anergia and anhedonia. 
This thesis investigates the claim that the feelings associated with depression 
represent an abnormal variant of the normal mammalian separation response. Specifically, it 
asks the question: does an artificially stimulated PANIC/GRIEF system and dampened 
SEEKING system produce declarative depressive affects (the reportable human equivalents 
of ‘protest’ and ‘despair’ behaviours, respectively) in a sample of healthy volunteers? 
In order to contextualize this research, the literature review that follows provides an 
overview of: (a) the empirical neuroscientific literature on depression; (b) Panksepp’s model 
of social attachment and associated emotion; and (c) the neurochemistry of the opioid and 
dopaminergic systems. There is a considerable body of knowledge on each of these topics and 
this review is not intended as a comprehensive summary, but rather focuses on aspects of the 
literature that are most pertinent to the question under investigation. The aim is to position 
this investigation within a theoretical framework that allows us to better understand how (and 
whether) depression might be conceptualized as pathological 'despair' – that depression may 
be considered an abnormal variant of the typical mammalian separation response. 
If the neurochemistry of the mammalian separation response can be shown to 
underpin the feeling states that characterise (indeed, in a sense, constitute) human depression, 
then this research will not only provide ‘proof of concept’ but it might also lay the 








Dating back to classical times, portrayals of major depression, a condition previously 
referred to as melancholia, have appeared in accounts of human psychological suffering 
(Akiskal et al., 2000). While referent terms have changed over time, many of the key 
symptoms that inform modern diagnoses were recognized in the Hippocratic era, already, as 
was the acknowledgment of both mental and physical ailments in the symptom complex. 
Depression might as such be regarded as a prototypical human experience that transcends 
both time and culture, that is currently the leading cause of disability in many Western 
societies due to its profound disruption of social functioning (Lopez, Mathers, Ezzati, 
Jamison, & Murray, 2006). 
Epidemiology. Presently, Major Depressive Disorder (MDD) has been reported as 
one of the most common mood disorders in Psychiatric and Primary Care settings and is 
often accompanied by decreased physical and social functioning (Gili et al., 2014). There are 
approximately 350 million people worldwide with depression, and it is the leading cause of 
disability in the world (D’Souza & Jago, 2014). Prevalence estimates vary, from 3% in Japan 
to 16.9% in the U.S., but in most countries the disorder is common, with a frequency 
typically varying from 8% to 12% (Flint & Kendler, 2014). Epidemiological studies report 
that approximately ten percent of all individuals will develop this condition at some point in 
their life, and women are twice as likely as men to become depressed (Albert, 2015). Global 
prevalence rates are 5.1% for women and 3.6% for men (WHO, 2017). 
Diagnosis. The fifth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) now recognises four main disorders: MDD, Dysthymia (now called 
Persistent Depressive Disorder), Disruptive Mood Dysregulation and Premenstrual Dysphoric 
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Disorder. The diagnosis of MDD requires that five (or more) of the following symptoms are 
present during the same two-week period, at least one of the symptoms being either (a) 
depressed mood; or (b) loss of interest or pleasure; significant changes in weight or appetite; 
insomnia or hypersomnia; psychomotor changes; fatigue; feelings of worthlessness or 
excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness; 
recurrent suicidal ideation (American Psychiatric Association, 2013).  Although this 
diagnosis is atheoretical in principal, perhaps the most intriguing symptom with regard to the 
pathophysiology of depression is that previous editions of the DSM included a bereavement 
exclusion criterion for a major depressive episode that was applied to depressive symptoms 
lasting less than two months following the death of a loved one. The bereavement exclusion 
has now been omitted, one of the reasons cited is that “bereavement is recognized as a severe 
psychosocial stressor that can precipitate a major depressive episode in a vulnerable 
individual, generally beginning soon after the loss” (American Psychiatric Association, 2013, 
p. 811). This suggests an inherent link between depression and social loss. 
 
Etiologies. Recent attempts to understand depression have emphasized the highly 
subjective nature of the diagnosis; no fixed objective criteria exist and the experience of 
MDD may therefore be extremely variable across individuals (Anisman & Matheson, 2005). 
Accordingly, criticism has mounted against the notion of depression as a discrete ‘illness’, 
rather than a heterogeneous syndrome (Nestler et al., 2002). Indeed, converging evidence 
from neuroimaging, biochemical, clinical and post-mortem studies have pointed to a highly 
complex systems-level disorder that is unlikely to be the result of a single 
neurochemical/anatomical brain disease (Mayberg et al, 2005; Nestler et al., 2002; Watt & 
Panksepp, 2009; Yohn, Gergues, & Samuels, 2017). Despite the dramatic surge in 
neurobiological research over the past few decades, a clear appreciation of the basic brain 
foundations of MDD remains elusive and the mechanisms underpinning depression are still 
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poorly defined. Many hypotheses of depression have been introduced through antidepressant 
drug/medication research. However, the rationales of these hypotheses often follow from 
pharmacological manipulations in depressed patients (based in serendipitous drug discovery) 
and are not necessarily based on a theoretical conceptions of the pathophysiology of the 
disease. Depression research has focused largely on the physical correlates of depression, 
such as neurotrophic changes, rather than the brain mechanisms of depressive affect and 
behaviour itself. What follows is a brief account of some of these current hypotheses. 
Studies suggest that while genetic factors appear to be substantial in the etiology of 
MDD, accounting for up to 37% in heritability, genetics alone do not affirm the veracity of 
any particular biological theory (Flint & Kendler, 2014). Even if heritability features strongly 
in the etiology of MDD, a true ‘depression gene’ (Krishnan & Nestler, 2008) has not been 
identified, and life events account for a substantial variance in vulnerability (Sullivan, Neale, 
& Kendler, 2000). The gene encoding for the serotonin transporter (5-HTT) has been 
associated with neuroticism and susceptibility to depression (Bufalino, Hepgul, Aguglia, & 
Pariante, 2013; Canli & Lesch, 2007; Caspi et al., 2003; Levinson, 2006) but subsequent 
studies have reported non-specific results. A meta-analysis conducted by Risch et al. (2009) 
did not support the association between the risk of depression and this particular gene variant. 
Epigenetic research has focused on two chromatin-modifying actions, DNA methylation 
(Goud-Alladi, Etain, Bellivier, & Marie-Claire, 2018), and histone acetylation, implicated in 
emotional processing and social defeat, respectively (Krishnan & Nestler, 2008). Drugs that 
increase histone acetylation, such as, glyceryl triacetate and l-acetylcarnitine, are being 
evaluated for their efficacy in psychiatric disorders (Peedicayil, 2018). Studies involving 
genotype-guided antidepressant treatments have identified the following genes as particularly 
relevant: SLC6A4, HTR2A, ABCB1 and cytochrome P450 genes (Fabbri & Serretti, 2015). 
One of the major drawbacks of genetic studies (linkage and candidate gene association 
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studies, as well as more recent genome-wide association studies) is that these studies require 
very large sample sizes (around 10 000 or more cases and controls) to achieve sufficient 
power to detect effects. In small samples with unmatched phenotypes, there is also an 
increased risk of false-positive findings. Furthermore, the possible heterogeneity of 
depression has been argued to be a major stumbling block to significant findings, in that 
similar symptoms might arise from different disorders, or different gene-environment 
interactions may lead to the same disorder. To illustrate, Bosker et al. (2011) used data from 
the ‘Genetic Association Information Network genome-wide association study’ (p. 516), to 
investigate candidate gene and single-nucleotide polymorphism (SNP) associations that have 
previously been reported in MDD. They could only identify four significant candidate genes, 
out of a possible 55 candidate genes that had previously been reported in the literature to be 
associated with MDD. They were, C5orf20, NPY, TNF, and SLC6A2. However, more 
importantly, the authors argued that even their four significant findings could be false- 
positives, because of possible publication bias, previously reported false-positive findings, 
heterogeneity of the MDD phenotype and differences in contextual genetic or environmental 
factors. 
With regards to neural circuitry, dysfunctional changes within certain brain regions 
and circuits that regulate emotion and reward have been implicated in depression. Three 
popular models of the neural circuitry involved in MDD include the limbic-cortical, cortico- 
striatal, and default mode network models. A meta-analytic study by Graham et al. (2013) 
reviewed functional magnetic resonance imaging (fMRI) evidence in support of these three 
models and found stronger evidence for the limbic-cortical and cortical-striatal models than 
for the default mode network model. Furthermore, they suggested that associated subcortical 
regions may act as trait vulnerability markers, whereas the more frontal cortical areas may act 
as state markers of MDD. A meta-analytically informed network analysis of resting state 
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fMRI identified a depression-related introspective socio-affective (ISA) network that partially 
overlaps with the default mode network model. The ISA network included hyperconnectivity 
among areas similar to those of the default mode network that may contribute to altered 
introspection and rumination in depression (Schilbach et al., 2014). The ISA network also 
contained additional depression-related areas, such as those involved in the processing and 
regulation of emotions. Lui et al. (2011) also used resting state data to investigate depression, 
but they compared patients with refractory and nonrefractory MDD. They found that 
disrupted functional connectivity in the thalamo-cortical circuits was related to refractory 
depression, whereas more distributed reductions in connectivity of the limbic-striatal-pallidal- 
thalamic circuit were related to nonrefractory depression. Korgaonkar, Fornito, Williams, and 
Grieve (2014) used diffusion tensor imaging (DTI) to investigate the structural changes in 
brain networks related to MDD, and found alterations in the structural connectivity between 
nodes of the frontal-thalamo-caudate regions and the default mode network. 
Much of the current research on the neural circuitry of depression seems to involve 
various loops between the cortex, basal ganglia, limbic system and thalamus, as well as the 
default mode network, but these different circuits appear to link to different aspects of 
depression. In this regard, Foti, Carlson, Sauder, and Proudfit (2014) reported that MDD was 
associated with reduced reward-related neural activity but only in a subgroup of MDD 
patients with impaired mood reactivity to positive events. They argued that MDD was 
associated with dysfunction in multiple aspects of reward processing, that is, the primary 
characteristic in some cases of MDD may be a deficit in opioid-mediated “liking”; in other 
cases a deficit in dopamine-mediated “wanting” or learning (Berridge & Kringelbach, 2015). 
Morgan, Olino, McMakin, Ryan, and Forbes (2013) found that reduced striatal and enhanced 
medial prefrontal responses to reward to be particularly predictive of depressive symptoms in 
adolescents. Familial risk for MDD has been characterized by the dysregulation of affective 
11  
circuits for evaluating salient emotions (Watters, Korgaonkar, Carpenter, Harris, Gross, & 
Williams, 2018). Anhedonia has been shown to correlate with reduced connectivity of the 
ventral caudate to the dorsolateral prefrontal cortex, the parietal and temporal cortices and 
enhanced connectivity with the occipital cortex (Yang et al., 2017). Certain neural correlates 
of depression have been identified. Reductions in grey-matter volume and glial density in the 
prefrontal cortex and hippocampus are associated with depression (Krishnan & Nestler, 
2008). Functional abnormalities in the amygdala and subgenual cingulate are correlated with 
negative emotions (Drevets, 2001) and stimulation of the dopaminergic nucleus accumbens 
(NAc) has been shown to have ameliorative effects in refractory depression (Schlaepfer et al., 
2008). Increased amygdala, insula and ventrolateral prefrontal cortex activation in response 
to social exclusion has been reported in subjects with MDD (Kumar, Waiter, Dubois, 
Milders, Reid, & Steele, 2017). 
The popular monoamine hypothesis posits that depression involves low levels of 5- 
HT, norepinephrine (NE), and/or dopamine (DA) levels in the CNS.  It has been the 
prevailing hypothesis for several decades and originated from mechanistic studies of the 
serendipitously discovered tricyclic antidepressants and monoamine oxidase (MAO) 
inhibitors. Selective serotonin and norepinephrine reuptake inhibitors (SNRIs) remain first 
line treatments for MDD (Dale, Bang-Andersen, & Sáncheza, 2015). There are numerous 
findings in support of this hypothesis: drugs that deplete serotonin and other catecholamines 
can lower mood (Ruhé, Mason, & Schene, 2007); reduced serotonin levels (through 
tryptophan depletion) can alter emotional processing and lower mood in individuals with a 
vulnerability to MDD (Fukuda, 2014; Roiser et al., 2009); there are reported changes in the 
functional connectivity of the raphé during tryptophan depletion (Salomon et al., 2011; 
Weinstein et al., 2015); reported reductions in serotonin transporter (SERT) binding in key 
limbic regions in depression (Kambeitz & Howes, 2015); and clinical trials demonstrating the 
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benefit of SSRIs in MDD (Fournier et al., 2010). MDMA (which has the highest efficacy for 
5-HT release via SERT) in post-traumatic stress disorder (PTSD) is being implicated as a 
potential rapid-onset antidepressant (Patel & Titheradge, 2015). Even though SSRIs and 
MAO inhibitors are strong antidepressant agents, a meta-analysis conducted by Fournier et al. 
(2010) showed that true drug effects (defined as an advantage of antidepressant medication 
over placebo) were negligible for depressed patients with mild to moderate baseline 
symptoms, and were only noticeable in patients with very severe symptoms. According to the 
STAR*D report (Rush et al., 2006), approximately 50% of patients went into clinical 
remission after two treatment steps with SSRIs/SNRIs. For four consecutive treatment steps, 
the overall cumulative remission rate was 67%, leaving a large group of patients who 
responded inadequately to treatment. In an overview by Khan and Brown (2015), it was 
reported that the effect size of clinical depression trials was only 0.30, and when comparing 
data from industry (pharmaceutical) and non-industry clinical trials, the extent of reported 
symptom reduction on placebo was higher in non-industry trials. Furthermore, not all 
depressed patients exhibit serotonergic inconsistencies (Jans, Riedel, Markus, & Blokland, 
2007) and there are studies that show that monoamine depletion does not affect mood in 
normal controls (Delgado & Moreno, 2000; Ruhe et al., 2007). It has also been demonstrated 
that critically low levels induced by tryptophan depletion does not cause depression in 
healthy subjects (Neumeister et al., 1997). The therapeutic response to SSRIs/SNRIs is often 
delayed (Dale et al., 2015) and the monoamine hypothesis fails to explain this latency of 
response (Boku, Nakagawa, Toda, & Hishimoto, 2018). Moreover, many antidepressants 
have adverse side-effects, such as nausea and sexual dysfunction (Anderson, Pace, Libby, 
West, & Valuck, 2012). Thus, although both noradrenergic and serotonergic systems are 
implicated in depression, the exact nature of the correlation with affective states remains 
unclear (Watt & Panksepp, 2009).  Neither norepinephrine nor serotonin appear to be “the 
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final common pathway for the therapeutic effect of antidepressant drugs” (Delgado & 
Moreno, 2000, p.5) and depression is not simply a result of a “serotonergic vulnerability” or a 
neurotransmitter deficiency state (Krishnan & Nestler, 2008; Watt & Panksepp, 2009). 
According to the neurotrophic hypothesis of depression, reduced levels of certain 
neurotrophic factors predispose to depression and an increase in these levels can have 
antidepressant effects (Zhang, Li, Sha, & Bu, 2015). Neurotrophic factors that have been 
linked to depression include brain-derived neurotrophic factor (BDNF; Koziek, Middlemas, 
& Bylund, 2008; Molendijk et al., 2014), glial cell line-derived neurotrophic factor (Lin & 
Tseng, 2015), insulin-like growth factor, vascular growth factor (VGF; Tseng, Cheng, Chen, 
Wu, & Lin, 2015), fibroblast growth factor (Borroto-Escuela et al., 2012), neurotrophin-3 
(NT3), and nerve growth factor (NGF; Chen et al., 2015). However, research findings have 
not been consistent and meta-analytic methods are being employed more regularly in an 
attempt to review the evidence for and against these neurotrophic factors. BDNF seems to be 
one of the most popular neurotrophic factors currently linked to depression (Zhang et al., 
2015). Research has demonstrated that several forms of stress reduce BDNF mediated 
signalling in the hippocampus and that long-term use of antidepressants could reverse 
neuronal atrophy and cell loss (Duman & Monteggia, 2006; Nibuya, Morinobu, & Duman, 
1995; Sheldrick, Camara, Ilieva, Riederer, & Michel, 2018). However, these findings are 
once again not consistent, and, in some cases, the opposite effect has been shown, that is, that 
stressors can increase BDNF levels in the hippocampus (Groves, 2007). Haase and Brown 
(2015) suggest a reciprocal regulatory mechanism between serotonin and BDNF that 
contributes to neuronal activity homeostasis in the hippocampus, prefrontal cortex and other 
brain regions. According to their model, this homeostasis may be disrupted by long-term 
inflammatory responses, with subsequent negative effects on the survival and maintenance of 
neurons and dendrites in the hippocampus and the development of depressive symptoms. 
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From a neuroendocrine perspective, dysregulation of the hypothalamic-pituitary- 
adrenal (HPA) axis is implicated in the pathophysiology of depression (Horowitz & 
Zunszain, 2015; Martinac et al., 2014), as it coincides with depressive episodes and partially 
reverses after successful treatment (Fassbender et al., 1998). Hypercortisolemia in depression 
can be demonstrated at several levels: (a) impaired glucocorticoid-receptor-mediated negative 
feedback (Brown, Varghesea, & McEwen, 2004), this theory posits that abnormally high 
activity in the HPA axis, as a result of chronic stress, may result in excess cortisol production 
and subsequent depression-related neuropathology in susceptible individuals; (b) adrenal 
hyper-responsiveness to circulating adrenocorticotrophic hormone (ACTH; Parker, 
Schatzberg & Lyons 2003); and (c) hypersecretion of corticotrophin releasing factor (CRF; 
Arborelius, Owens, Plotsky, & Nemeroff, 1999; Nemeroff & Owens, 2002; Ogłodek, Szota, 
Just, Moś, & Araszkiewicz, 2014) where CRF and ACTH affect the metabolism of 
neurotransmitters and cortisol decreases tryptophan availability, impacting the synthesis of 
serotonin. Some findings suggest that hypercortisolemia is mostly found in inpatients and that 
the in/outpatient distinction is relevant to the presence of endocrine changes in major 
depression (Brouwer et al., 2005). In this regard, Herane-Vives et al. (2018) reported higher 
cortisol levels in severely depressed outpatients displaying melancholic features. Evidence 
from preclinical studies shows that exposure to episodes of severe separation distress in early 
life results in lasting changes to HPA axis and upregulation of CRF and could lead to a 
phenotype that is more vulnerable to stress and depression in adulthood (Heim & Nemeroff, 
1999; Heim, Newport, & Mletzko, 2008). Moreover, different configurations of depressive 
symptoms may be related to different HPA-axis dysfunctions (Blatt & Luyten, 2009; Juruena, 
Bocharova, Agustini & Young, 2018). In this regard, hypercortisolemia may be linked to 
melancholic depression and HPA hypoactivation to atypical depression (Tofoli, Von Werne 
Baes, Martins, & Juruena, 2011). 
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Another approach to understanding the pathophysiology of depression is to consider 
the mechanisms of allostasis in response to stress. Several resilience factors have been 
identified in animal models: stress-induced upregulation of the transcription factor ∆FOSB 
inhibits stress-induced release of substance P, thereby promoting active defense responses 
(Berton et al., 2007); increased excitability of ventral tegmental area DA can moderate 
vulnerability to development of social avoidance (Krishnan et al., 2007); and the release of 
neuropeptide Y onto amygdala neurons produces resilient behavioural responses (Sajdyk et 
al., 2008). 
Overactive immune system functioning is often observed in depressed individuals 
(Dantzer, 2009; Horowitz & Zunszain, 2015). Proinflammatory cytokines can produce the 
types of neurological changes that are commonly associated with depression, such as 
monoamine system changes, decreased neurogenesis, neurodegeneration, and regional brain 
abnormalities (Miller, Maletic, & Raison, 2009). The cytokine theory of depression evolved 
from findings showing that (a) there is an increased incidence of depression in patients with 
medical illness; (b) there are overlaps between depression and cytokine-induced sickness 
behaviour; (c) depression can be induced via stimulation of cytokine production; and (d) that 
the reduction of cytokine levels has antidepressant effects. Interestingly, Miller and Cole 
(2012) found that childhood adversity promotes a phenotype in which depression and 
inflammation co-occur. However, studies reporting on the neuroimmune interactions of 
increased cytokine in depression can be highly variable (Glassman, 2007). In their review 
article, Dunn, Swiergiela, and de Beaurepaire (2005) concluded that although immune 
activation and cytokines feature in depressive symptoms in some patients, cytokines are not 
essential mediators of depression. In a review of the inflammatory biomarkers of depression, 
patients with depression have been shown to have increases in peripheral levels of 
proinflammatory cytokines interleuken (IL)-6, IL-1β and tumour necrosis factor (TNF) (Han 
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& Yu, 2014). Moreover, polyunsaturated fatty acids (PUFAs), glucocorticoids, gut 
microbiota and microglia have also been implicated in inflammation and depression alike 
(Ma et al., 2017). These findings have been fairly consistent, but are not always present 
because of the heterogeneity of depression. Another review by Young, Bruno, and Pomara 
(2014) report elevated serum levels of TNF-α, IL-1, IL-6, monocyte chemoattractant protein- 
1 (MCP-1) and C-reactive protein in depressed patients. Results were more mixed with 
regards to cerebrospinal fluid (CSF) levels of IL-6 and MCP-1 and IL-8 serum levels. Despite 
the demonstrated relationships between proinflammatory cytokines and depression, research 
has thus far not been able to identify cytokines that are highly specific to MDD. Eyre, Stuart, 
and Baune (2014) suggest that immune factors beyond pro- and anti-inflammatory cytokines 
come into play during different phases of depression, such as macrophages, astrocytes and 
microglia. 
The glutamate hypothesis of depression posits that excitatory transmission of 
glutamate plays a key facilitatory role in the emotional and cognitive changes associated with 
depression. In their review, Sanacora, Treccani, and Popoli (2012) emphasise how cognition 
and emotion are largely mediated by glutamate synaptic transmission. Furthermore, they 
reported that there is compelling evidence to suggest that glutamate transmission is 
abnormally regulated in several limbic/cortical areas in depressed individuals and that 
atypical glutamatergic signalling is related to maladaptive changes in the function of 
excitatory circuitry. In addition, preclinical data has shown that environmental stress can alter 
synaptic transmission in limbic/cortical areas. Changes in plasma and CSF levels of 
glutamate, brain glutamate and glutamine levels have been found in patients with MDD, but 
results are inconsistent (Dale et al., 2015). Reduced levels of glutamate levels in the anterior 
cingulate have been reported in subjects with unipolar and bipolar depression (Wise et al., 
2018). Ketamine (Zarate et al., 2006) and scopolamine (Furey, Khanna, Hoffman, & Drevets, 
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2010) in particular have been shown to produce rapid antidepressant actions and the 
development of nasal ketamine is being fast tracked by the FDA (Lapidus et al., 2014). Their 
actions are related to the reversal of synaptic atrophy caused by stress and depression which 
in turn leads to the reconnection of cortical-limbic circuits, lending support to the hypothesis 
that changes of neuroplasticity, that result in functional disconnections, might underlie the 
pathophysiology of depression (Duman, 2014). Other potential glutamatergic agents being 
investigated are: the nonselective N-methyl-D-aspartate (NMDA) antagonist, lanicemine 
(Zarate et al., 2013); the GluN2B selective antagonist, MK-0657 (Ibrahim et al., 2012); 
rapastinel (Burgdorf et al., 2013); 4-Cl-KYN (Zanos et al., 2015) and Gamma-Amino Butyric 
acid (GABA)-A alpha-5 (Gerhard, Wohleb, & Duman, 2016). 
According to the adrenergic-cholinergic imbalance hypothesis of affective disorders, 
depression is associated with cholinergic hyperactivation and as a consequence of decreased 
noradrenergic activity (Janowsky, el-Yousef, Davis, & Sekerke, 1972). In particular, the 
muscarinic cholinergic receptor system is implicated in depression. Specifically, muscarinic 
receptor supersensitivity in depressed individuals (Riemann et al., 1994) and type 2 
muscarinic (M2) cholinergic receptor gene (CHRM2) associations with increased incidence 
of unipolar depression and abnormal decreases in M2 receptor binding in bipolar depression 
(Comings et al., 2002). Numerous clinical and preclinical studies have shown that decreasing 
acetylcholine transmission at specific nicotinic acetylcholine receptors has a positive effect 
on mood (Mineur & Picciotto, 2010). 
The co-occurrence of depression and type 2 diabetes, and of depression and 
coronary disease, has given rise to the hypothesis that lipid metabolism disturbances may be 
involved in the pathogenesis of depression (Puiu, Manea, Frunza, & Manea, 2014). Studies 
have investigated various components of lipid metabolism and have proposed different 
mechanisms for their relationship to depression, such as changes in cell membrane fluidity 
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with subsequent effects on serotonergic transmission, HPA axis and autonomic nervous 
system (ANS) dysfunction, higher levels of inflammatory markers, and Leptin resistance (to 
name a few). Research findings have varied, however, and it is not yet clear whether 
depression is a risk factor for lipid metabolism disturbances or whether these disturbances 
may increase the risk of depressive symptoms. Recent research found that middle-aged 
depressive patients with suicidal behaviour were more likely to have glucose and lipid 
metabolism disturbances, as well as insulin resistance (Koponen, Kautiainen, Leppänen, 
Mäntyselkä, & Vanhala, 2015). A longitudinal study of ageing found that the association 
between glucose metabolism (diabetes) and depressive symptoms was bidirectional in 
individuals aged 52 to 64, but not in those 65 years and older (Demakakos, Zaninotto, & 
Nouwen, 2014). 
The following are all additional targets for depression research and could produce 
further pathophysiological insights and treatment advances. Melanin-concentrating hormone 
(MCH): SNAP-7941, a selective, high-affinity MCH1 receptor antagonist has been shown to 
produce antidepressants effects in preclinical models of depression (Borowsky et al., 2002; 
Schmidt et al., 2015). The orexigenic hormone, ghrelin, could act as a possible mediator of 
the adverse effects of stress on behaviour (Bali & Jaggi, 2015; Ishitobi et al., 2012; Lutter et 
al., 2008; Murgatroyd, Peña, Podda, Nestler, & Nephew, 2015). The orexin system has also 
been implicated in maternal care (D'Anna & Gammie, 2006) and depressive behaviour 
(Nollet & Leman, 2013). Low levels of the adipocyte hormone, leptin, have been associated 
with depressive behaviours in preclinical and clinical studies (Haleem, 2015; Lu, Kim, 
Frazer, & Zhang, 2008). The preclinical data demonstrating the role of Neuropeptide Y1 and 
Y2 receptors in emotional responses and stress is robust. In human studies, Neuropeptide Y 
plays a role in “buffering” the negative effects of stress (Fu, Acuna-Goycolea, & van den Pol, 
2004; Morales-Medina, Dumont, & Quirion, 2010; Treutlein et al., 2017). 
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Undoubtedly, much progress in this field has been made, yet the shortcomings of the 
current research paradigms are exemplified by a number of conflicting clinical and 
neurophysiological findings. For example, although the influence of monoaminergic 
transmission in the modulation of emotion is well-established, there is no direct evidence for 
a causal relation between depression and monoaminergic dysregulation (Dale et al., 2015). 
The ardent focus on SSRIs as targets for efficacious treatment is possibly misleading since 
serotonin exerts widespread modulatory effects on the brain with modest overall efficacy as 
reported by the STAR*D findings (Rush, 2007). Approximately one-third of people 
diagnosed with depression do not respond to two or more of preferred SSRI treatments and 
are labelled treatment resistant (Trivedi et al., 2006). Moreover, anhedonia—a core symptom 
of depression—is often not alleviated with SSRIs. Interestingly, when the DA system is co- 
targeted, as with triple reuptake inhibitors (for example, DOV 216,303; Korte et al., 2015), 
antidepressant treatment seems to be more effective (Prins et al., 2012). In light of the 
variable resistance and delayed onset of monoamine-targeted antidepressants, Hasler (2010) 
proposes that monoaminergic dysfunction in MDD may represent the subsequent effects of 
other core abnormalities. Even stress, while most certainly a major contributing factor in the 
development of a depressive episode, is unsatisfactory as a simple casual mechanism since 
many individuals do not become depressed after excessive exposure to stress (Nestler et al., 
2002), and moreover, intense stressful experiences have been linked to many psychiatric 
conditions, particularly, PTSD. Many people treated for MDD show no HPA dysfunction 
(Belmaker & Agam, 2008) and drugs targeting the HPA axis have not consistently shown 
antidepressant effects. There is likewise no concrete evidence in humans for the specific 
neurobiological mechanisms of the neurotoxic and neurotrophic hypotheses of depression 
(Hasler, 2010). Similarly, although there has been evidence of reduced CNS GABA in MDD 
patients since the 1980s (Hasler et. al, 2007; Romeo, Choucha, Fossati & Rotge, 2018), there 
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is also data to suggest that increases in GABA neurotransmission leads to negative mood 
(Levinson & Devinsky, 1999), and that a reduction in some aspects of GABA 
neurotransmission improves mood (Pehrson & Sanchez, 2015). Moreover, fluoxetine and 
vortioxetine (both effective serotonergic antidepressants) have opposite effects on GABA 
neurotransmission (Alvarez, Perez, & Artigas, 2014; Pehrson & Sanchez, 2015). This 
evidence all points to the fact that a simple reduction in GABA neurotransmission is not 
likely at the root of MDD. Furthermore, despite the numerous drugs under investigation that 
target the glutamate system, the specificity with regards to depression is questionable as 
glutamate is involved in almost every brain activity (Hasler, 2010). Elevated cytokine levels 
are implicated in the pathophysiology of depression but not all depressed patients have 
neuroinflammation (Bhattacharya, Derecki, Lovenberg, & Drevets, 2016). In studies 
identifying areas that correlate with depression and its symptoms, it is unclear whether the 
neural circuitry is altered as a consequence of depression or whether depression is a 
consequence of these alterations. Findings are inconsistent and confounded by comorbid 
diagnoses, with limited success in demonstrating cause-effect relationships. Lastly, a possible 
reason for the limited success of genetic studies could be that a diagnosis of depression 
typically relies on current classification criteria from the DSM or ICD-10 that are based on 
the presence of a cluster of symptoms. These clusters of symptoms do not necessarily refer to 
a homogenous disorder and therefore the current classification criteria of depression do not 
conform to genetically relevant phenotypes (Hasler, 2010). 
Conceptual Foundations of the Affective Model of Depression 
 
The present thesis is grounded in the affective neuroscience model of depression. 
 
What follows below are descriptions of several foundational principles on which this model 
of depression is conceptualized. 
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Depression is about feelings. It is evident from the many novel targets of therapeutic 
intervention currently under investigation that depression is a heterogeneous syndrome. There 
is no current treatment that has proven to be effective in all clinically depressed patients, 
reinforcing the view that depression may consist of etiologically distinct subgroups. 
Typically, subgroups of depression are either classified according to their clinical 
symptomology or identified on a pathophysiological basis. What is arguably more 
generalizable is the underlying affective state of depression. In other words, what is common 
to all depressed patients is that they experience psychological pain and/or hopelessness. Most 
lines of investigation into depression discussed above draw attention to factors of potential 
causal significance, but do not provide any insight into why depression feels the way it does. 
Although the predominant classification is one of symptomology, depression for the 
individual sufferer is a complex and subjective experience which has meaning. The 
symptoms of depressed affect, like low self-esteem, low motivation, hopelessness and 
anhedonia, signify a loss of expectant interest in the real world. In depressed adolescents, the 
presence of anhedonia is a significant predictor of poor recovery (McMakin et al., 2012). 
This leads us to the introduction of one of the first conceptual principles central to this 
research: Depression is about affect, and yet the underlying mechanisms of the subjective 
experience of the psychological pain and despair of depression remain largely unexplored. I 
argue that the relative lack of neuroscientific investigation into depressive affect has left a 
significant gap in our understanding of depression because the psychological essence of the 
felt experience is arguably the common denominator. It is surely not fortuitous that 
irrespective of the type or duration of the depressive state, it consistently feels bad. This must 
have biological significance. 
Moreover, it is not mere coincidence that the core criteria of the DSM conceptualise 
MDD as primarily a ‘felt disorder’ (low mood, low self-esteem, loss of motivation, guilt, loss 
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of pleasure and so on). Without these feelings present, a patient is not likely to be diagnosed 
with depression. And yet, there has been a great hesitancy on the part of the general 
neurosciences to approach the subjective aspect of depression as a fundamental symptom for 
guiding research. This neglect is arguably a repercussion of archaic behaviouristic principals, 
which limit scientific inquiry to tangible, observable events; but, as Solms (2011) argues, to 
deny the causal contribution of subjective feelings in the behavioural and cognitive 
components of depression is to deny the very nature of the disorder itself. Certainly, a 
bereaved individual can look very much like a case of clinical depression, a resemblance that 
was cordially noted in the DSM-5 criteria; a resemblance that was also previously recognised 
by Freud (1917) who considered melancholia (depression) to be a pathological product of 
mourning (grief). Freud observed that symptoms such as sadness, loss of appetite, disturbed 
sleep and withdrawal from social activities were similar in depressed individuals and those 
suffering from a loss of a loved one. The purpose of including this differential diagnostic 
criterion was therefore precisely because bereavement could be mistaken for depression, 
since many of the symptoms of depression resemble that of bereavement. Symptoms such as 
anhedonia, low mood, guilt, sleep disturbance and occasionally suicidal ideation may be 
present in both conditions (Iglewicz, Seay, Zetumer, & Zisook, 2013). 
This bereavement exclusion criterion has been removed from the DSM-5 for the 
reason that (a) “bereavement is recognized as a severe psychosocial stressor that can 
precipitate a major depressive episode in a vulnerable individual”, and (b) “evidence does not 
support the separation of loss of a loved one from other stressors in terms of its likelihood of 
precipitating a major depressive episode” (APA, 2013a, p.5). 
This acknowledgement introduces and in fact reinforces a further basic principle of 
the affective neuroscience model of depression, which is that there is an entailment in 
depression of the brain mechanisms of social loss. 
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Love is an attachment. Attachment theory presupposes an innate bonding system, 
presumably analogous with the attachment circuitry in other mammals, that operates to keep 
infants near their caregivers in the presence of threats and to modulate seeking support when 
necessary (Nelson & Panksepp, 1998). This system continues to regulate social interactions 
in intimate relationships into adulthood (Hazan & Shaver, 1987). Adult attachment styles 
typically vary on the dimensions of anxiety and avoidance (Brennan, Clark, & Shaver, 1998; 
Fraley, 2002). Differences in adult attachment have been shown to modify the activation of 
corticolimbic circuits in response to social and emotional stimuli, to the extent that an 
anxious attachment style seems to increase the responsiveness of brain circuits to negative 
social cues, and an avoidant attachment style lowers responsiveness to socioemotional 
processing (Vrticka, Sander, & Vuilleumier, 2012). More importantly, high avoidant 
attachment (as measured by the Experiences in Close Relationships-Revised (ECR-R)) has 
been associated with low μ-opioid receptor (MOR) availability in areas that form part of the 
social distress circuit (Nummenmaa et al., 2015). These findings correspond to the animal 
research that has established how the opioid system modulates bonding and attachment in 
other mammals (Nelson & Panksepp, 1998). 
Separation hurts. According to attachment theory, attachment styles reflect mental 
representations about the primary caregiver and the self; representations not only about the 
care received but the worthiness to receive it (Bowlby 1969). These representations, 
established in childhood, are considered to be stable and can be triggered during episodes of 
distress (Mikulincer & Shaver, 2007). There is an abundance of literature in animal models 
that provides evidence that early adverse experience such as the separation distress following 
prolonged maternal separation can lead to structural and functional changes in an 
interconnected network of brain regions that are involved in neuroendocrine control, 
autonomic regulation and emotional regulation. Such changes translate into an integrated 
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network failing to compensate adequately for additional stressors in adult life and manifesting 
in behavioural and physiological changes that form the clinical phenotype of depression 
(Lupien, McEwen, Gunnar, & Heim, 2009; Slavich, Monroe, & Gotlib, 2011). From this 
perspective, depression has been conceptualised as an “inappropriate adaptation to stress” 
(Bali, Singh, & Jaggi, 2014, p.347), and Panksepp and Watt (2011a) argue that chronic stress 
(i.e. separation distress) may be the “gateway” into depression, since depression and 
separation-distress share neurobiological and emotional characteristics. 
The historic human literature recognizing the precipitating effect of social loss on 
depressive episodes is extensive (Bowlby, 1969, 1973, 1980; Freud & Burlingham, 1944; 
Spitz, 1946). Childhood adversities and early life stress are consistently associated with an 
increased risk of initial onset of depressive episodes (Hovens, Giltay, Spinhoven, van 
Hemert, & Penninx, 2015) and constitute a major risk factor for the subsequent development 
of depression (Charney & Manji, 2004; Post, 1992). The structural and functional changes 
following early life stress episodes are similar to those seen in adults with depression (Anda 
et al., 2006; Kaufman, Plotsky, Nemeroff, & Charney, 2000). Alterations include 
glucocorticoid resistance; increased levels of inflammation; increased CRH activity; 
decreased oxytocin activity (Danese et al., 2011; Heim et al., 2008; Heim, Young, Newport, 
Mletzko, Miller, & Nemeroff, 2009) and reduced hippocampal volume (Buss et al., 2007). 
Early life adversity also impacts on other key brain regions implicated in stress and 
depression: reduced medial prefrontal cortical volume in adults having suffered previous 
emotional abuse (van Harmelen et al., 2010); reduced orbital-frontal cortical volume (Pollak 
et al., 2010); increased amygdala volume in children who have been institutionalized 
(Tottenham et al., 2010); and altered cortical affective processing in adults with various 
psychiatric disorders (Weber et al., 2009). Although the evidence from animal models and 
human studies that early life stress is a general risk factor which can lead to enhanced stress 
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vulnerability and depression is strong, not all those exposed to early life stress develop 
depression when confronted with stressors as adults (Heim & Binder, 2012). Factors that 
could account for these differential effects are: sensitive periods of increased brain plasticity 
throughout development, maturation rates of different brain regions (Tau & Petersen, 2010), 
puberty (McEwen, 2001) and interactions between individual genotypic variations and early 
life stress (Heim & Binder, 2012). 
The addictive quality of love relationships is not as readily recognized as is the 
addictive character of dependence upon artificial opiates like heroin and morphine. Love is 
surely the primal addiction. Panksepp calls it the PANIC/GRIEF instinct. This dual name 
reflects the fact that the experience of loss (in the context of attachment bonding, which 
occurs in all mammals) produces a biphasic instinctual response (Panksepp & Solms 2012). 
The despair that can follow the loss of a loved one is all too familiar. Bowlby (1973) 
considered childhood attachment relationships to be akin to representations of adult romantic 
relationships and it is thus not surprising that adolescent romantic losses are a significant risk 
factor for the onset of the first episode of MDD (Monroe, Rohde, Seeley, & Lewinsohn, 
1999). Keller, Neale, and Kendler (2007) describe how death of a loved one and romantic 
breakups are associated with a distinct pattern of depressive symptoms characterised by high 
levels of sadness, anhedonia, appetite loss, and guilt. Social rejection, more than any other 
type of stress, can increase the risk for depression (Kendler, Hettema, Butera, Gardner, & 
Prescott, 2003; Slavich, Thornton, Torres, Monroe, & Gotlib, 2009). Intimate relationships 
are closely related to the neuromechanisms of depression because of their essential link to 
stress, cytokine and various changes in neuropeptide systems (Watt & Panksepp, 2009). 
Social relationships have such a great impact in our lives because they essentially promote 
survival and a rejection could signal a threat to our self-preservation (Slavich, O’Donovan, 
Epel, & Kemeny, 2010). Many acts of suicide are attempted following interpersonal loss or 
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rejections (Richards, 1999). De Rubeis, Lugo, Witthöft, Sütterlin, Pawelzik, and Vögele 
(2017) found that ‘rejection sensitivity’ was a significant and independent predictor for the 
worsening of symptoms in men with depressive spectrum disorder. In fact, it seems that a 
rejection-related stressor is one of the better predictors of MDD (Slavich et al., 2009). 
In summary, the second conceptual principle fundamental to this research is that 
depression is centrally linked to the loss of social attachment figures, social worth and 
standing, and separation distress, in particular, is critical to the nurturance of social bonds. It 
should be noted that the activation of separation distress mechanisms does not necessarily 
occur only in the context of actual separation from attachment figures. The etiological 
mechanism may also be, for example, an overly sensitive PANIC/GRIEF system, on the basis 
of genetic factors and/or early developmental separation trauma. We should also recognise 
that, in humans, with our expansive association cortex, ‘attachment figures’ may be highly 
abstract and symbolic – one may even become attached to an idea, such as a flag or one’s 
symbolic position in a social hierarchy (such as the workplace). Surprisingly, the relationship 
between depressive feelings and the psychology of attachment and loss remains largely 
unexplored by cognitive neuroscientists. Overcoming this disjuncture between brain and 
mind may therefore go a long way towards integrating the disparate findings from 
neurobiological and psychological fields (Zellner, Watt, Solms, & Panksepp, 2011). 
Why depression feels bad. These guiding principles, that is, the subjective 
experience of the psychological pain of depression and the relationship between depression 
and social loss, direct the current focus of this research towards the brain systems that 
generate raw affect, and encourage the problem of “why depression feels bad” (Solms, 2011, 
p.3) or what Panksepp refers to as the “painfulness” (2010, p. 540) of social loss– a problem 
which simultaneously contextualizes the conceivable environmental and brain foundations of 
the condition. From this perspective, depression feels bad because it is underpinned by 
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affective systems that give rise to specific ‘bad’ feelings, and a thorough articulation of how 
depression feels bad (sadness, hopelessness, irritability, loss of pleasure or interest), provides 
meaningful indications as to its specific neuroaffective foundations. 
The affective brain systems of PANIC/GRIEF and SEEKING evolved to mediate 
attachment and loss. When social bonds are broken, the mammal feels a certain kind of 
psychological pain termed separation distress, the purpose of which is to encourage 
reattachment with the lost object. If this goal is not achieved, despair soon follows, and it is 
this despair that most closely resembles depression (Harris, 1989). George Engel’s (1962) 
clinical observation was that the purpose of ‘giving up’ in despair or the ‘depression- 
withdrawal reaction’ as he termed it, was to reduce the pain associated with loss and 
separation. Thus, depression feels bad because (a) it causes psychic pain that promotes 
reattachments, and (b) it urges us to give up on reunification when such attempts have failed. 
This leads us to the central hypothesis under investigation in this thesis: The 
cornerstone of depression has something to do with unremitting or too easily provoked 
experiences (real or perceived) of social loss (Solms, 2011) and that the evolutionarily 
conserved brain mechanisms that regulate the progression from loss to “protest” to “despair” 
to recovery may underlie the pathophysiology of depression (Solms, 2011; Zellner et al., 
2011). In other words, clinical depression may in some way be an aberration of the normal 
affective response to separation distress. Korf and Bosker’s (2013) perspective is similar to 
the extent that they too consider depressive mood to be a normal state of the brain but that in 
MDD, there is an inability to engage in what they refer to as antidepressive transitions. From 
an affective neuroscience perspective, the subjective experience of depression feels bad 
because it is intimately linked to the PANIC/GRIEF system; a system that creates social 
connections and influences adult relationships. When such bonds are broken, the kind of 
psychological pain which people suffer is akin to grief (Panksepp, 2010). This intense period 
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of emotional anguish, when unresolved, is followed by psychological and behavioural 
shutdown, most probably due to an inhibition of global SEEKING activity (Alcaro, Huber, & 
Panksepp, 2007; Solms, 2011; Watt & Panksepp, 2009; Zellner, et al., 2011). An enhanced 
intrinsic reactiveness of the PANIC/GRIEF system coupled with an intrinsic hypoactivity of 
SEEKING impulses could promote depression in response to stressors (Panksepp, 2010). At 
present, this conceptualization of the brain basis of depression most closely aligns with the 
clinical realities of the condition, and indeed, there is a great deal of neurophysiological data 
that supports this proposal. In fact, Coenen and colleagues (2012) recently identified an 
‘affect-regulating fiber system’ (p. 233) consisting of the medial forebrain bundle (MFB) and 
anterior thalamic radiation pathways which appear to be the anatomical underpinnings of the 
SEEKING and PANIC/GRIEF systems. 
The affective neuroscience approach. Numerous competing models of human 
emotion have  been developed. The central premise of the affective neuroscience model is 
that emotions arise from ancient subcortical brain processes, and that many of the more 
psychologically elaborate emotions experienced by humans arise from the interactions of 
core emotions with higher brain functions (Panksepp, 1998, 2006). Instinctual behaviours 
reflect basic affective feelings (Panksepp, 2006). This model considers basic mental 
processes, brain functions, and emotional behaviours that all mammals share with the purpose 
of locating the neural mechanisms of emotional expression. A recent meta-analysis of 
neuroimaging studies by Vytal and Hamann (2010) added support to this approach by 
concluding that the emotions of happiness, sadness, fear, anger, and disgust were associated 
with consistent neural correlates. 
What is meant by emotion? Panksepp (1998) defines emotions as “psychoneural 
processes” (p. 48) mediating the behaviour of animals during their interactions with one 
another and their environment. They are genetically encoded into the subcortical 
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neurocircuitry of the mammalian brain. They are raw affects that form the bedrock of our 
mental being and reflect ancient brain/mind processes that are value-laden and shared 
homologously by all mammals (Panksepp, 2006). These core emotions elicit a particular 
feeling which guides the encoding of the value of interactions, that is: does the interaction 
contribute towards survival (positive affects) or hinder survival (negative affects). Although 
emotions are unconditioned, they are adaptive to experience and promote, via learning, the 
adoption of strategies (existing or new) that will ensure survival. The brain regulation of 
emotion is hierarchical. Panksepp (2011) differentiates between: primary processes 
(instinctual unconditioned stimuli and responses), secondary (conditioned emotional learning 
and memory), and tertiary (thoughts, reflexive awareness, abstraction) processes, which arise 
through neocortical interactions with paralimbic and limbic structures (Panksepp & Watt, 
2011b). Affects are distinguishable from emotional feelings in that they have an intense 
developmental influence on the more integrated cognitive mentation of adults. That is, 
affective experiences at a primary process level influence developments at a secondary and 
tertiary level (Panksepp & Watt, 2011b). These bottom-up processes have a significant 
impact on how we feel or think about our experiences. For example, feelings of loneliness 
and sadness could be cognitively elaborated manifestations of primary separation-distress. 
Moreover, affects start out without any particular connection to things in the environment; it 
is through experiential maturation that we become invested in objects in the world. Failing to 
achieve or sustain relationships with our desired objects causes us psychological pain which 
can, in some individuals, be the catalyst for the onset of depression. Human emotions are so 
varied and complicated that in order to gain a better understanding, we are compelled to go 
back to basics, that is, to the basics of emotion. 
Why the affective neuroscience model in particular? Since a major aim of affective 
neuroscience is to delineate primary-process consciousness into its various networks and 
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related functions, with a special focus on emotional feelings (Panksepp, 2004), it is a 
uniquely appropriate conceptual framework for studying the brain basis of depression. 
Psychiatric disorders cannot be fully understood without a fundamental grasp of the 
neurobiological essence of core affects, since neurochemical changes within these primordial 
emotion systems lead to changes in affect that are of psychological significance. The 
empirical value of this approach rests on two fundamental assumptions; firstly, emotions 
have been evolutionary preserved to do something specific in relation to biologically 
important and life-threatening events, and secondly, these emotions are felt as specific 
positive or negative feelings for the purpose of promoting behaviours that encourage survival 
and avoid destruction (Panksepp, 2005a; Zellner et al., 2011). The model is framed within a 
dual-aspect monism philosophy: core emotional behaviours and their subjective affects 
originate from the same subcortical neural dynamics (Panksepp, 2011). Unlike other models 
of emotion that focus either on purely top-down mental processes (psychoanalytically based) 
or on reductionist biological principles (psychiatrically based), the affective neuroscience 
model adopts a neuropsychological perspective, studying the mind and brain, where brain and 
mind are conceptualized as two different aspects of the same ‘thing’ (Solms & Turnbull, 
2002). In this regard, Hofer (2005) argues that evolutionary principles provide a common 
theoretical basis that can be shared by both neuroscientists and psychoanalysts. Affects are 
further distinguishable from emotional feelings in that the origin of regulation of affective 
consciousness is subcortical, whereas that of cognitive consciousness is neocortical. The 
neocortex is not implicated in the experience of core affects. Such a distinction allows for the 
integrated study of psychiatric illnesses from a joint neurobiological and psychological 
perspective, whilst recognising the complex interaction of affects and cognitions in adult 
psychology (Panksepp, 2006). 
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The affective neuroscience model stands apart from other models of emotion in that 
this approach relies on preclinical evidence to identify basic emotional networks in 
mammalian brains; affective mechanisms that are homologously identifiable in humans. 
Animal models lend themselves to levels of neuropsychological investigation that are more 
exact than the levels of analyses that can be achieved by human or brain imaging studies 
(Panksepp, 2014a). There is substantial cross-species evidence to support Panksepp’s claim 
that many affects arise from subcortical brain functions shared by all mammals (Alcaro, 
Panksepp, Witczak, Hayes, & Northoff, 2010; Damasio et al., 2000; Mobbs et al., 2007). For 
example, Buhle et al. (2013), using fMRI with normal participants, confirmed that the 
periaqueductal gray (PAG) plays an important role in human negative affect, supporting 
previous evidence from research in animals (Panksepp, 1998). However, this approach is not 
uncontested. Blumberg and Sokoloff (2001) argue that the use of ‘anthropomorphic’ 
reasoning in animal research is inappropriate. But there is categorical behavioural data for 
animal emotions; from Darwin (1872) who claimed that the difference between humans and 
other animals is one of degree and not of kind, to more recent research by Mendl, Burman, 
and Paul (2010), who showed that dogs who exhibited separation-type behaviour were also 
likely to be experiencing a negative affective state. More importantly, this model allows for 
predictions to be made about affective changes in humans following manipulations similar to 
those undertaken in animal research, since the tertiary processes that arise from separation 
distress in humans, such as shame or guilt, are founded on the more rudimentary processes of 
subcortical brain regions shared by all mammals (Panksepp, 2005b). 
Core emotion systems. Panksepp has identified seven primary-process emotion 
systems, namely: SEEKING, LUST, CARE, and PLAY (emotionally rewarding states) and 
FEAR, RAGE, and PANIC/GRIEF (emotionally punishing states), that can be elicited 
through activation of subcortical networks (Panksepp, 2014b). 
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The core emotion systems of depression. The separation-distress hypothesis of 
depression allocates a role to two, closely interactive, systems in the genesis of depression: 
SEEKING and PANIC/GRIEF. 
The SEEKING system is a positively motivated action system that when activated, 
encourages the organism to engage with the real world in order to satisfy its needs; it is a 
“foraging/exploration/investigation/curiosity/interest” system (Panksepp, 1998, p.145). 
Optimal functioning of this system leads to positive feelings of engagement, anticipation 
 
and excitement which mediate reward-learning. The mesolimbic dopamine (ML-DA) system 
is the principal neurochemical involved in the SEEKING system (Alcaro & Panksepp, 2011) 
DA is the main catecholamine in the mammalian brain and is implicated in inter alia: 
cognition (Nieoullon, 2002); emotional memory (Labar & Cabeza, 2006; Richardson, 
Strange, & Dolan, 2004); positive reinforcement (Tripp & Wickens, 2012); reward (Zweifel 
et al., 2009); fear (Carvalho, De Oliveira, Da Silva, & Brandao, 2009); regulation of 
locomotor activity (Medvedev et al., 2013); anxiety (Zarrindast & Khakpai, 2015); learning 
and choice incentives (Collins & Frank, 2014), behavioural arousal (Taylor et al., 2016) and 
depression (Lemke et al., 2006; Porcelli, Drago, Fabbri, & Serretti, 2011). Animal research 
has shown that a deficit in DA transmission in the ML pathway can lead to both helplessness 
and anhedonia (Nestler & Carlezon, 2006) and down-regulation of the SEEKING system 
leads to feelings of disinterest, apathy and hopelessness (Zellner et al., 2011). The ‘dopamine 
pleasure hypothesis’, originally proposed by Wise (1980), stipulated that DA was a 
mechanism for pleasure. More recently, however, and with particular reference to anhedonia, 
this view has been challenged in light of increasing evidence that loss of DA does not 
necessarily result in a loss of pleasure. In this regard, Berridge & Kringelbach (2015), argue 
that anhedonia should be interpreted not as ‘loss of pleasure’ but rather as a deficit in 
incentive motivation and that the role of DA in pleasure relates more specifically to ‘wanting’ 
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(mediated primarily by the NAc core) than ‘liking’ (mediated primarily by processes in the 
NAc shell; Saddoris, Cacciapaglia, Wightman, & Carelli, 2015). 
The ML-DA system is also often referred to as the “reward system”. But this is an 
overgeneralisation as mesolimbic DA also plays a role in aversive motivation (e.g. social 
defeat; Salamone & Correa, 2012). Furthermore, the word ‘reward’ is often used to refer to 
different things such as pleasure, learning, motivation or emotion. However, there are distinct 
aspects of motivation that are differentially influenced by DA. For example, accumbens DA 
does not mediate appetite (Smith, Berridge, & Aldridge, 2011), but is involved in appetitive 
and aversive motivational processes such as behavioural activation (Lex & Hauber, 2010), 
exertion of effort (Mai, Sommer, & Hauber, 2012) and approach behaviour (Nicola, 2010). 
Of particular significance in the context of this piece of research is that DA’s prominent role 
in reward is that it activates approach. Thus, it is important here to emphasise that it is the 
“euphoria of appetitive eagerness”, not the “pleasure of sensation”, that drives the SEEKING 
system (Alcaro & Panksepp, 2011, p.1807). 
Other neurochemicals, in addition to DA, are also implicated in reward (for example, 
GABAergic and glutamatergic mechanisms). For instance, opiates are self-administered into 
the lateral hypothalamic area and PAG, indicating that there are additional trigger zones for 
reward (Ikemoto, 2010). Although typically, substances of abuse exert their influence by 
increasing DA in the NAc, there is increasing evidence that endogenous opioids are also 
implicated in the rewarding effects of substances of abuse (Colasanti et al., 2012). To 
illustrate, the opioid receptor antagonist naltrexone has been used successfully for the 
treatment of alcoholism, as alcohol increases DA via its effects on opioids and GABA 
(Volkow, 2010). Furthermore, MOR availability has been found to be increased in the limbic 
brain regions of cocaine users (Ghitza et al., 2010). This interaction also effects the 
regulation of mood and motivation. 
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PANIC/GRIEF is a ‘bidimensional’ system that regulates social affect. It generates 
painful feelings associated with social loss and gratifying feelings associated with social 
inclusion. Interestingly, often the terms we use to describe the pain of a physical injury are 
also used to describe the pain we feel following a romantic breakup or some sort of social 
rejection. There is accumulating research to show that this might not be mere coincidence. 
Social and physical pain share overlapping neuroanatomy and some neurotransmitter 
substrates (Way, Taylor, & Eisenberger, 2009). The unpleasantness of physical pain is 
associated with various parts of the anterior cingulate cortex (ACC) and anterior insula 
(Peyron, Laurent, & Garcia-Larrea, 2000). These same parts of the ACC and anterior insula 
are also associated with social pain (Hadland, Rushworth, Gaffan, & Passingham, 2003). 
Eisenberger, Taylor, Gable, Hilmert, and Lieberman (2007) demonstrated how people who 
had close and socially supportive daily interactions exhibited less activity in the dorsal ACC 
and Brodmann's area. The importance of the ACC in mood regulation is widely reported. 
Mayberg et al. (2005) has shown that deep brain stimulation (DBS) of the white matter just 
beneath the ACC has significant antidepressant effects in refractory MDD. Better responses 
to cognitive behavioural therapy have been linked to ACC volume and functional 
connectivity with the fronto-parietal cortex in subjects with MDD (Sambataro et al., 2018). 
Dewall et al. (2010) demonstrated how acetaminophen (a physical pain reliever) lessened 
hurt feelings by reducing activity in brain regions involved in social pain processes (that is, 
the dorsal anterior cingulate cortex and anterior insula), confirming the overlap between the 
social and physical responses to pain. 
Along similar lines, we often use terms such as ‘warm and fuzzy’ and ‘heart- 
warming’ to refer to intimate experiences and this too is more than mere coincidence. Social 
and physical warmth may be closely related based on some shared neurocircuitry (Panksepp, 
1998). It is known that opioids mediate changes in body temperature (Adler, Geller, Rosow, 
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& Cochin, 1988). It has been shown that in humans, morphine can reduce the unpleasantness 
of noxious thermal stimuli and is implicated in the subjective experience of warmth (Morin, 
Duncan, Lavigne, Boily, & Bushnell, 1999). Imaging studies have shown that there is an 
overlap between neural activity during social and physical warmth in opioid-dense regions 
such as the insula and ventral striatum (VS; Inagaki & Eisenberger, 2013). More recently, 
Inagaki, Irwin, and Eisenberger, (2015) provided additional support that social and physical 
warmth share opioid dependent mechanisms, by demonstrating that naltrexone could reduce 
feelings of social connection in relation to a warm object but not to a cold object. Moreover, 
opioidergic blockade by naltrexone (an opioid antagonist) can reduce affiliative feelings such 
as cosy, comforting and secure (Schweiger, Stemmler, Burgdorf, & Wacker, 2014). 
At a neurochemical level, there is considerable preclinical evidence that opioids 
feature prominently in mediating social bonds. Separation distress circuits are closely linked 
to opioid-sensitive pain regulation (Panksepp, 2005a) since MOR agonists such as morphine 
have been shown to reduce separation-distress crying, while blocking the receptors with an 
opioid antagonist can induce separation distress behaviours in various animal infants (Nelson 
& Panksepp, 1998; Panksepp, 2004; Panksepp, Herman, Vilberg, Bishop, & De Eskinazi, 
1980). In various non-human primate studies, it has been demonstrated how exogenous 
opiates can act as a substitute for social contact and how blocking the MOR system 
encourages social interaction (Graves, Wallen, & Maestripieri, 2002; Martel, Nevison, 
Simpson, & Keverne, 1993). Even prosocial activities like play and grooming are associated 
with µ-opioid release (Loseth, Ellingsen, & Leknes, 2014). Likewise, in humans, social 
rejection activates the endogenous opioid system (Eisenberger, 2012b) and disruption of the 
MOR system affects the ability to form social bonds (Loseth et al., 2014). The role for MOR 
in response to negative affects related to social loss (Zubieta et al., 2003) and in social 
bonding and reward (Tops, Koole, Ijzerman, & Buisman-Pijlman, 2014) are evident. MOR 
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enhancement increases the seeking of high-value rewards (Taha, 2010) and is also implicated 
in sexual preference. In a recent study using male participants, Chelnokova et al. (2014) 
showed that facial attractiveness was increased by morphine and decreased by naltrexone. 
Reductions in µ-opioid neurotransmission in the rostral anterior cingulate have been shown to 
correlate with experimentally induced sadness states (Zubieta et al., 2003) and 
hypermetabolism in the same area is associated with a poor response to antidepressants in 
patients with unipolar depression (Mayberg et al., 1997).  Separate MOR mechanisms 
mediate positive (social acceptance) and negative (social rejection) affects (Hsu et al., 2013). 
Thus, the pleasant feelings of social contact (such as contentment and well-being) are induced 
by endogenous opioid release, while the unpleasant feelings, like separation distress, are 
associated with social isolation and are induced by opioid withdrawal (Panksepp, Herman, 
Conner, Bishop, & Scott, 1978b; Panksepp, Nelson, & Bekkedal, 1997). It is important to 
note that the different chemistries involved in mediating social interactions are very complex. 
Other than µ-opioid s, κ-opioids, δ-opioids, oxytocin, DA and serotonin are also involved. 
For instance, there is evidence that points to the possible involvement of the DA system in 
human mothering. fMRI studies have shown that the brain activity of mothers exposed to 
infant stimuli, coincide with regions of the mesocorticolimbic DA system (Barrett & 
Fleming, 2011). Mileva-Seitz et al. (2012) found an association between genetic variation in 
two DA receptor DRD1 and DRD2 and maternal responsiveness. Furthermore, MOR 
mechanisms interact with the DA system in reward processing (Colasanti et al., 2012) and 
with oxytocin and DA in social bonding (Tops et al., 2014). 
To summarise, the PANIC/GRIEF and SEEKING symptoms interact in the 
separation-distress hypothesis of depression in the following way: (a) sustained overactivity 
of the PANIC/GRIEF system (the protest phase, also known as separation distress) can, if 
prolonged, lead to a downward cascade of depressive affects or hopelessness; (b) the despair 
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phase that follows (and shuts down) protest, due mostly to underactivity of the SEEKING 
system, can lead to the chronic anhedonic states typical of depression; (c) the protest phase is 
associated with aroused DA-mediated SEEKING urges (i.e. attempts at reunion) and (d) 
kappa opioids partly mediate despair by shutting down SEEKING through their effect on 
ventral tegmental area (VTA) output. The sequence just described occurs in the context of 
normal bereavement (where the loss, despite protest, is not followed by a reunion) and 
depression is the pathological (excessive or maladaptive) engagement of this mechanism 
(Panksepp & Watt, 2011a; Panksepp, Solms, Schläpfer, & Coenen, 2014; Zellner et al., 
2011). The shutting down of protest by prolonged kappa opioid receptor signalling, is also 
coupled to sustained stress cascades (Knoll & Carlezon, 2010). These processes have a de- 
energizing effect on the SEEKING system. Essentially, in this condition, the organism is 
unmotivated, anergic and unable to experience pleasure -- feelings characteristic of 
depression. 
The purpose of this shutdown mechanism is survival: the termination of separation- 
distress vocalizations has been theorised to protect against predators, to ensure the juvenile 
does not wander too far from home-base and to preserve metabolic resources. There is an 
adaptive risk to remaining attached to an absent caregiver and hence the despair phase 
evolved to shut down the attachment seeking behaviours of protest (Freed, 2009). Shutdown 
mechanisms that are used in early separation-distress situations can be re-engaged by adults 
in response to social losses experienced later in life. Normally, these shutdown mechanisms 
are self-limiting, but in depression, it seems that the adaptive purpose of such mechanisms 
goes awry (Watt & Panksepp, 2009). People who are unable to “self-limit” are more prone to 
depression. The despair persists in these cases, leading to a stress cascade that becomes 
metabolically over-demanding (HPA axis activation; CRF effects; reduction of oxytocin and 
opioids; cholecystokinin, and dynorphin effects; hypoactivity in brain areas involved in 
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executive functioning; increased processing in limbic and paralimbic regions; BDNF 
decreases and hippocampal atrophy), along with the accompanying and inescapable 
symptoms of depressed affect. This leaves unanswered the question as to how some people 
are able to make a healthy recovery from mourning a loss, while others are unable to “self- 
limit” and remain chronically depressed. Zellner et al. (2011) argues that part of the answer 
relates to the extent to which a recent loss evokes feelings that relate to unresolved early 
losses. Certain types of losses, such as a child losing a mother or loss of a beloved partner, 
can be particularly painful leaving some people feeling especially vulnerable and exposed. 
The separation distress in these instances is often penetrating, and acceptance of the loss very 
hard to achieve. Another factor to consider is that of emotional resilience. Some individuals 
are more vulnerable to stress and cannot cope with even minor losses. They are more 
sensitive to the psychological pain of separation distress, possibly because of genetic 
susceptibility (Barr et al., 2008). 
DSM revisited. Before proceeding with a more detailed discussion of the 
PANIC/GRIEF and SEEKING systems, it is worth revisiting the DSM-5 classification of 
depression in light of the separation-distress hypothesis. Sadness and hopelessness are 
commonplace feelings that depressed patients use to describe their mood. Yet these 
symptoms are not adequately addressed in the current DSM-5 classification of depression and 
require further elaboration as they relate particularly to the separation-distress model of 
depression adopted here. Specifically, there are patients who report feeling depressed and 
sad, pointing to the fact that depression often comes after a loss of some kind. Some 
depressed patients on the other hand, do not report any feelings of sadness, supporting one of 
the central themes of the separation-distress hypothesis of depression, namely, that sadness is 
extinguished by worsening depression. Hopelessness, likewise, is closely related to 
depression. The feeling of not being able to go on, of ‘giving-up’ on the daily struggle, also 
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lends support to the separation-distress hypothesis in that depression must have some kind of 
constraining effect on motivational arousal systems, that is, the SEEKING system. 
Furthermore, a core criterion in the DSM-5 for MDD is loss of interest, specifically 
“markedly diminished interest or pleasure in all, or almost all, activities” (APA, 2013, p. 
160). Taking interest in the world and the rewards it has to offer is essentially linked to the 
operations of the SEEKING system (Watt & Panksepp, 2009). 
The PANIC/GRIEF system, the social bond and protest. Because of the 
fundamental survival value of social attachments, especially the bond between infant and 
mother, it is likely that the PANIC/GRIEF system was strongly selected for early on in 
mammalian evolutionary history, and possibly intensified in the hominoid brain (Watt & 
Panksepp, 2009). To this end, the exceptional regulatory capacities of these systems, quite 
conceivably an evolved extension of more basic homeostatic processes (Nelson & Panksepp, 
1998), far exceed simple conceptualisations of separation distress and attachment as being 
akin to operant functioning (Freed, 2009). Rather, they are an essential form of behaviour 
motivated by its own internal dynamics (Panksepp, 1998). Harry Harlow’s seminal 
observations on infant monkeys demonstrated that maternal bonding arises independently 
from the rewarding properties of other biological necessities such as food (Harlow & 
Zimmerman, 1959). These findings have been replicated in humans and other species and it is 
now well established that youngsters fail to thrive in socially impoverished environments 
(Panksepp, 1998). The central function of the PANIC/GRIEF system appears to be the close 
monitoring of social proximity, such that if separation occurs from an attachment figure, 
activity in this system encourages the seeking of reunion (Nelson & Panksepp, 1998). 
Activation of this system therefore requires that an attachment does indeed exist. Two key 
processes underlie this capacity: firstly, that attachment promotes a sense of security and 
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comfort, and secondly, that when broken, induces a particular kind of psychological pain and 
behavioural arousal, namely separation distress. 
The concept of attachment is well established in scientific literature, and is generally 
defined as a selective emotional or social bond, which appears to function as a ‘secure base’ 
for interaction with the environment (Ainsworth, 1989) and group cohesion (Smith, Murphy, 
& Coats, 1999). While social bonds are not always easily measured, a number of 
physiological correlates and behaviours index the existence of a secure attachment. Close 
physical contact is the hallmark of an attachment; for example, young rat pups will 
preferentially huddle around their mother (Kojima & Alberts, 2011) and bonded prairie voles 
share nests and remain side by side until death (Wang & Aragona, 2004). Allogrooming is 
another common behavioural display of social bonding (Saltzman & Maestripieri, 2011), 
involving the cleaning and maintenance of another individuals’ bodily surface as is 
commonly observed in primates (Dunbar, 2010). Visual tracking of the attached figure has 
also been used to index close affiliation (Kraemer, 1992). In humans, the ‘strange situation’ 
test, first introduced by Ainsworth (1989), in which a young child’s response to an unfamiliar 
situation is assessed, has become a landmark in human attachment research and is thought to 
reveal attachment styles with primary caregivers. However, across the field, reactions to 
separation, commonly referred to as ‘protest’ behaviours, constitute the core criterion against 
which an attachment is judged (Carter, 1998; Panksepp, 1998). 
During the acute protest phase, an infant will typically emit distress vocalizations and 
begin to search for its lost caregiver. In young mice, these ultrasonic calls tend to range in 
frequencies between 70 and 80 kHz and were described as ‘whistles of loneliness’ when they 
were first discovered in 1956 by Zippelius and Schleidt (1956). At this point already, these 
calls were understood to reflect both an adverse affective state and an attempt by the pup to 
commutate this distress to the mother. Indeed, caregivers of many different species readily 
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respond to these sounds (Bos, Hermans, Montoya, Ramsey, & van Honk, 2010; Nelson & 
Panksepp, 1998) and they have been clearly dissociated from other kinds of distress 
vocalizations (Panksepp, 1998). “Crying is the human homologue of the separation call” (Bos 
et al., 2010, p.114) and subserves a similar role in mother-infant bonding (Christensson, 
Cabrera, Christensson, Uvnas–Moberg, & Winberg, 1995). Infant separation calls seem to be 
mediated by neural systems similar to those that mediate anxiety in adult animals and humans 
(Hofer, 2005). In humans, however, real protest only occurs once the motor systems are 
developed and prior to this, crying behaviour is soothed by non-specific caregivers 
(Panksepp, 1998). Once the child reaches approximately six months, stable attachments begin 
to develop. The disappearance of the attached figure usually precipitates this distress 
response, and in rats is amplified if the pup is in unfamiliar surroundings (Pettijohn, 1979). 
Physical contact is not typically necessary at all times, but in the form of touch, it has been 
shown to be particularly effective in soothing distressed animals (Bermant, 1963) even 
though the relative proximity of the mother is enough in most cases for inhibiting PANIC. 
The affective valence of the PANIC/GRIEF system is experienced as psychological 
suffering, not simply as a metaphorical expression. This is because it appears to have evolved 
in part from brain mechanisms that mediate the perception of physical pain (Panksepp, 1998, 
2005a). From an evolutionary perspective, this is a reasonable proposition as humans are 
born entirely reliant on caregivers to provide for all basic needs, thus a painful symptom 
indicating that the caregiver bond is under threat, would essentially promote survival. Recent 
evidence from neuroimaging studies confirms this suggestion (Eisenberger, Lieberman, & 
Williams, 2003; Eisenberger, 2012a). It is known that social rejection and physical pain share 
common neuronal pathways (Kross, Berman, Mischel, Smith, & Wager, 2011), but it was the 
observation of the striking parallels between opiate addiction and social dependence that 
initially informed this impression (Panksepp et al., 1978b) in that the molecules which are 
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effective in alleviating physical pain are intimately tied to those that mediate psychological 
pain (Panksepp, 2010). 
Bereavement in adult humans provides an important window into the subjective 
reality of this kind of psychological pain, one that is very similar to protest behaviours 
described in the animal literature. In their comprehensive account of the processes of 
bereavement, Stroebe and Stroebe (1987) write: 
The initial numbness gives way to a period of strong emotions, with extreme 
psychological distress and physiological arousal as awareness of the loss develops. 
This is accompanied by intense yearning for the lost person, with pangs of deep 
pining, and spasms of uncontrollable sobbing. At this stage there is often an 
overriding urge to search for the deceased…The bereaved moves restlessly around the 
environment, searching, and is intensely, almost obsessively preoccupied with 
memories, thoughts and possessions of the deceased. Eventually …searching for the 
lost person is abandoned …the bereaved person despairs that anything worthwhile in 
life can be salvaged, and apathy and depression set in. (p.14) 
References here to ‘deep pining’, ‘uncontrollable sobbing’, ‘obsessive searching’ and 
‘despair’, establish important congruencies with animal models of separation distress. Terms 
like ‘agitated searching’, calling and ‘deep depression’ are commonly used to describe 
separation distress in infant animals (Kaufman & Rosenblum, 1967). Moreover, somatic 
distress, including sighing, respiration and a loss of strength, have also been described in the 
acute stages of loss (Lindemann, 1944), and are indicative of the systems-level dysregulation 
(panicked state) induced by the PANIC/GRIEF system. Subjective reactions to loss have 
been described as ‘painful’ (Bonanno & Kaltman, 2001), ‘shocking’ and ‘deeply saddening’ 
(Anderson & Dimond, 1995), always imbued with a deep sense of loneliness. While human 
research into the ancient sources of core affect are always confounded to some extent by 
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cognitive ruminations, the cross-species parallels in reactions to loss strongly indicate 
subcortical brain foundations of this affective state. We assign an intrinsic value to our own 
emotional experiences—they are felt to be positive or negative, rewarding or punishing, 
pleasant or unpleasant, and so forth. Likewise, there is considerable research into the 
affective states of animals, showing that animals too can suffer or experience pleasure 
(Boissy et al., 2007; Mendl, 2001; Mendl & Paul, 2004; Mendl, Burman, Parker, & Paul, 
2009). Moreover, there is conclusive evidence for the existence of experimentally evoked 
subcortical reward and punishment functions, providing substantial support for the idea that 
raw affective feelings are a product of ancient subcortical midline brain networks, and that 
these states also feel good or bad to animals. It is from these same brain areas that self-reports 
of particular affective experiences in humans can be elicited, and the descriptions of these 
feelings are analogous to the emotional behavioural patterns elicited in animals (Panksepp, 
2011). Subcortical stimulations (EBS) can elicit meaningful emotional behaviours in animals 
(emotional vocalizations) and humans alike (Panksepp, 1985). To illustrate, the 
PANIC/GRIEF system is highlighted by the density of glutamate, CRF and endorphin 
receptors that run between the midbrain PAG and dorsomedial thalamus, down to the ventral 
septal area, preoptic areas and bed nucleus of the stria terminalis, and in higher species, the 
anterior cingulate (Panksepp, 1998). Localized electrical stimulation of these brain regions 
has yielded similar findings in a variety of animals ranging from dogs and Guinea pigs to 
chickens (Panksepp, Herman, Vilberg, Bishop, & De Eskinazi, 1980). In humans, DBS of the 
anterior mid-cingulate cortex (aMCC) yielded feelings of anticipation of a challenge coupled 
with strong motivation to “overcome it” or as the authors described it, the “will to persevere” 
(Parvizi, Rangarajan, Shirer, Desai, & Greicius, 2013, p.1362). Feelings of apathy have been 
reported following DBS of the subthalamic nucleus (STN) in Parkinson's patients (Ricciardi 
et al., 2014). Furthermore, DBS studies also report that the ventral part of the STN is 
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implicated in the emotional valence of stimuli that is, in the representation of the affective 
value of the environment, and that DA enhances the processing of pleasant information (Buot 
et al., 2013). With regards to depression, DBS of the subgenual cingulate white matter have 
resulted in significant improvements of symptoms (Johansen-Berg et al., 2008; Mayberg et 
al., 2005). Coenen et al. (2011) reported similar improvements in depressed patients with 
DBS of the medial forebrain bundle. 
Panksepp and Watt (2011a) argue that it is sudden opioid cessation that contributes to 
the negative feelings in animals and humans that ensue after separation from attachment 
figures. For example, Naloxone, an opioid antagonist, increases distress vocalizations, which 
are effectively attenuated by morphine, even at extremely low doses (Herman & Panksepp, 
1978, 1981). The modulating effects of opioids operate primarily through µ-receptors, which 
are involved in reward processing (le Merre, Becker, Befort, & Kieffer, 2009); hedonic 
mediation (Smith & Berridge, 2007); positive affect (Negus et al., 1993), negative affect 
states (Kennedy, Koeppe, Young, & Zubieta, 2006), stress-associated behaviour (Bali, 
Randhawa, & Jaggi, 2015), memory (Iordanova, McNally, & Westbrook, 2006), and 
decision-making (Laurent, Morse, & Balleine, 2015). The intrinsic rewarding effects of µ- 
opioids have been demonstrated through the use of place preference and stimulation 
paradigms (Negus et al., 1993; Olmstead & Franklin, 1997). Opioids appear to exert their 
remarkable appeasing effects by re-establishing an affective state of social connectedness, to 
the extent that animals without this system are numb to the rewarding effects of maternal 
comfort (Moles, Kieffer, & D'Amato, 2004). Animals experiencing low opioid activity will 
actively seek out social connection (Nelson & Panksepp, 1998). Rodents kept in isolation 
consume more morphine compared to situations where social interaction is allowed 
(Consorti, Castellano, Oliverio, & Pavone, 1992). Social play in rats is heightened by low- 
dose morphine treatment (Trezza & Vanderschuren, 2008).  Increased levels of social 
45  
approach exhibited by rats experiencing periods of prolonged social isolation can be curbed 
by morphine (Hol, Ruven, Van Ree, & Spruijt, 1996). Taken together, these studies confirm 
that opioid-mediated circuits and social interaction are closely related and that the rewarding 
properties of morphine can be altered by changes in the social environment and that 
manipulating endogenous opioid systems in turns affects social interactions. 
To a lesser extent, prolactin, oxytocin and cholecystokinin have also been found to 
relieve separation distress (Panksepp, 1998; Weller & Feldman, 2003) but the major 
tranquilizers, which may at face value seem like an obvious candidate, have minimal effect 
(Panksepp, 1998). Neuroimaging studies in humans have now begun to contribute to the 
cross-species relevance of this body of literature, with evidence coming from positron 
emission tomography (PET) studies in which feelings of sadness, a variant of the social pain 
elicited by social isolation, have been associated with low opioid activity in the brain 
(Zubieta, Dannals, & Frost, 2003). Hsu et al. (2013, 2015) used positron emission 
tomography (PET) to demonstrate that µ-opioid receptor activation is ‘protective’ and 
implicated in reducing social distress and mediating social reward in human subjects. They 
showed that despite the negative affect of rejection, only healthy controls exhibited MOR 
activation whereas the depressed patients exhibited MOR deactivation and slower recovery 
from rejection, confirming that altered endogenous opioid activity is implicated in impaired 
emotion regulation. Yovell et al. (2016) showed that Buprenorphine, a partial µ-opioid 
agonist and kappa antagonist, significantly decreased suicidal ideation in severely suicidal 
patients. Furthermore, they made the tentative inference that ultra-low-dose Buprenorphine 
could be more effective in ameliorating feelings related to rejection and abandonment and 
less effective in addressing the symptoms of anhedonia. In terms of Panksepp’s theory, this 
translates to “attenuation of the hyperactivation of the endorphinergic PANIC/GRIEF system, 
without reversing the partial shutdown of the aminergic SEEKING system” (p.6). Lending 
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support to Yovell’s view, Bershad, Seiden, and de Wit (2016) demonstrated how 
Buprenorphine was linked to decreases in perceived social rejection, independent of any 
subjective feelings of euphoria. 
Of the key activators of PANIC episodes, glutamate and CRF appear to play a 
primary role (Panksepp, 1998). Studies have demonstrated that activating receptors for 
glutamate and CRF can elicit distress vocalizations (Panksepp, Solms, Schläpfer, & Coenen, 
2014). Hormones secreted by the HPA response, particularly cortisol, both initiate, and are 
released following separation and decline considerably upon reunion with the attached figure 
(Hennessy, 1997; Levine, 1994; Reite & Boccia, 1994). It has been shown that µ-opioid 
agonists reduce cortisol concentrations and stimulate prolactin and growth hormone (Hoehe, 
Duka, & Doenicke, 1988). Other physiological outcomes of the separation distress response 
include cardiac acceleration, alterations in temperature and sleep, generalized brain and 
behavioural arousal as well reductions in growth hormones (Hennessy, Deak, Schiml-Webb, 
Carlisle, & O'Brien, 2010; Hofer 2005), many of which are observed in human bereavement 
(Hofer, 1984), and which are argued to pose an increased risk of metabolic exhaustion for the 
distressed individual (Watt & Panksepp, 2009). To this end, when the biologically optimal 
outcome of reunion with the attached figure fails to occur, protest dissolves into a state of 
despair, signaling that the infant has ‘given up’ their pursuit. 
The despair phase, SEEKING system and depression. As previously mentioned, 
Bowlby (1973) noticed that an initial phase of separation anxiety was followed by an acute 
decline in behavioural responsiveness in maternally deprived infants. The process through 
which this termination of protest occurs appears to facilitate a withdrawal from all pursuits of 
normal rewards (Zellner et al., 2011). Tsiouris (2005) describes a kind of metabolic 
depression, marked by lethargy and negative affective tone, which is akin to a state of 
hibernation, and which underlies the vegetative symptoms of major depression. For instance, 
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during this second phase of social loss (despair), infant pig-tailed or rhesus macaques will sit 
hunched, cradling their bodies with their heads held low, droop the corners of their mouths 
and refrain from all play activities with the rest of the group (Keedwell, 2008). Similarly, 
young Guinea pigs submitted to extended isolation retreat into a passive, crouched stance, 
with their eyes closed and their hair on end (Hennessy et al., 2004). Maternal figures 
separated from their young also present with despair. Mother rats exhibit reduced mobility, 
indicative of poor coping, which subsequently impairs their normal maternal functioning 
(Boccia et al., 2007). 
The brain mechanisms of this shutdown process are less well known than those of 
active separation distress, but the sequel of neurophysiological events that characterise protest 
are acknowledged as the establishing factors in the subsequent development of despair 
(Hennessy, 1997), and which are now widely implicated in the genesis of depression. Of 
these factors, the activation of the HPA axis and the release of corticosteroids figures 
prominently (Hennessy, 1997), establishing social loss as a robust and indisputable 
psychogenic stressor. Cascade effects include the increased production of proinflammatory 
cytokines and lymphocyte proliferation suppression, both of which are associated with 
‘sickness behaviours’ in which animals display increased sleepiness and reductions in 
exploration and social or sexual activity (Hennessy, Kristopher, Caraway, Schiml, & Deak, 
2011). Two major neuropeptides, CRF and dynorphin, mediate exposure to stress (Nestler & 
Carlezon, 2006) in the following way: stress increases the release of CRF; CRF activation 
induces dynorphin release; dynorphin selectively activates κ-opioid receptor (KOR); KOR 
activation induces a negative affective state (Bali et al., 2015; Land et al., 2008; Van’t Veer & 
Carlezon, 2013; Van't Veer et al., 2013). The pathway via which stress exerts its effect on 
dynorphin production appear to be stress-induced cAMP response element binding protein 
(CREB) activation (Bruchas, Land, & Chavkin, 2010; Nestler & Carlezon, 2006) and the 
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release of DA (Preusner, Champagne, Meaney, & Dagher, 2004), perhaps via glutamate 
receptor stimulation (Suaud-Chagny, Chergui, Chouvet, & Gonon, 1992). Dynorphin is 
released in the striatum and NAc in response to DA activation of the D1 D2 DA receptor 
(Shippenberg, Zapata, & Chefer, 2007; Walker & Koob, 2008). This effect is sustained for 
some time following the cessation of stimulation, indicating that it may be a compensatory 
response to elevations in extracellular DA levels and may play an important role in 
counteracting the inflammatory effects of DA in these regions (Wang et al., 2012). Ultimately 
however, overproduction of dynorphin sustains a feedback loop to decrease DA transmission 
by inhibiting medial forebrain DA (Di Chiara & Imperato, 1988) and increasing DA 
transporter (DAT; Thompson et al., 2000), which is thought to account for the dysphoric 
effects of dynorphin, and which characterizes the despair phase. 
How precisely KOR systems influence mood is not yet fully understood but the 
prevailing opinion is that their effects are influenced by the mesolimbic DA reward circuit 
and KORs within this circuit directly regulate DA function and behaviour (Donahue et al., 
2015). KOR activation in the serotonergic neurons of dorsal raphe nucleus (DRN), the 
dopaminergic neurons of the VTA, and neurons of the NAc are all implicated in the stress 
response (Bruchas et al., 2010; Van't Veer & Carlezon, 2013), suggesting that dynorphin 
regulates mood by controlling serotonergic and dopaminergic inputs to the NAc, but these 
circuit mechanisms are not yet clear (Ehrich et al., 2015b). It is known that KOR agonists can 
induce dysphoria and anxiety in humans (Taylor & Manzella, 2016; Vortherms & Roth, 
2006) and that drugs with KOR antagonist activity have been shown to produce 
antidepressant activity in patients with MDD (Ehrich et al., 2015a). The relationship between 
dynorphin and dysphoria in animal models is likewise well documented. Repeated 
immobilization stress reduces motivational behaviour and correlates with dynorphin/κ-opioid 
changes (Lucas et al., 2011);   there are increases in dynorphin A and B in the hippocampus 
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and NAc during learned helplessness (Shirayama et al., 2004); prolonged stress can produce 
learned helplessness and dysphoria, which is attributable to an increase in dynorphin in the 
striatal region (Lucas, Dragisic, Duwaerts, Swiatkowski, & Suzuki, 2011) and lastly 
activation of dynorphin/κ-opioid receptor system leads to prolonged stress-induced 
depression-like behaviour in rodents (Land et al., 2008). It is also known that KOR agonists 
induce inhibition of DA signaling in the NAc in animal models. The infusion of KOR 
agonists into the NAc results in anhedonic and dysphoric behaviours in animal models 
(Muschamp et al., 2011), meaning that alterations in the expression of KORs in the NAc 
could possibly lead to long term changes in the function of the mesolimbic system. Studies 
have shown that without KOR, as seen in knockout mice, these animals function in a 
‘sensitized state’ in which the behavioural effects of psychostimulants are ineffective in 
altering behaviour demonstrating that dynorphin is critical in regulating the reward functions 
of the DA system (Chefer et al., 2005). What these various studies appear to suggest is that 
the effects are causal, that is, the aversive effects of KOR agonists are mediated by inhibition 
of NAc DA signaling. In relation to depression then, the down-regulation of the mesolimbic 
DA system may be linked to increased dynorphin signaling. This dynorphin-driven 
shutdown of SEEKING systems (i.e. ‘giving up’ in despair) may represent a subset of cases 
where loss of motivation is the most prominent feature (Zellner et al., 2011). Recently 
though, Ehrich et al. (2015b) demonstrated that the aversive effects of κ receptor activation 
required arrestin-dependent p38α MAPK activation in DA neurons but did not require 
inhibition of DA release in the NAc, which is contrary to the prevailing view that inhibition 
of mesolimbic DA release mediates the aversive effects of KOR activation. Although they 
confirmed that KOR activation does inhibit DA release in the NAc, they argued that KOR 
activation had other actions in the VTA-reward circuit and that aversion was not the result of 
a simple reduction in DA transmission. They further hypothesised that KOR activation in 
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different circuits could mediate different types of aversion, such as anhedonia, depression, 
dysphoria, or anxiety. 
The most marked feature of despair is a generalized behavioural and psychic lethargy, 
in which motivated engagement with the environment and the ability to actively cope is 
diminished. First discovered in 1954, Olds and Milner noticed that electrical stimulation to 
key brain regions, namely the lateral hypothalamic-medial forebrain trajectory, resulted in a 
‘reward phenomenon’ for which rats would repeatedly self-stimulate. Later on, Glickman and 
Schiff (1967) observed that stimulation of this same area produced species-typical 
engagement with the environment and it has subsequently been referred to as “the brain 
reward system” (Moriyama, Ichimaru, & Gomita, 1984), the “behavioural activation system” 
(Gray, 1985), and the “reward system” (Koob, 2009) in recognition of its role in learning and 
appetitive motivation. 
Conceptualised more recently as the SEEKING urge, Panksepp (1998) has brought 
attention to the intrinsic emotional properties of this system, which encompasses the 
continuum spreading from the VTA to the NA and is potently activated by DA, but many 
other chemistries too. In this region, DA is thought to promote high frequency gamma 
oscillations, emerging from deep limbic zones and diffusing across basal ganglia-thalamo- 
cortical circuits (Alcaro et al., 2007). The activity along this trajectory promotes a basic 
impulse with a positive hedonic tone to investigate and interact with the environment. This 
exploration activity is driven by a curious, energized, expectancy state in which organisms 
are motivated to make sense of their surroundings and anticipate its resource potential. For 
instance, research in rats has shown that motor and locomotor activity increases when 
animals enter a place of familiarity, or where previous social or rewarding experiences have 
been had. This activity involves excited sniffing and vigorous searching of oddities in the 
environment (Panksepp, 1998) and is accompanied by 50-kHz vocalizations, which are now 
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commonly accepted to reflect a positive internal state (Brudzynski, 2007) and also occur 
during other pleasurable activities such as during rough-and-tumble play (Panksepp, 1998). 
The administration of DA has been found to spontaneously induce this psychobehavioural 
response in rats, and is reversed by D1D2 receptor antagonists (O’Neill, Dourish, & Iversen, 
1991). Likewise, mesolimbic DA has been found to increase in response to novel 
unconditional stimuli (De Leonibus, Verheij, Mele, & Cools, 2006) and anticipation of 
reward. For example, in male rats, the sniffing of female urine stimulates DA in the NA 
(Malkesman et al., 2010). 
The vast majority of research done on this region has focused on phasic DA activity 
and its effects on learning and reward, as measured by self-stimulation and conditioned place 
preference paradigms (Alcaro et al., 2007). Rats rapidly learn to self-administer various 
chemicals that act on receptors in the DA system (Ikemoto, 2010), sometimes self-stimulating 
to the point of exhaustion (Panksepp, 1998). Correspondingly, they develop preferences for 
locations associated with DA administration (Spyraki, Fibiger, & Phillips, 1982), indicating 
learning via reward mechanisms. However, when DA transmission is blocked, these learning 
effects are mitigated (Wise & Schwartz, 1981). Of course, the addictive properties of 
psychostimulants such as cocaine and amphetamine underlie their initial allure for human 
subjects. Importantly though, this kind of reward has been differentiated from those that are 
associated with consummatory pleasures, which in fact, have been found to shut off neuronal 
SEEKING activity. For instance, in rats, recordings of electrical activity in this trajectory 
have shown that neurons aroused prior to the administration of food, shutdown during 
feeding (Hamburg, 1971). Instead, the ML-DA system appears to underpin appetitive drive, 
which ensures a global, but flexible, state of psycho-behavioural approach (Ikemoto, 2010), 
sustained by the formation of incentive representations (Ikemoto & Panksepp, 1999). Indeed, 
DA has been linked to active behavioural coping (Alcaro et al., 2007) and is thought to 
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underlie innately positive feelings of agency and engagement (Zellner et al., 2011), 
promoting expectant ruminations and positive excitement (Alcaro & Panksepp, 2011). 
The down-regulation of the SEEKING system that is characteristic of the despair 
phase of social loss, provides a brain model of depression that closely represents the 
subjective and physiological reality of the condition. In support of this hypothesis, there is a 
substantial body of evidence linking reductions in DA to animal models of depression, and 
which align the neurophysiological and behavioural phenotypes of despair with core features 
of a variant of clinical depression in which apathy and amotivation figure most prominently. 
Animal models of depression tend to be organised around the two major symptoms of 
clinical depression, namely, anhedonia and depressed mood, both of which have been linked 
to hypo-functionality in DA systems (Alcaro & Panksepp, 2011). Validity of these models 
tends to be judged on the basis of the efficacy of known antidepressant treatments, 
provocation by etiological factors thought to be involved in human cases, and finally, similar 
neurochemical foundations (Nemeroff & Owens, 2002). 
Dysregulation of neural activity along the SEEKING trajectory appears to underlie 
anhedonia and amotivation (Alcaro et al, 2007) and is markedly reduced in response to 
appetitive novelty and stress in behaviourally depressed animals (Harro, Kanarika, Matrova, 
& Panksepp, 2011; Stone, Lehmann, Lin, & Quartermain, 2007). Research has indicated that 
serotonergic and noradrenergic medications which alleviate depression in animal models 
exert their therapeutic effects via adaptations at the level of the mesolimbic DA system. For 
instance, chronic desipramine, a trycyclic antidepressant, has been shown to potentiate 
somatostatin-induced DA release in the NAc in rats (Pallis, Thermos, & Spyraki, 2001), 
while many others enhance the sensitivity of DA D2-like receptors in this same region, 
underlying their therapeutic efficacy (Gershon, Vishne, & Grunhaus, 2007). Repeated 
treatment with antidepressant drugs enhance DA agonist-induced locomotor hyperactivity in 
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rats (Maj, Rogóz, Skuza, & Sowinska, 1984). In animals, reduced response rates to electrical 
self-stimulation of DA-mediated reward sites or an increase in the amount of current required 
to sustain operant responses has been used to infer anhedonia (Anisman & Matheson, 2005). 
Failure to cope with unpleasant stimuli results in a syndrome of helplessness and  
motivational blunting, and is linked to reduced mesoaccumbens DA (Cabib & Puglisi- 
Allegra, 1996). These effects, most often induced experimentally by chronic stress, are 
attenuated by administration of treatments which systemically increase DA activity 
(Zacharko & Anisman, 1991). Other research has shown that this diminished reward 
responsiveness is underpinned by reductions in D2 DA receptor function in the NAc (Klimke 
et al., 1999) and applies equally to other natural rewards such as highly prized foods (Willner, 
Towell, Sampson, Sophokleous, & Muscat, 1987). Since DA release in the NA is implicated 
in motivation and reward, these findings are not surprising. The mechanism underpinning this 
phenomenon is likely the role of dopaminergic neurons in labelling and predicting the 
appetitive value of environmental rewards (Ikemoto & Panksepp, 1999), such that low DA 
transmission translates into a reduction of interest in the pursuit of cues that signal reward. 
This is consistent with numerous other animal studies showing that a reduction in DA reduces 
the willingness to work for reward (Salamone, Correa, Farrar, & Mingote, 2007). Also, drugs 
that act on DA transmission are effective in reversing the effects of Tetrabenazine, which 
alters effort-based choice in rats, making animals choose the lower effort activity. These 
findings lend support to the hypothesis that drugs that enhance DA transmission may be 
effective at counteracting effort-related depressive symptoms such as anergia, psychomotor 
retardation and fatigue in humans (Yohn et al., 2016). 
The presence of ‘depressed mood’ in animals has evidently posed a greater challenge 
for research models; however, the phenomenon of ‘learned helplessness’ has commonly been 
used to infer a state that most closely represents the human symptom of hopelessness that 
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forms part of this criterion. Here, hopelessness is thought to represent the inevitable sense of 
impotence that is experienced as part of the subjective reality of despair (Alcaro & Panksepp, 
2011) and in animals, is epitomized by a failure in active coping. The forced swim test in 
which animals are placed in an inescapable cylinder of water is a commonly used procedure 
to induce depressive-like states in rats. Although its validity as a proxy for psychological 
despair has been questioned (Holmes, 2003), studies indicate that circumstances that 
predispose a depressive state in humans commonly increase immobility in these tasks (Barr 
& Markou, 2005) and are associated with depletion of DA in the caudate nucleus and NA 
(Dunlop & Nemeroff, 2007). The experience of learned helplessness may be related to 
uncoordinated activity between the midbrain/diencephalon and the limbic forebrain 
(Shumake, Conejo-Jimenez, Gonzalez-Pardo, & Gonzalez-Lima, 2004) and furthermore, 
cross-species data show that areas known to actively inhibit activity in this network, are 
hyperactive in depressed animals (Alcaro et al., 2010). Furthermore, known antidepressant 
medications are effective in reinvigorating locomotor activity in the forced swim test 
(Thompson et al., 2004), an effect which appears to be mediated by activation of D2-like 
receptors (Barr & Markou, 2005) and which can be inhibited by D2 / D3 antagonists (Basso 
et al., 2005). 
The use of genetically vulnerable rodent strains is particularly important in animal 
models of depression, since in most human cases, MDD probably results from an interaction 
between environmental and genetic factors (Kendler, Neale, Kessler, Heath, & Eaves, 1992). 
Rats bred for a genetic vulnerability to depression, specifically, the Flinders Sensitive Line, 
who show anhedonia and other symptoms associated with depression such as reduced 
appetite and behavioural responsiveness, and increases in REM sleep, are known to have low 
extracellular levels of DA in key reward sites (Friedman et al, 2007) and display reduced 
mobility on the forced swim test (Overstreet, Pucilowski, Rezvani, & Janowsky, 1995). 
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Similarly, the C57BL/6 strain of mice, bred for their susceptibility to despair, show a much 
stronger activation of mesocortical DA metabolism in response to stressors, leading to an 
inhibition of mesoaccumbens DA release (Ventura, Cabib, & Puglisi-Allegra, 2002). These 
findings implicate a dysregulation of the stress-induced activation of cortical DA in 
predispositions to depressive states. The DA system is especially vulnerable to powerful 
homeostatic influences that exert compensatory effects for imbalances in DA levels (Belujon 
& Grace, 2015). Tonic DA controlled via prefrontal cortical glutamatergic afferents, and 
released in response to stress, determines the level of responsivity to phasic DA (associated 
with environmental reward). As such, chronic stress may be capable of reducing the 
amplitude of DA reward responsivity within subcortical sites (Grace, 1991), underpinning the 
observed reductions in motivation and interest in pleasurable activities seen in depression. 
Since the stress-facilitated release of tonic DA may function to support active 
psychobehavioural coping, consequently it is not observed in uncontrollable situations in 
which animals are compelled to ‘give-up’ in despair (Cabib & Puglisi-Allegra, 1996). The 
important role that VTA dopamine neurons play in mediating stress responses was reaffirmed 
by Chaudhury et al. (2013) who demonstrated neural-circuit-specific mechanisms of 
depression. That is, phasic activation of VTA neurons projecting to the NAc, promotes 
susceptibility to stress; optogenetic inhibition of VTA-NAc projection promotes resilience 
and inhibition of the VTA-medial prefrontal cortex (mPFC) promotes susceptibility. 
Moreover, longitudinal studies in rats have indicated that DA activation in the prefrontal 
cortex in response to chronic social stress during adolescence leads to higher density of DAT 
(dopamine transporter) in the infralimbic area of the medial prefrontal cortex which may 
underpin behavioural alternations observed in adult life (Novicka, Forstera, Tejani-Buttb, & 
Watt, 2011). DAT functions to clear synaptic DA and may therefore underlie the reduced 
levels of DA content reported in these regions. Preclinical studies show that exposure to early 
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life stress alters VS and NA DA responses to stress in later life (Jahng et al., 2010). This kind 
of research adds to the growing body of evidence implicating adolescence as a particularly 
vulnerable developmental period for the DA system (Caballero, Granberg, & Tseng, 2016; 
Wahlstrom, Collins, White, & Luciana, 2010); in particular, a developmental surplus 
followed by the pruning of DA receptors (in both humans and rats), and an alteration in the 
balance between mesocortical and mesolimbic DA systems (Spear, 2000). 
Moreover, increases in VTA DA neuronal activity, in particular with regards to NA 
projections, have been shown to predict social behaviour in mice (Gunaydin et al., 2014). 
More recently, Matthews et al. (2016), identified a functional role for DRN DA neurons in 
states of loneliness. Specifically, social contact following isolation resulted in an increase in 
DRN DA activity and that these same neurons were implicated in ‘rebound sociability’ 
following an acute period of isolation. 
Together, these findings position DA as a key mechanism in animal models of 
depression. Evidence from a variety of sources extends this idea to support the proposal that 
depression might best be conceptualised as a state of reduced activity in global SEEKING 
networks, as is observed following social loss in despair. However, since psychologically 
valid animal models can only be developed once the pathophysiological matrix of human 
depression is better understood (Nestler et al., 2002), this poses a great challenge for 
depression research. Nonetheless, investigations of the brain basis of depression in animals 
have provided an invaluable paradigm for directly manipulating variables that would 
otherwise be highly unethical in human subjects. Specifically, this line of research has 
contributed quite considerably in elucidating some of the proposed pathophysiological 
mechanisms underpinning the etiology of depression, in which aberrant DA activity emerges 
as a principal mechanism. Preclinical research has also generated a great deal of knowledge 
about emotional and stress-related changes in the brain that could not be obtained in other 
57  
ways. However, animal-based research cannot access the higher order and abstract thoughts 
that make up our complex and elaborate mental lives (Panksepp, 2010) and the core 
subjective features of MDD remain inaccessible in this line of investigation. More 
specifically, with regard to the current theoretical framework, the central psychic features of 
the SEEKING system will never be modelled successfully in nonhuman subjects, rendering 
animal models somewhat inadequate in this approach to depression. Although subjective 
feelings can be indirectly measured on the basis of affective vocalizations in animals 
(Panksepp, 1998), when it comes to unravelling the subjective experience of clinical 
depression, which in humans is a highly cognitive process, and within the current framework 
likely valenced with feelings of loss emerging from PANIC/GRIEF, animal models can be 
limiting (Watt & Panksepp, 2009). The insights derived from animal work must be endorsed 
in human research where self-reported changes and experiences can be recorded (Panksepp, 
2005c). Research in humans therefore has the advantage that subjects can uniquely express 
their feelings, making the diagnosis and monitoring of ‘depressed mood’ more reliable and 
valid. Human studies consequently have a fundamental role to play in triangulating findings 
in the field, and in fact, the evidence from the clinical research has paralleled many 
observations in the animal literature with regard to the dopaminergic hypothesis of 
depression. What follows is an overview of some of the clinical research trends on DA and its 
role in depression. 
Human research: Dopamine. Post-mortem studies point to changes in D2/3 receptor 
and lower DAT binding in the amygdala of depressed subjects (Klimek, Schenck, Han, 
Stockmeier, & Ordway, 2002) and decreased expression of D4 DA receptor messenger RNA 
in the lymphocytes in patients with MDD (Rocc et al., 2002). Reward processing is 
dependent on tonic DA levels and phasic DA in mesolimbic structures. The ability to assess 
the value of rewards and to anticipate future rewards has an effect on the motivation to 
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participate in goal-orientated behaviour (Zisner & Beauchaine, 2016). Thus, reward learning 
is often disrupted in depressed patients, in particular those with elevated anhedonic 
symptoms, and is a predictor of outcome (Vrieze et al., 2013). Tremblay et al. (2005) 
confirmed previous findings that MDD patients experience enhanced dextroamphetamine- 
induced rewarding effects (for example, euphoria and increased energy) compared with 
controls. The reward scores of patients in this study correlated with underlying changes in 
brain activity in DA-rich regions such as the prefrontal region, caudate and putamen. 
Furthermore, Grace (2016) reported that prefrontal cortical-amygdala hyperactivity reduces 
reward-related DA neuronal activity leading to anhedonia in depression. 
There is a substantial literature on DA and depression in patients with Parkinson’s 
Disease (PD). The depression that commonly accompanies PD is marked by an absence of 
gamma wave activity, thought to represent SEEKING impulses (Alcaro et al., 2007), in the 
basal ganglia-thalamo-cortical circuits (Brown, 2003). This absence of DA is corroborated by 
findings frequently reporting reduced levels of homovanillic acid, the main metabolite of DA, 
in the CSF of clinically depressed patients (Kapur & Mann, 1992; Reddy, Khanna, Subhash, 
Channabasavanna, & Rao, 1992). Dopaminergic and noradrenergic innervation of the VS is 
implicated in both endogenous and PD depression, and in particular apathy (Remy, Doder, 
Lees, Turjanski, & Brooks, 2005). The association between apathy and reduced striatal DAT 
levels in PD patients was again recently demonstrated by Santangelo et al. (2015). The lower 
DAT binding potential in striatal regions in depressed patients is consistent with a 
downregulation of DAT in response to a DA lowering process (Meyer et al., 2001). Frisina 
and Libow (2008) reported a seven times greater nigral neuronal loss in post-mortem brains 
of PD patients with depression compared to non-depressed PD patients. Furthermore, L-dopa 
treatment has been shown to improve motivation in some Parkinson's patients (Czernecki et 
al., 2002). Chong et al. (2015), demonstrated how DA improved motivational deficits in PD 
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patients by promoting willingness to exert effort. However, in a review by Jaunarajs, Angoa- 
Perez, Kuhn, and Bishop (2011), L-dopa treatments did not reliably improve affect in PD 
patients, and in some cases (Hanganu et al., 2014), affect was worsened. The authors suggest 
that this was possibly due to the depletion of NE and 5-HT levels consequent to DA 
processes. 
DA release in the VS in response to psychosocial stress is elevated in humans with 
poor quality early life maternal care. Pruessner et al. (2004) reported that exposure to 
psychosocial stress increased markers of extracellular DA in the VS in a manner that was 
correlated with increased cortisol release. Similarly, Oswald et al. (2014) showed that 
childhood adversity and high levels of perceived stress were each associated with higher VS 
DA responses to amphetamine. 
There are numerous studies that report promising results from deep brain stimulation 
in depressed patients. DBS of (a) the subcallosal cingulate gyrus in patients with treatment 
resistant depression (TRD) has resulted in significant decreases in depression scores at 1 year 
post intervention (Lozano et al., 2012); (b) the ventral capsule/ventral striatum, where 35% of 
TRD patients in a study conducted by Malone et al. (2009), remained in remission at an 
average of 37 months follow-up; (c) the NA, where the core symptoms of clinical depression, 
particularly anhedonia, were relieved (Bewernick et al., 2010). In a study by Schlaepfer et al. 
(2008) patients undergoing stimulation in this region spontaneously reported desires to 
engage in activities which had previously been considered pleasurable. Of note though, the 
authors described these phenomena as “unprompted behavioural responses” (p.372), 
indicating an essential neglect of the intrinsic motivational properties of feelings in these 
kinds of statements; and lastly, Schlaepfer, Bewernick, Kayser, Mädler, and Coenen (2013), 
reported that bilateral stimulation of the superolateral branch of the medial forebrain bundle 
was efficacious in rapidly reducing symptoms in TRD. In this instance, the easing off of 
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depressive symptoms argues Panksepp (2014b), is attributable not to aroused sensory 
hedonics, but to aroused states of enthusiasm, with resultant positive engagement in social 
activities. In this regard, Boccard et al. (2014) argue that brain stimulation contributes to an 
improvement in mood by attenuating negative affective states and (d) hypomania can be 
induced following STN DBS, along with the left-sided co-activation of the medial forebrain 
bundle (MFB) which leads to the activation of Panksepp’s SEEKING system (Coenen et al., 
2009). 
Human studies have also demonstrated a particular role for the VS in aspects of 
aversive motivation and learning. Specifically, war veterans with post-traumatic stress 
disorder showed increased blood flow in VS/NA in response to the presentation of aversive 
stimuli (e.g. combat sounds; Liberzon et al., 1999). Similar findings were reported by 
Niznikiewicz and Delgado (2011), who demonstrated that ventral striatal BOLD responses 
were increased during aversive conditioning to a primary aversive stimulus (shock) as well as 
monetary loss. Likewise, Baliki, Geha, Fields, and Apkarian (2010), reported that in normal 
subjects, phasic BOLD responses occurred both to the onset and the offset of a painful 
thermal stimulus. Elevated ventral striatal BOLD responses have also been reported in 
response to prediction errors regardless of whether the stimulus predicted rewarding or 
aversive events (Jensen et al., 2007), and aversive prediction errors have been blocked by the 
DA antagonist Haloperidol (Menon et al., 2007). Although many studies have indicated that 
mesolimbic-mesocortical DA activation correlates with loss aversion, Voigt, Montag, 
Markett, and Reuter (2015), reported that loss aversion could be related specifically to 
genetic differences in DA functioning. They found that subjects who carried the allelic 
constellation 66Met+/A1+, which is characterized by a relatively low D2/3 receptor binding 
in the striatum, displayed the lowest loss aversion. Furthermore, an improvement in apathy in 
brain damaged patients following treatment with DA agonists has been demonstrated by 
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Blundo and Gerace (2015). Along similar lines, Farinelli et al. (2013) showed that patients 
with lesions in the anterior medial subcortical-cortical regions, displayed lower SEEKING (as 
measured by the Affective Neuroscience Personality Scale (ANPS) and higher depression 
scores. Lastly, Volkow et al. (2007) reported that reduced DA activity in the caudate and 
limbic areas in adults with Attention Deficit Hyperactivity Disorder (ADHD) was associated 
with inattention. 
The role of DA in depression has and continues to be well-explored but what is clear 
from some authors is that they still adopt a fundamentally cognitivist appreciation of 
‘depressed mood’ in which feelings of hopelessness and worthlessness are attributed to 
neocortical structures (Nestler et al., 2002). The burden of a shift in this kind of corticocentric 
thinking is required and will rest upon new evidence clarifying the intrinsic intentionality of 
SEEKING dynamics, supporting the direct relationship between subcortical structures and 
subjective feelings (Alcaro et al., 2007). Human studies using pharmacological stimulation of 
SEEKING and PANIC/GRIEF networks are needed in order to corroborate the brain 
foundations of depressed mood, and aid tremendously in addressing the question of where the 
primal affective feelings of ‘worthlessness’, ‘hopelessness’ ‘despair’ and ‘emptiness’ might 
emerge. 
Pharmacological research and the subjective experience. Surprisingly, despite a 
considerable amount of research, the question of subjective feelings has not been adequately 
addressed. With regards to DA, much of the work has focused on the efficacy of DA agonists 
developed for treating clinical depression, and as such, relies largely on formal diagnostic 
criteria such as those stipulated in the DSM, and which do not look specifically at qualitative 
changes in subjective affect. Nonetheless, research has shown that many DA agonists, such as 
bromocriptine, bupropion, ropinirole, pramipexole and nomifensine have antidepressant 
effects (Treadway & Zald, 2011). For instance, chronic pramipexole treatment has been 
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shown to enhance the positive subjective effects (in particular, feeling stimulated) produced 
by cocaine (Newton et al., 2015) and to reduce the severity of depression and anhedonia in 
Parkinson’s patients (Lemke, Brecht, Koester, & Reichmann, 2006). More recently, Fawcett 
et al. (2016) reported favourable and lasting (16-month follow-up) clinical responses to 
pramipexole in 75% of their patients with treatment resistant depression. 
Descriptions of subjective effects are more commonly cited in studies on 
psychostimulants. Selective DA manipulations can alter subjective pleasurable responses 
(such as ‘arousal’, ‘elation’, ‘vigor’) to psychostimulant drugs as evidenced by self-report 
measures (Brauer & de Wit, 1996; Romach et al., 1999). This body of research has indicated 
that feelings of euphoria (amphetamine administration; Martinez et al., 2003) and 
arousal/stimulation (cocaine administration; Schlaepfer, Pearlson, Wong, Marenco, & 
Dannals, 1997), underpin their appeal in human subjects (Johanson & Uhlenhuth, 1980). 
Others have also reported sexual arousal, love, happiness, peace and a sense of connection 
(Cohen, 1995). Drevets et al. (2001) demonstrated how the euphoric response to 
dextroamphetamine correlated positively with the magnitude of DA release in the 
anteroventral striatum, demonstrating how a stimulated SEEKING system leads to an 
increase in “enthusiastic positive excitement”. 
Psychostimulants are known to exert their effects through the mesolimbic DA system. 
Specifically, their reinforcing effects are associated with increases in DA, especially in limbic 
areas such as the NAc, by either binding to the DA transporter to inhibit DA reuptake (as in 
the case of cocaine and methylphenidate), or to cause reverse transport of DA via the DA 
transporter (as in the case of amphetamine). Recent evidence also points to the involvement 
of non-dopamine transporter-mediated mechanisms of DA release by psychostimulants 
involving norepinephrine transporters in the prefrontal cortex (dela Peña, Gevorkiana, & Shi, 
2015). However, it is important to note that psychostimulants can also act on opioid and 
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serotonin systems (Soderman & Unterwald, 2009; Urban et al., 2012). Serotonergic networks 
are implicated in cocaine addiction (Burmeister, Lungren, Kirschner, & Neisewander, 2004) 
and methamphetamine can increase serotonin receptor levels (Berger, Gu, & Azmitia, 1992). 
There is also considerable evidence for the role of norepinephrine, GABA and glutamate in 
the subjective positive effects of psychostimulants (Zack & Poulos, 2009). This may partially 
explain why results from human studies do not consistently show that DA antagonists are 
successful in attenuating the subjective effects of d-amphetamine. For example, pimozide 
does not appear to inhibit the self-reported experience of arousal and elation following d- 
amphetamine administration in healthy subjects (Jacobs & Silverstone, 1986 in Brauer, 
Goudie, & de Wit, 1997). On the other hand, risperidone has been shown to attenuate some 
subject-rated effects of d-amphetamine, confirming the notion that monoamine systems do 
influence the behavioural effects of methamphetamine in humans (Rush, Stoops, Hays, 
Glaser, & Hays, 2003). Similarly, the DA antagonist ecopipam has been shown to attenuate 
the euphoric and stimulating effects of cocaine (Romach et al., 1999). 
Furthermore, many studies rely solely on established psychometric scales in the 
assessment of subjective feelings, such as, to mention but a few, the ‘Addiction Research 
Center Inventory’ (Jasinski, Johnson, & Henningfield, 1984) or behavioural measures such as 
the ‘Brief Psychiatric Rating Scale’ (Bossong et al., 2009). Others, like Rutledge, Skandali, 
Dayan, and Dolan (2015), use computational models to assess the subjective effects of DA on 
momentary happiness associated with the receipt of rewards. While findings of ‘vigor’, 
‘elation’, ‘arousal’ and ‘positive mood’ have been unequivocal across subjects in response to 
amphetamines (Johanson & Uhlenhuth, 1980), little room has been left for more qualitative 
accounts of self-reported emotional experiences. Moreover, many of these studies make use 
of retrospective data from regular drug users (Cohen, 1995), making inferences about the 
functioning of the normal DA system less generalizable. 
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With regards to opioids, the vast majority of research on the pharmacological 
properties of µ-opioids in humans has focused on their analgesic effects in the treatment of 
physical pain. Subjective effects have become a point of interest because of the potentially 
addictive consequences of opioid administration, and research here has reported that 
tramadol, a pain medication with moderate affinity for the µ-opioid receptor, enhances 
subjective ratings of ‘liking’ and feeling ‘high’, which have been linked to their reinforcing 
effects (Babalonis, Lofwalla, Nuzzob, Siegelc, & Walsh, 2013). Likewise, morphine and 
oxycodone, both mu agonists, have been shown to increase subjective feelings of being ‘in 
control’, ‘relaxed’, ‘sedated’, ‘carefree’ and ‘elated’ (Wightman, Perrone, Portelli, & Nelson, 
2012; Zacny & Lichtor, 2008). In contrast to most observations, some research has failed to 
report on the euphoric effects following µ-opioid manipulation. Wagner et al. (2010) 
observed an increase in negative affect following administration of remifentanil which is 
known to promote µ-opioid activity. These discrepancies might be accounted for by multiple 
opioid systems and that pharmacological manipulation will invariably affect many systems 
that are not related (Nelson & Panksepp, 1998). Sex differences have been reported in µ- 
opioid receptor concentrations, for example, deactivation of µ-opioid neurotransmission in 
NAc, in women, in response to painful stimuli (Zubieta et al., 2003). Furthermore, the 
menstrual cycle influences neuroendocrine responses to opiate manipulation (Hoehe et al., 
1988). 
As in the pharmacological literature on DA, most studies on opioids employ fixed 
response formats in the exploration of subjective emotional effects, and consequently, they 
are only as useful as the questions that they ask and the theoretical orientation of the 
researcher. This issue has been addressed to some extent in a study that investigated the 
antidepressant effects of Buprenorphine, which is a partial µ-opioid agonist that has κ-opioid 
antagonist properties, and subsequently prevents addiction (Bodkin, Zornberg, Lukas, & 
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Cole, 1995). Although assessments of clinical depression were measured using standardized 
criteria, the authors provided detailed, qualitative reports of the experience of participants’ 
remission from depression. These accounts indicated that buprenorphine was remarkably 
successful in promoting feelings of subjective well-being and alertness and improving 
sociability, goal-directed intent and behaviour and sleeping patterns. Additionally, they 
reported increases in feelings of ‘elation’, ‘friendliness’ and ‘vigor’ on the widely used 
Profile of Mood States. 
The significance of the Bodkin study is that it highlights the central role of social 
chemistries in the maintenance of depressive affect. Adopting this theoretical standpoint 
helps to interpret findings from studies reporting feelings of being ‘in control’ and ‘care free’ 
(Zacny & Lichtor, 2008), which may relate directly to brain affective systems that mediate 
attachment and social bonding, promoting feelings of security and social warmth. 
Furthermore, since µ-opioids have been shown to increase DA in the NA (Koob, 2008), this 
may underlie their stimulating effects on motivated goal-directed behaviour. 
To summarize, subjective reports of the chemistries that promote and antagonize the 
 
µ-opioid and DA systems are sparse and usually carried out within constricting experimental 
designs. There is therefore a pressing need for data that describes succinctly these human 
subjective homologues of established basic emotion systems. In other words, we need to 
establish in human subjects, that SEEKING will be able to counteract the psychic pain caused 
by a protracted and overactive PANIC/GRIEF system (Panksepp & Yovell, 2014). This data 
will contribute in an important way to understanding the uniquely human experience of 
clinical depression, which is typified by higher mental processes of rumination and the like 
that become layered upon the more basic, prototypical affect states that underlie mammalian 
despair, and which have informed, undoubtedly, by the current criteria by which we define 
the condition. 
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Psychodynamic Perspectives on the Subjective Experience of Depression 
 
Notwithstanding its many critics, the psychodynamic tradition has at least always 
taken seriously the subjective aspect of mental disorders. The classic text in the present 
context is of course Freud’s. As previously mentioned, Freud (1917) was the first to draw 
attention to the close similarity between clinical depression (‘melancholia’) and normal grief 
(‘mourning’). He suggested that mourning and melancholia are both responses to the loss of 
a love object. In mourning, the loss is clearly identifiable, and the mental work of grieving 
enables recovery from the loss. In time, the reality of the loss is accepted and clinging to the 
lost object ceases, as despair ends, enabling the process of finding a new object. However, in 
melancholia, the loss is not accepted or even fully acknowledged; ‘reality-testing’ remains a 
struggle and separation from the lost object remains incomplete. Thus, despair may persist 
indefinitely (in Freud’s theory, anger towards the ‘abandoning’ object is an additional major 
factor, but this aspect is not pertinent to the present study). 
Some have argued that the neglect of the critical mediating role of such abstracted and 
symbolic mental representations and systems of meaning in depression remains a 
fundamental challenge to the prevailing reductionist research enterprise (Blatt & Luyten, 
2009). It has long been recognized in the psychodynamic literature that the interpersonal 
interpretive mechanisms that process the self in relation to significant others, commonly 
referred to as internal working models (Bowlby, 1969), may constitute the fulcrum of 
depressive states. Self-monitoring or ‘conscious metacognition’ (Joensson et al., 2015) is 
partly regulated by DA. Indeed, recent findings from neuroimaging support these intuitive 
ideas, indicating that overactivity in the cortical midline structures (default mode network – 
DMN), specifically area 25 of the cingulate cortex, which are thought to be involved in self- 
referential processing, may contribute to depressive feelings. Specifically, these authors 
report that when activity in this area is inhibited, patients spontaneously report a sense of 
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social connection and warmth (Mayberg et al., 2005). Importantly, DA appears to help in 
deactivating the DMN (Delaveau et al., 2010; Tomasi et al., 2009). Moreover, acute stress 
leads to an increase in DA release in the prefrontal cortex (PFC) which in turn dampens DA 
release in the NA (Shippenberg, et al., 2007), whereas prolonged stress attenuates baseline 
DA release in the PFC (Goto, Otani, & Grace, 2007). The bi-directional nature of DA 
changes may provide a mechanism via which clinical depression is sustained. Thus, the 
implication here is that cortical-self-referential processes may play a prominent role in 
influencing DA activity via its role in stress-related DA activation in the PFC, and may also 
explain why, once the self is ‘impoverished’ (Freud, 1914), a cycle of depression is 
maintained in a synergistic fashion by both cortical and subcortical processes. Self-referential 
processing in this context is described by Northoff et al. (2006) as the ‘experiential self’, or 
‘core-self’, that is, the basic way in which we reflect on our own individual experiences, and 
this level of processing may be subserved by an even more fundamental and affective level of 
processing which relates to the subjective experience of internal and external stimuli. 
Neuroimaging studies show that self-referential processing is mediated by cortical midline 
structures, which are reciprocally connected to subcortical midline regions, and in particular, 
the anterior cortical midline structures which are implicated in depression (Lemogne, 
Delaveau, Freton, Guionnet, & Fossati, 2012). SEEKING is essential to self-experience as it 
promotes interaction with the external world, allowing for the objectification of internal 
needs (Alcaro & Panksepp, 2011). This could be linked with the ‘giving up’ response in 
depression, and with Bibring’s (1953) concept of ‘learnt helplessness’. 
Psychodynamically, all types of distress, including separation distress, lead to the 
enlisting of cognitive-affective schemas to mediate such distress (Blatt & Luyten, 2009). An 
analysis of the affective schemas that characterise the depressive mind may -- as such -- go a 
long way in elucidating the primary process emotions upon which they are elaborated. 
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The possibility must also be considered that the critical role of area 25 represents its 
connectivity not only with the SEEKING system but also (more directly, in fact) with the 
PANIC/GRIEF system itself. Panksepp (1998) summarizes the data implicating area 25 in the 
‘protest’ phase of separation distress. 
A shortcoming of the psychoanalytic tradition is the empirical gulf separating it from 
the mainstream of modern psychiatric and neuroscientific research on depression. Kandel 
(1999) proposed that one reason for this hiatus is that psychoanalysis has not adopted a 
scientific or empirically-based methodology to test its ideas, preferring to rely, in most part, 
on clinical observation alone. Psychoanalysis has not made any significant progress in 
relation to other disciplines of the mind because it has largely failed to subject its claims to 
experimental testing and consequently has now lost the influence it enjoyed in the first half of 
the twentieth century. Neuroscience on the other hand continues to make ongoing 
contributions to the study of the mind by identifying the biological basis for various 
conscious and unconscious mental processes. This hiatus however is now being filled by 
‘Neuropsychoanalysis’; an approach to the study of the mind of particular relevance to the 
present study, as it recognises not only the biological foundations of the affective mind but 
also that how we reflect on our individual experiences is subserved by such affective 
foundations (Solms & Turnbull, 2011). Solms (1997) and Kaplan-Solms and Solms (2000) 
pioneered this approach by studying the subjective effects of focal brain lesions using 
psychoanalytic methods and theories. Solms and Turnbull (2011) have made the point that, in 
principle, the same could be done using pharmacological probes (as opposed to lesions) to 
examine the subjective experience of psychotropic medications, which is what the current 
thesis explored. 
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Specific Aims and Rationale 
 
It is evident from the preceding review that a satisfactory model of depression has not 
been established, especially one that accounts for the ‘felt’ aspects of this disorder in relation 
to its neural underpinnings. It is, after all, the psychological pain of depression - the 
hopelessness, despair, and loss of motivation - that define it, rendering many individuals 
emotionally, and in some cases, even physically stuck. The separation-distress model of 
depression attempts to address this. It accounts for the way in which depression makes people 
feel by seeking to identify the specific changes from ‘protest’ to ‘despair’ that lead to the 
psychological pain and hopelessness associated with depression. It hypothesizes that two 
mechanisms are implicated in depression: a hypoactive SEEKING system, which can cause a 
lack of interest in life (‘despair’) and a hyperactive PANIC/GRIEF system, which generates 
psychological pain (‘protest’). Presently, this conceptualization of the brain basis of 
depression aligns with the clinical realities of the condition more closely than most (Solms & 
Panksepp, 2010). Even though there is abundant preclinical literature that supports the 
separation-distress model of depression, the core human experience of depression remains 
largely inaccessible in this kind of research. Animal research is foundational as it allows for 
predictions to be made about affective changes in humans following manipulations similar to 
those undertaken in this research. The human data that is currently available is minimal and 
not directly focused on the affective systems of SEEKING and PANIC/GRIEF. The present 
study aims to address this hiatus. 
The rationale underlying the current study was to pharmacologically manipulate the 
SEEKING and PANIC/GRIEF systems in humans for the purposes of (a) generating much 
needed subjective data that can corroborate the subjective states that could perforce only be 
inferred in the animal studies of separation distress and animal models of depression, and 
thereby contribute additional insights into the human homologues of the established 
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mammalian basic emotion systems. This should aid in identifying the neurochemical 
substrata of the primal affective feelings of ‘worthlessness’, ‘hopelessness’ ‘despair’ and 
‘emptiness’, which are so ubiquitous in depression; and (b) begin to assess the influence of 
‘attachment’ traits and separation/loss events in relation to the role of the SEEKING and 
PANIC/GRIEF systems in separation distress. Further insights into the affective dynamics 
that characterise the depressive mind would go a long way in elucidating the primary process 
emotions upon which they are elaborated, and the data generated from this study could 
potentially contribute towards understanding the uniquely human experience of clinical 
depression. Over and above the use of standardised psychometric measures, the study also 
employed psychoanalytic techniques to qualitatively explore how each participant 
experienced social loss following manipulation of the SEEKING and PANIC/GRIEF 
systems. 
The aim of this study was thus to examine the subjective effects of once-off doses of 
 
µ-opioid agonists and antagonists, dopamine agonists and antagonists, and a placebo, on 
certain psychological variables, in healthy volunteers. The emphasis of the study was to 
obtain structured self-report data (both quantitative psychometric data and qualitative 
psychoanalytic data) in relation to pharmacological manipulations of these affective systems 
– in other words, to obtain the sort of data that cannot be obtained in animal studies. 
 
Data collection was multi-levelled. In the broader context of the whole sample, the 
hypothesised medication effects on the psychological variables of SEEKING, 
PANIC/GRIEF, affective valence and mood were investigated using two approaches: (1) 
formal psychometrics (questionnaire-based), and (2) informal psychological probes (non- 
questionnaire-based). In the first approach, all four variables (SEEKING, PANIC/GRIEF, 
affective valence and mood) were psychometrically quantified, with specific reference to 
standardised questionnaires. In the second approach, that is, the psychological probes, the 
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qualitative aspects of some of the variables were further explored and measured. Participants 
were asked to describe the effects of the five medications upon their subjective state using 
their own words (‘free association’), to rate any subjective change in SEEKING and 
PANIC/GRIEF as defined by the investigator (‘directed probes’), and to rate any change in 
the degree of separation distress experienced when recalling personal memories of social loss 
(‘memories of loss’). 
The separation-distress constructs of ‘despair’ and ‘protest’ were in turn investigated 
separately. Since the despair phase of the separation distress model is the normal prototype 
for depression, the sample was split into High and Low depression groups based on the Major 
Depression Inventory (MDI) scores, where High ‘despair’ was operationalised as a relatively 
high score on the MDI and vice versa (i.e., High-MDI represents High ‘despair’). 
Since ‘protest’ represents a response to separation from an attachment figure, the 
sample was again split into High and Low-Avoidance and High and Low-Anxiety groups 
based on scores from an attachment questionnaire, the Experiences in Close Relationships- 
Revised (ECR-R) scale. The ECR-R has two sub-scales: avoidance and anxiety. Thus High 
‘protest’ was operationalised as High-Avoidance and/or High-Anxiety and vice-versa. 
The same four psychological variables (i.e., SEEKING, PANIC/GRIEF, affective 
valence and mood) were investigated in the High and Low ‘despair’ and ‘protest’ groups as 
in the whole (undivided) sample. Formal statistical analyses were carried out on this data. 
 
 
The following heuristic predictions were investigated: 
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For the whole sample. 
 
Hypothesis 1: A dopamine agonist (Madopar) will significantly increase SEEKING3 
and positive affect (PA) and significantly improve depressive mood (MDI) on psychometric 
testing, relative to baseline. Madopar will likewise increase SEEKING and improve affective 
valence and mood as qualitatively described during the psychological probes (directed 
probes, memories of loss and free associations). 
Hypothesis 2: A dopamine antagonist (Haloperidol) will significantly decrease 
SEEKING, increase negative affect (NA) and significantly worsen depressive mood (MDI) 
on psychometric testing, relative to baseline. Haloperidol will likewise decrease SEEKING 
and worsen affective valence and mood as qualitatively described during the psychological 
probes (directed probes, memories of loss and free associations). 
Hypothesis 3: A µ-opioid agonist (Morphine4) will significantly decrease 
PANIC/GRIEF3, increase PA and significantly improve depressive mood (MDI) on 
psychometric testing, relative to baseline. Morphine will likewise reduce PANIC/GRIEF and 
improve affective valence and mood as qualitatively described during the psychological 
probes (directed probes, memories of loss and free associations). 
Hypothesis 4: An opioid antagonist (Naltrexone) will significantly increase 
PANIC/GRIEF and NA and significantly worsen depressive mood (MDI) on psychometric 
testing, relative to baseline. Naltrexone will likewise increase PANIC/GRIEF and worsen 
affective valence and mood as qualitatively described during the psychological probes 






3As defined by Panksepp (1998). 
4 Morphine is primarily a µ-opioid receptor agonist, and acts to a lesser degree upon δ- and κ- 
receptors. Naltrexone is likewise most potent at the µ-opioid receptor. Levodopa acts on both 
D1 and D2 receptors and Haloperidol is a D2-preferring receptor antagonists. 
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For the split samples. 
 
Hypothesis 5: The magnitude of change for SEEKING, PA, NA and MDI on the 
dopamine-based medications will be significantly different between the low and high 
baseline-MDI groups (i.e. high and low baseline ‘despair’). The groups will likewise differ in 
relation to their psychological probes (directed probes, memories of loss and free 
associations) on the Dopamine-based medications. 
Hypothesis 6: The magnitude of change for PANIC/GRIEF, PA, NA and MDI on the 
opioid-based medications will be significantly different between the low and high baseline- 
ECR ‘anxious’ and ‘avoidant’ attachment groups (i.e., high and low baseline ‘protest’). The 
groups will likewise differ in relation to their psychological probes (directed probes, 








This was an exploratory study, with a double-blind, placebo-controlled, repeated- 
measures design. The outcome variables (SEEKING, PANIC/GRIEF, affective valence, and 
mood) were investigated in data derived from both formal psychometric measures (i.e. 
standardised questionnaires) and informal psychological probes (i.e., non-questionnaire 
based). The pharmacological intervention consisted of five conditions: µ-opioid agonist and 
antagonist; dopamine agonist and antagonist; and placebo. The study incorporated one group 
of healthy individuals who participated in all pharmacological intervention conditions. None 
of the participants met the diagnostic criteria for depression or anxiety disorders at the time 
participation in the study commenced. All participants were assessed both on and off 
medications (that is, at baseline). The order of administration of the pharmacological 
interventions and placebo (hereafter referred to as the medications) was counterbalanced, as 
randomization was not possible due to the small sample size. Likewise, the order in which the 
measures were presented was counterbalanced across participants. Both the participants and 
the psychoanalyst conducting the interviews were blind to the medications but not to the 
underlying study hypothesis (i.e., that depressive affect is linked with the dynamics of the 
separation distress system.). A quasi-experimental design was adopted in order to test 
descriptive causal hypotheses about pharmacological interventions in the absence of 
randomization. Specifically, this study was a “one-group pretest-posttest” study, a commonly 
used type of quasi-experiment (Harris et al., 2006). Quasi-experimental designs are useful in 
establishing potential associations (Thompson & Panacek, 2006). 
This project was undertaken by an assembled team of experts from different specialist 
fields to assist with various aspects of the study. Firstly, a registered psychoanalyst, Professor 
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Mark Solms (University of Cape Town; UCT), performed all the psychoanalytic sessions 
with the participants. This expertise ensured that the most pertinent data was derived from the 
participants’ subjective experiences and accounts whilst they were on the medications. 
Secondly, the team included a registered psychiatrist, Dr Tinus Brink (Panorama Hospital, 
Cape Town), who prescribed the medications to be administered and oversaw the drug 
administration process during data collection in order to ensure the health and wellbeing of 
the participants. The research team also comprised a qualified and experienced 
pharmacologist, Dr Georg Schoenbaechler (University of Zurich), who advised on the 
specific medication, optimal dosages to be administered and the optimal times at which each 
of the five medications were to be taken prior to the interview. 
Ethical considerations. Ethical approval for this study was granted by UCT (see 
Appendix A) and the study was conducted in accordance with the principles for research with 
human participants outlined in the Declaration of Helsinki (2008). Participation in the study 
required a great deal of personal commitment from each subject, both physical and 
psychological, which raised the issue of cost versus benefit of active participation. Most of 
the participants were members of professional psychoanalytic associations and were in 
private clinical practice (N = 10). The balance had undergone some form of psychoanalytic 
psychotherapy. They all had personal experience of the debilitating effects of depression – 
either through their patients or from their own lives – and were acutely aware of the 
limitations of current theories and interventions. Therefore, when presented with the 
opportunity to participate in a study designed to explore a novel approach to the 
psychodynamics and neurodynamics of depression, centered on the subjective experience, 
their scientific curiosity prevailed. Moreover, they were aware that their participation could 
potentially benefit others in future as the results of this study could contribute towards laying 
the foundations for new approaches to the pharmacological treatment of depression. Lastly, 
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the psychoanalyst who conducted the interviews was well known to all participants which 
greatly allayed their concerns relating to the disclosure of intimate experiences and 
confidential information. Every effort was made to minimize discomfort to participants and 
to ensure their wellbeing and a medical doctor was on call in the event that participants 
experienced any negative side-effect to one of the medications. 
Sample 
 
A purposive (also referred to as subjective) sampling approach was utilised to identify 
potentially suitable participants. This particular type of sampling strategy was necessary since 
a certain group of participants was needed who possessed specific skills (e.g., introspection 
and psychological vocabulary). Potential participants were mainly sourced from various 
professional psychoanalytic organisations. Other participants that were approached were 
individuals in private psychotherapeutic practice and individuals who, although not practicing 
psychoanalysts or psychotherapists, had been in psychoanalytic therapy for a considerable 
period. These individuals, one could reasonably assume, would be very familiar with the 
concept of introspection, the need for full disclosure, etc. This was an essential requirement 
since the lowest possible effective dose of each of the medications was given and each 
medication was only taken once-off. It was anticipated that the possible effects of the 
medications on mood would be subtle. It was therefore important that each of the participants 
would be able to utilise good insight into their own psychological functioning and, most 
importantly, would be able to discern and describe changes in their mood, and at the same 
time be able to articulate possible changes in rich qualitative detail. In short, participants were 
required who were ‘psychologically-minded’. Furthermore, all the participants that were 
approached to participate were previously known to the study’s psychoanalyst. The study 
required each participant to share intimate and, in many cases, painful information. The safe 
interpersonal relationship between the psychoanalyst and the participant was therefore crucial 
77  
to the success of the psychoanalytic sessions. In short, all the participants were familiar with 
the psychoanalyst, to varying degrees, and felt secure enough to share intimate details of their 
lives with him. 
Nineteen individuals were deemed suitable for inclusion and were willing to 
participate. There were two central inclusion criteria: (a) Participants were either practicing 
psychotherapists or had undergone their own psychotherapy and (b) they were physically 
healthy. Of these 19, three dropped out at various points post enrolment. 
Dropouts. In total, three of the 19 participants deemed suitable for inclusion dropped 
out at some point following the first induction session, of these, two were male and one 
female. The first male dropped out immediately following his induction session (i.e. prior to 
his first psychoanalytic interview session) because his partner did not feel comfortable with 
him participating in the study. The female participant withdrew after two of her 
psychoanalytic interview sessions for emotional reasons, as she reported that she could not, at 
that time, deal with the emotional effects that the study was having on her home life. Finally, 
the third participant withdrew from the study at the time of his first psychoanalytic interview 
session due to the nausea that resulted from taking the DA agonist. 
Final sample. 16 participants went on to complete the entire study: six males and ten 
females. The participants ranged in age from 21 to 58 years (Mage = 35±11.84 years). The 
average male was 30 years of age (SD = 5.79), while the average female was 38 years of age 
(SD = 13.60). 
Procedure 
 
Recruitment. All potential participants who volunteered for this study were recruited 
from the membership of either the South African Psychoanalytic Association, the 
International Neuropsychoanalysis Society, or the South African Psychoanalytic Initiative, 
and postgraduate students of the International Psychoanalytic University in Berlin, Germany, 
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or the Department of Psychology at UCT. The rationale for selecting these participants has 
previously been described. Participants were first contacted via email to ascertain whether 
they would be interested in participating. A brief explanation of the nature and the underlying 
hypothesis of the study was provided. Potential participants were also informed in this 
introductory email that, should they agree to participate, they would be administered once-off 
doses of four psychotropic medications in general clinical use and one placebo. Participants 
who expressed interest in participating were then sent a Health Screening Questionnaire 
(Appendix B), so that their physical suitability could be confirmed. The primary exclusion 
criterion was any participant with either a history of pre-specified medical conditions, or who 
was currently symptomatic, and who could potentially be harmed by any of the medications. 
These exclusion criteria were: (a) asthma, (b) respiratory or hepatic insufficiency, (c) serious 
medical conditions (such as renal, neurological, coronary artery disease, circulatory vascular 
disease, peripheral vascular disease; metabolic diseases; hormonal diseases), (d) any major 
psychopathology, including affective and psychotic disorders, (e) use of psychoactive 
medication, (f) previous head injury, (g) any other neurological condition, and (h) pregnancy 
or lactation. The Health Screening Questionnaires were anonymised and sent to a medical 
colleague for assessment. None of the individuals who expressed interest in participating 
were excluded on the grounds of a prohibitive medical condition. Participants were once 
again contacted via email to set up an appointment for the initial ‘induction’ session. The 
total number of sessions included one induction and five experimental/psychoanalytic 
sessions. All sessions took place in the Psychology Department at UCT. All sessions were 
audio recorded and the interviewing psychoanalyst also recorded, in writing, each of the 
sessions. 
Induction. The purpose of the induction session was threefold: (a) Completing and 
signing of the Participant Information Sheet (Appendix C) and consent forms (Appendix D), 
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(b) completing baseline psychometric measures, and (c) the recording of three memorable 
episodes of personal loss that each participant had experienced throughout the course of their 
lives. This session was conducted with each participant individually and in strict privacy, as 
were all the other sessions attended by the participants throughout the duration of the study. 
This induction session provided an introductory forum, where participants were briefed 
orally, in greater detail, with the aid of the Participant Information Sheet, about the nature and 
intended purposes of the study. They were also informed of the specific types of medications 
that would be administered. Throughout this session, participants were afforded the 
opportunity to ask any questions that they might have. This briefing process included 
emphasising how all the data to be collected would be kept confidential and that the 
anonymity of each participant would be ensured. It also involved emphasising to the 
participants how their participation was entirely voluntary and that they could freely 
withdraw from the study at any point in time. This was done with the aid of the consent form 
which each participant then signed. 
Stage two of the induction session required participants to complete four standardised 
questionnaires, described in detail in the ‘Materials’ section. These served as baseline trait 
measures. The questionnaires administered were the: ECR-R, ANPS, MDI, and the Positive 
and Negative Affect Schedule (PANAS). 
Similar to the protocol adopted by Zubieta et al. (2003), during stage three of the 
induction session, participants were instructed to focus on three autobiographical events 
associated with a significant personal loss (for example, the death of a loved one, a romantic 
break-up, loss of a job). These episodes needed to be established ahead of the five 
experimental/psychoanalytic sessions, and participants were advised that they would be 
required to mentally re-experience these episodes during the five subsequent experimental 
sessions. For this purpose, each of these three episodes were rehearsed and assigned a ‘key’ 
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title which was chosen together by the analyst and the participant. The purpose of the ‘key’ 
title was to act as a memory trigger of the particular episode for recall during all subsequent 
sessions. Stages one and two above were conducted by the principal investigator and stage 
three by the psychoanalyst. 
Following the induction session, five appointments were made with each of the 
participants for the experimental phase of the study. The time-span required to complete the 
five experimental sessions varied amongst the participants and was dictated mainly by their 
availability. The experimental sessions were booked at least one week apart to ensure that 
there were no possible interaction effects between the different drugs. Some participants were 
able to adhere to the pre-assigned weekly appointment schedule, but others had to reschedule 
some of their dates, thus the time-to-completion of the five experimental sessions varied from 
three to six months. Appointments were scheduled for a Saturday morning. The purpose of 
this was to firstly not interfere with any participant’s work commitments and secondly, to 
ensure that they would have the rest of the weekend to recover from any possible side-effects 
they might experience. The medications were delivered to each participant’s home the day 
before their scheduled session. Included with the medication were instructions about when to 
take the medication and an antiemetic, in the event that they experienced any nausea as a 
consequence of taking the medication. It was left to the discretion of each participant to 
decide whether the antiemetic was necessary. The time to take the medication was specified 
to ensure that it had its peak effect at the time of the session. These specified times varied 
according to the medication in question and ranged from one to three hours before the 
interview sessions. These times were determined by a qualified pharmacologist and were 
based on the time required for peak concentration to be reached after a single dose 
administration of each drug. The comfort and safety of the participants was our prime 
concern. For this reason, all 16 participants were fetched from their homes for each session 
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and were driven to the research venue, to ensure that they would not have to drive under the 
influence of the medications. Likewise, once they had completed their sessions, they were 
driven back home with express instructions to refrain from any strenuous activity and to not 
operate a vehicle for the remainder of the day. All participants were blind to the specific 
medication that they had taken for each of their sessions. Similarly, the psychoanalyst 
conducting each session was blind to the medication each participant was on, for each of their 
respective sessions. 
Experimental/analytic sessions. These sessions entailed two parts: an interview with 
the psychoanalyst and the completion of four standardised questionnaires. The order in which 
the participants completed these two parts was counterbalanced. These sessions were 
designed with two key purposes in mind. Firstly, they served to psychologically probe, 
qualitatively and via self-report measures (described below), through the session with the 
psychoanalyst, what the subjective state of the participants was under the influence of each of 
the psychoactive medications and the placebo. The second purpose was to quantify the 
emotional states of the participants using various standardised measures, which they also 
completed during this session (see ‘Materials’ section below). They were: the State Adult 
Attachment Measure (SAAM), the MDI, the ANPS (abridged, including only the SEEKING 
and PANIC/GRIEF items), and the PANAS. All of these were current ‘state’ (versus stable 
‘trait’) measures. Each session lasted approximately 45 minutes. 
Experimental/analytic protocol. Depending on the counterbalancing order, 
participants would, on arrival, either first complete the questionnaires and then proceed to the 
interview with the psychoanalyst or vice versa. 
The interview protocol proceeded as follows. The participant would be escorted to the 
office and welcomed by the psychoanalyst. Except for their first experimental session, the 
psychoanalyst would begin each session by doing a general follow up to ascertain how each 
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person felt during the day/s immediately following their last session. The purpose was to 
explore if participants experienced any delayed effects of the medication or if they had any 
further thoughts about or insights into their previous session. Participants were then asked to 
lie down on the psychoanalytic couch and were asked the open-ended question: “How do you 
feel right now, under the influence of today’s medication?” The purpose of this question was 
to encourage participants to freely associate and describe their current mental state in their 
own words, knowing that their current state was likely to have been altered by a psychotropic 
medication. Once this process was complete, the psychoanalyst proceeded with asking 
specific questions, the so-called directed probes, to ascertain whether participants 
experienced any changes in SEEKING and PANIC/GRIEF since taking the medication. The 
description of each directed probe was adapted from Panksepp (1998) and outlined below. 
Participants then had to describe their current affective state in relation to the specific probe 
and rate any changes on a Likert-type scale, ranging from 0 (no change) to +3 (the largest 
possible change). 1 was defined as ‘slight change’; 2 as ‘moderate change’ and 3 as ‘extreme 
change’. 
The following identical script was repeated to each participant, on each occasion: 
“The drug you have taken may have affected two emotion systems which 
neuroscientists call ‘SEEKING’ and ‘PANIC’. The emotions associated with these 
systems can be increased or decreased by the drug you have taken. Please describe 
how each of the following emotions has been increased or decreased, if at all: 
Increased PANIC would involve the following types of feelings (these are just 
examples): “Mental suffering or mental pain of the kind caused by the prospect or 
experience of separation, loss, or rejection; or the ensuing mental anguish, torment or 
distress caused by separation, loss, or rejection.” 
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The participant’s verbal response was recorded, and they were asked to rate the 
degree of change in ‘increased PANIC’ they felt following the medication, as detailed 
above. 
Decreased PANIC would involve the following types of feelings (these are just 
 
examples): “Feelings of safety and security; warm fuzzy feelings, like being loved 
and cared about; the feeling of being bonded or attached; and the associated feelings 
of being confident about the reliability of intimate others and durability of 
relationships.” 
The participant’s verbal response was recorded, and they were asked to rate the 
degree of change in ‘decreased PANIC’ they felt following the medication. 
Increased SEEKING would involve the following types of feelings (these are just 
 
examples): “Wanting to find or discover something; searching or looking for 
something; feeling inquisitive about or interested in something; actively looking 
forward to or anticipating something; being positive; being hopeful.” 
The participant’s response was recorded, and they were asked to rate the degree of 
change in ‘increased SEEKING’ they felt following the medication. 
Decreased SEEKING would involve the following types of feelings (these are just 
 
examples): “Despair or despondency caused by failure, separation, loss, or rejection; 
hopelessness or giving up; lack of drive or interest in the world; lack of positive 
expectation or anticipation; lack of enthusiasm and energy.” 
The participant’s response was recorded, and they were asked to rate the degree of 
change in ‘decreased SEEKING’ they felt following the medication. 
 
 
The order of the directed probes was counterbalanced. Thereafter, the participants 
were asked to “mentally travel back” or re-experience each of the three episodes of loss that 
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they had related to the analyst during the induction session. The order of re-experiencing of 
the three episodes was counterbalanced. The psychoanalyst would give the participants the 
key title of one episode as a prompt, ask them to re-experience this episode in their own 
minds, and this was then followed by the instruction to verbally describe and subjectively rate 
any change in emotional intensity since the previous time that they had recalled the episode. 
The change was rated on a scale, ranging from 0 (no change) to 3 (the highest possible 
change in intensity; see above for definitions). Once this scoring had been completed, this 
process was repeated for the second and third episodes. Finally, once all three episodes had 
been recalled by the participants, the psychoanalyst was required to record his prediction as to 
what substance he thought each participant had taken for each experimental session. 
At the end of the final psychoanalytic session with the analyst, each participant was 
thoroughly debriefed regarding the research process and each was reminded of the study’s 
overall goals and the fact that all the data that had been collected was strictly confidential. 
Each participant was then given the opportunity to reflect on their individual sessions and 





Prior to induction session. 
 
Health Screening Questionnaire. This questionnaire was sent to each potential 
participant to ensure that they were cleared to enrol on medical grounds. After receiving each 
participant’s completed questionnaire, they were anonymized and sent to the study’s 
psychiatrist for perusal and comment. 
During the induction session. 
 
Participant Information Sheet. This sheet provided detailed information regarding the 
nature and purpose of the study, along with relevant information about the substances that 
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would be taken. Here, it was clearly specified to the participants that the study would be 
investigating the effects that the four psychoactive medicines have on the brain, and that the 
key aims were: (a) to begin to systematically explore the subjective components of some 
basic emotion command systems that animal models have suggested may be relevant to the 
phenomena of separation, loss and attachment; and (b) to lay the groundwork for clinical 
exploitation of this knowledge for the treatment of emotional disorders. The Participant 
Information Sheet also explained that further requirements would be to complete a set of 
psychological questionnaires, and to participate in five psychoanalytic interviews with an 
experienced psychoanalyst. Finally, this sheet informed the participants that the interviews 
would be audio recorded. 
Consent Form. This emphasised that participation in the study was entirely voluntary, 
and that each participant could withdraw at any point without any consequences. It specified 
that all the data and personal information would be entirely confidential. It also served to 
check that each participant fully understood the aims and purpose of this study, and that they 
knew that they would be required to ingest psychoactive medicines and a placebo substance. 
The Affective Neuroscience Personality Scale 2.4 (Davis, Panksepp, & Normansell, 
2003). This scale is based on Panksepp’s research and his model of the basic emotion systems 
and was used as the basis for the directed probes and as a measure of key outcome variables. 
Seven of the primary-process subcortical brain emotion systems identified by Panksepp 
(1998) are SEEKING, LUST, ANGER, FEAR, CARE, PANIC/GRIEF and PLAY, and are 
considered as important foundations of the human personality. Therefore, the ANPS serves as 
a tool for the assessment of emotional personality by measuring how much of personality 
variability is related to the strengths and weaknesses of each of these six systems (Davis et 
al., 2003). It was designed essentially as a research tool with the aim of positioning the adult 
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human temperament within the primary-process affective systems of the brain (Davis & 
Panksepp 2011). 
The items on all the scales were developed in such a manner as to access feelings and 
actual behavioural inclinations rather than cognitive social judgments (Davis et al., 2003). 
The ANPS scale comprises 112 items in total. Each of the basic emotions is represented by 
14 items/statements. Filler items are included as validity checks. The ANPS displays good 
internal consistency for its scales, with reported Cronbach’s alpha values ranging from 0.65 
to 0.86 (Davis et al., 2003). With regards to construct validity, the ANPS has been compared 
with other models of personality, including the Five-Factor Model and Cloninger’s 
biobehavioural model of personality. The ANPS scores were found to co-vary with FFM 
scores: SEEKING with openness to experience, PLAY with extraversion, CARE with 
agreeableness, FEAR and SADNESS with neuroticism, ANGER with neuroticism and low 
levels of agreeableness (Barrett, Robins, & Janata, 2013). When comparing the ANPS to 
Cloninger’s Temperament and Character Inventory (TCI; Cloninger, Svrakic, & Przybeck, 
1993), Davis and Panksepp (2011) refer to an overlap between ANPS SEEKING and the 
TCI’s novelty seeking dimension, in that both are DA driven and appetitive. 
Experiences in Close Relationships-Revised (ECR-R; Fraley, Waller, & Brennan, 
2000). This measure is designed as a revision of the original Experiences in Close 
Relationships (ECR) measure that was first created by Brennan et al. (1998). The ECR-R was 
then compiled by Fraley et al. (2000). This tool is a self-report measure that is designed to 
assess adults’ attachment on two subscales of attachment, with the items divided into either 
the anxiety (i.e. fearing of being rejected and/or abandoned; the extent to which one feels 
secure vs. insecure about romantic relationships) and avoidance (i.e. disliking 
intimacy/closeness and not wanting to be dependent on people vs. secure dependence on 
others) subscales of attachment (Fraley et al., 2000). Security is thus defined as low scores on 
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both dimensions. The ECR-R is comprised of 36 items that were derived from the same 
group as for the original tool; 18 Likert-type items that assess romantic attachment anxiety 
and 18 items that assess romantic attachment avoidance. The findings of research that utilised 
an item response theory analysis of four different attachment measures were used to select the 
most appropriate items for the revised tool (Fraley et al., 2000). 
The various properties of the ECR-R include sound construct validity (convergent 
validity and discriminant validity), good test-retest reliability, and good internal consistency, 
with Cronbach’s alpha values over 0.90 (Fraley et al., 2000; Sibley, Fischer, & Liu, 2005; 
Sibley & Liu, 2004). ECR-R is preferable in conditions where subtle attachment effects need 
to be measured with limited statistical power (Sibley et al., 2005). A central principle of 
attachment theory is that attachment style in adulthood reflects earliest attachment 
relationships and attachment security is moderately stable across the first 19 years of life 
(Fraley, 2002). This measure was included in the study as attachment is central to the study’s 
central hypothesis that, assuming a pre-existing attachment bond, depression may be an 
abnormal variant of the normal mammalian separation response. 
The Major Depression Inventory (MDI, Bech, Rasmussen, Olsen, Noerholm, & 
Abildgaard, 2001) is a widely used a self-report measure that is used for assessing the 
symptoms of depression. It was developed by the WHO in conjunction with a Danish 
psychiatric research group (Bech et al., 2001). The MDI includes the symptoms of major 
depression in the DSM-IV and the ICD-10 mild, moderate, and severe depression (Bech 
Timmerby, Martiny, Lunde, & Soendergaard, 2015). Each symptom is rated on a six-point 
scale, allowing clinicians to assess not only the presence of a depressive disorder according to 
the DSM-IV and the ICD-10, but also the severity of depressive symptoms (by summing up 
the scores of all symptoms, with a range of 0 to 50; Bech et al., 2001; Olsen, Jensen, 
Noerholm, Martiny, & Bech, 2003). It also correlates with other scales that measure the 
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severity of depression, such as the Hamilton Depression Rating Scale (Olsen et al., 2003). 
The scores on the MDI range from 0 to 50, with scores between 20-24 indicating mild 
depression, between 25-29 moderate depression and scores over 30, severe depression. The 
optimal cut-off score for a diagnosis of Major Depression, as suggested by the authors, is 26 
(Bech et al., 2001). 
As far as its properties are concerned, the MDI has been found to display adequate 
internal and external validity, along with adequate sensitivity and specificity by the authors 
who developed it. Crohnbachs alpha for the MDI is 0.89, which indicates satisfactory 
reliability (Bech et al., 2001; Cuijpers, Dekker, Noteboom, Smits, & Peen, 2007; Olsen et al., 
2003). The question of depression is central to this study; hence the MDI was utilised both as 
a baseline measure to exclude MDD in participants and as a trait and state measure. 
The Positive and Negative Affect Schedule (PANAS; Watson, Clark, & Tellegen, 
1988). The PANAS measures both positive and negative affect and can be used for both trait 
and state affect. In terms of the dimensions of affect that the PANAS represents, one can 
distinguish between high PA, involving focus, energy, alertness, enthusiasm, and 
engagement, and low PA, characterised by lethargy and sadness. In contrast, high NA can be 
seen to involve fear, anger, guilt, distress, contempt, nervousness and disgust. Low NA will 
involve serenity and calmness (Watson et al., 1988). The PA dimension reflects a pleasurable 
engagement with one’s environment while the negative affect dimension reflects personal 
distress and unpleasurable engagement (Tuccitto, Giacobbi, & Leite, 2009). It has been 
reported that the NA, but not the PA dimension, significantly contributes towards predicting 
self-reported anxiety whereas both the PA and NA significantly contribute towards predicting 
self-reported depression. For example, presentations of anxiety would be characterised by 
high negative affect, while depression would feature low PA (Tellegen, 1985). Watson, 
Wiese, Vaidya, and Tellegen (1999) argue that dimensions of the PA and NA represent first- 
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person components of a more general biobehavioural system of approach (i.e., the positive 
emotional states of PA are viewed as goal-directed behaviours) and withdrawal (i.e. the 
negative emotional states of NA encourage cautionary behaviour). Furthermore, the PANAS 
scales show a significant level of stability over time (from ‘at the moment’ … to … ‘in 
general’), reflecting the strong dispositional aspect of affect in that one’s mood at a specific 
moment can reflect one’s general affect (Watson & Clark, 1988). During the induction phase, 
the PANAS was used as a trait measure and participants were thus instructed to ‘indicate the 
extent you have felt this way over the past week’ as opposed to ‘right now’. This measure 
served the purpose of establishing participant’s experience of affect at baseline and it 
measured the changes in affect after administration of each medication. The PANAS was 
included as a measure as it is frequently used to gauge changes in emotional states following 
drug intervention and it has been shown to retain its psychometric qualities even in substance 
abusers (Soskin, Carl, Alpert, & Fava, 2012; Younger, Zautra, & Cummins, 2009). 
The PANAS has good internal consistency, with Cronbach’s alpha values of 0.89 for 
PA and 0.85 for NA (Crawford & Henry, 2004). Similarly, Watson, Clark, and Tellegen 
(1988) report Cronbach’s alpha values of between 0.86 and 0.90 for PA, and between 0.84 
and 0.87 for NA. In terms of the tool’s discriminant validity, correlation values ranged from - 
0.02 to -0.18, while for it its convergent validity, the correlation values ranged from 0.89 to 
 
0.95 (Watson et al., 1988). The PANAS has also been shown to be reliable and valid 
according to Crawford and Henry (2004), who investigated its properties on a non-clinical 
sample of over 1000 individuals. Its test-rest reliability is sound, with values of 0.79 for PA 
and 0.81 for NA (Watson et al., 1988). Similarly, they report reliability values of 0.89 for PA 
and 0.85 for NA (Crawford & Henry, 2004). Finally, in terms of discriminant validity, its two 
subscales have been shown not to correlate with each other, with reported correlation 
coefficient values ranging between -0.12 and -0.23 (Watson et al., 1988). The positive 
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subscale of the PANAS ranges from 10-50 with higher scores indicating higher level of PA. 
Similarly, the scores on the negative subscale range from 10 – 50, with lower scores 
representing lower levels of NA. 
During the experimental/analytic sessions. Three of the same measures used during 
the induction session were re-administered during the experimental sessions: ANPS, MDI 
and PANAS, but this time as state measures. One new state measure, the SAAM, was added. 
The PANAS was administered in its original form as it is both a state and trait 
measure, except that the instruction to participants during the experimental sessions was to 
‘indicate to what extent you feel this way right now’, as opposed to ‘over the past week’. 
The instruction to participants for the MDI was changed to read: “The following 
questions ask about how you are feeling right now as opposed to how you have been feeling 
over the past week”. Each item was also changed to reflect the present tense. 
A truncated version of the ANPS (including only the PANIC/GRIEF and SEEKING 
subscales) was administered. The reason for this was that completing all 112 items on the 
original ANPS during an experimental session would be too time consuming. As previously 
mentioned, participants had to complete four questionnaires and an analytic interview in a 
time period during which a particular medication was at peak plasma levels. To capitalise on 
limited time, therefore, only two subscales of the ANPS – SEEKING and PANIC/GRIEF – 
the basic emotions of primary interest in this study, were included. The particular items 
belonging to each subscale were identified from Davis and Panksepp (2011). Furthermore, 
the wording of the individual items on these two subscales was amended in such a way that 
the questionnaire could serve as a measure of state changes, that is, measuring possible 
changes in feelings ‘at the moment’. For example: ‘I often feel sad’ (original item) was 
amended to ‘I feel more sad than usual’; ’I rarely think about people or relationships I have 
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lost’ (original item) was amended to ‘I could more easily now think about people or 
relationships I have lost.’ 
The State Adult Attachment Measure (SAAM). The ECR-R was used at baseline as a 
measure of adult attachment style. However, the ECR-R was explicitly designed to measure 
stable dispositions as it asks subjects to reflect on their relationships in general, and for this 
reason, the ECR-R could not easily be converted into a state measure by simply changing the 
wording or instructions (Gillath, Hart, Noftle, & Stockdale, 2009). The items on the ECR-R 
are also more likely to access cognitive representations of how people feel about their close 
relationships and these representations tend to be resistant to change (Greenwald, 1980). 
During the experimental stage of the study, we therefore administered an alternative 
attachment measure, the SAAM, as this is a state measure designed specifically to capture 
temporary fluctuations in thoughts and feelings. Unlike the ECR, the SAAM explicitly asks 
participants what they think right now about their attachment relationships (Bosmans, 
Bowles, DeWitte, De Winter, & Braet, 2014) and is therefore ideal for measuring fluctuations 
in attachment (Xu & Shrout, 2013). Although attachment style is considered relatively stable 
(Fraley, 2002; Simpson, Collins, Tran, & Haydon, 2007), several authors have suggested that 
notwithstanding its stability, attachment can also be influenced by major life events 
(Cozzarelli, Karafa, Collins, & Tagler, 2003) and diverse contextual factors (Gillath & 
Shaver, 2007). Attachment styles can be impressionable for very short periods of time such as 
minutes or hours. For example, reminding someone of a time when they have felt secure or 
anxious can momentarily override a stable attachment disposition by affecting their 
perceptions and behaviours (Baldwin, Keelan, Fehr, Enns, & Koh-Rangarajoo, 1996). Hence 
the SAAM was administered to measure any fluctuations in attachment style caused by the 
medications. Importantly, it has been demonstrated that the SAAM displays convergent and 
discriminant validity with the ECR (Gillath et al., 2009; Xu & Shrout, 2013) and to have a 
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high three-month test-retest reliability. Gillath et al. (2009) report test–retest reliability as 
being in the range of .51–.59 for each of the subscales. There are three subscales to the 
SAAM: state security, which reflects feelings of trust and approval; state anxiety, the extent 
to which one experiences the need to be closer and accepted; and state avoidance, which is a 
disinclination to intimacy and closeness. All the SAAM subscales have adequate reliability 
ranging from .83 to .87 and Bosmans et al. (2014) demonstrated that SAAM scores are 
sensitive to priming effects. 
Medications. In total, each participant was administered five different substances 
(four being psychoactive drugs, and one a placebo substance) over the course of their 
participation. All these substances have been shown in previous clinical studies to be safe and 
well-tolerated in human subjects. 
Opioid antagonist. Naltrexone Hydrochloride (Naltima-50, Intas Pharmaceuticals) is 
a long acting competitive antagonist at opioid receptors with negligible opioid agonist 
properties, commonly used to treat alcohol and opioid dependence. It has a high affinity for 
µ-opioid receptors (Littleton & Zieglga¨nsberger, 2003) and acts by inhibiting DA neurons 
within the VTA and reducing DA function within the NA (Kim, Grant, Adson, & Shin, 
2001). Carmen, Angeles, Ana, and María (2004) reviewed 33 published studies published 
from 1990 to 2002 on the use of Naltrexone for alcohol dependence and found that 
Naltrexone was safe and acceptably tolerated. Dosages of Naltrexone ranging from 25- to 
100-mg have been used in clinical studies (Farren et al., 1999). A dose of 50-mg was 
administered to participants in this study. This dose has been proven in numerous clinical 
trials to be well-tolerated (O'Malley et al. 1992; Schmitz, Stotts, Rhoades, & Grabowski, 
2001; Volpicelli et al., 1997) and most research on the use of Naltrexone for alcoholism have 
administered a dose of 50-mg. This dose is also optimal for opiate-receptor blockade (Saitz & 
O’Malley 1997). The effective half-time for return to baseline opiate receptor occupancy of 
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50 mg of Naltrexone is 72 to 108 hours (Myung et al., 1988). Following oral administration, 
Naltrexone undergoes rapid and nearly complete absorption with approximately 96% of the 
dose absorbed from the gastrointestinal tract. Peak plasma concentrations occur at one hour 
and plasma terminal half-life at two to six hours (King, Volpicelli, Gunduz, O'Brien, & 
Kreek, 1997). 
The most common side-effect of Naltrexone at a 50-mg dose is nausea (Berg, 
Pettinati, & Volpicelli, 1996; Carmen et al., 2004). Other, less common, side effects of 
Naltrexone include vomiting, headache, light-headedness, anxiety, fatigue, skin tingling, 
stomach cramps, irritability, dizziness and nervousness (Farren et al., 1999).  The incidence 
of nausea is more common in women and participants of a younger age (O’Malley, Krishnan- 
Sarin, Farren, & O'Connor, 2000). To combat the possibility of Naltrexone-induced nausea, 
participants were instructed to take their dose with a meal (Rohsenow et al., 2000). 
Depression has also been reported as an adverse effect as Naltrexone blocks the positive 
effects associated with opioid peptides. However, there is conflicting evidence as to whether 
depression or dysphoria are clinically important adverse effects of Naltrexone. Mendelson, 
Ellingboe, Keuhnle, and Mello (1978) administered a single dose of 50-mg of Naltrexone to 
seven healthy adult males, with no history of opiate abuse. All subjects reported that 
Naltrexone produced dysphoric effects. Since then, other studies have also described 
depression or dysphoria as a side effect of Naltrexone in healthy volunteers (Hollister, 
Johnson, Boukhabza, & Gillespie, 1981) or opioid-free former addicts (Crowley, Wagner, 
Zerbe, & MacDonald, 1985). On the other hand, Dean et al. (2006) administered 50-mg of 
Naltrexone to subjects with opioid dependence for a period of one year and reported that 
depression was not a common adverse effect of Naltrexone treatment. A review published by 
Miotto, McCann, Basch, and Ling (2002) on the use of Naltrexone in alcohol, opioid, and 
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nicotine studies, concluded that dysphoria was not a serious side effect of Naltrexone. 
Participants took their Naltrexone one hour prior to their experimental sessions. 
Opioid agonist. MST Continus (morphini sulfas pentahydricus), a type of slow- 
release morphine, was used in this study. Morphine is primarily a µ-opioid receptor agonist, 
and to a lesser degree δ- and κ-receptors. It is metabolized into several metabolites; the major 
metabolic pathway of morphine includes the formation of morphine-3-glucuronide and 
morphine-6-glucuronide (M6G). The analgesic property of M6G is achieved through direct 
interaction with opioid receptors; M6G has a high affinity for µ1-opioid receptors (Janicki, 
1997). Slow-release morphine tablets reach peak concentration in three hours and are 
sustained for 12 hours (Yang, 2002). Participants were instructed to take MST Continus three 
hours prior to their experimental session. 
Variable dosages of MST Continus have been used in clinical studies involving 
healthy volunteers: 20-mg (Leslie, Rhodes, & Black, 1980), 30-mg (Westerling, Persson, & 
Höglund, 1995) and 90-mg (Bloomfield et al., 1993). Participants in the current study were 
administered 10-mg of MST Continus, a dose commonly given to healthy volunteers (Babul 
& Darke, 1993; Hoskin et al., 1989; Osborne, Joel, Trew, & Slevin, 1990). 
As to the question of the effects of food on morphine absorption, the data for MST 
Continus is contradictory, with some studies reporting no difference in maximum drug 
plasma concentration (Cmax) and time to reach maximum drug plasma concentration (tmax) 
between the fed and fasted states (Kaiko et al., 1990), while others (Drake et al., 1996), report 
that food consumption does affect the rate and extent of morphine absorption. A review 
published by Collins, Faura, Moore, and McQuay (1998) concluded that there was no 
difference in Cmax and tmax between fed and fasted healthy volunteers. In other words, there 
was bioequivalence under the fed and fasted conditions. Participants were thus encouraged to 
take their medication with food. 
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Commonly reported side effects of morphine include nausea, emesis, dizziness, 
pallor, diaphoresis, headache, pruritus and fainting. Other effects such as sleepiness, 
euphoria, dry mouth, vision disturbance, relaxation and dizziness have also been reported 
(Pud et al., 2006) At a dose of 90-mg of MST Continus, specific adverse effects that have 
been reported are somnolence, dizziness, dry mouth, pruritus, asthenia or headache, and 
nausea (Bloomfield et al., 1993). A concern in the current study was the sedating effects that 
Morphine could have on the cognitive demands of the behavioural tasks participants were 
expected to complete. Although opioids as a class of drugs generally do not significantly 
impair cognitive and psychomotor performance (Zacny, 1995), reported findings in the 
literature are highly variable. Some studies report impairments on memory tasks. Cleeland et 
al. (1996) found long term memory deficits in healthy volunteers on a 30mg dose of oral 
morphine. Kamboj, Tookman, Jones, and Curran (2005) found both an anterograde and 
retrograde aspect to memory impairments following morphine. However, subjects in this 
study were palliative care patients receiving chronic oral morphine. In contrast, and of 
relevance to this study as identical doses were used, Friswell et al. (2008) looked at the 
memory performance of healthy volunteers on 10-mg of morphine and found no significant 
effects on anterograde and retrograde memory performance. Similarly, Walker and Zacny 
(1998) found that doses of 40-mg of morphine did not produce significant psychomotor and 
cognitive deficits, including memory. Even on doses as high as 45-mg, no deficits on tasks 
measuring reaction time, eye-hand coordination, logical reasoning and short-term memory 
have been reported (Hanks, O Neill, Simpson, & Wesnes, 1995). Sex hormones may have a 
modest influence on opioid responses (Ribeiro-Dasilva et al., 2011; Zacny, 2001). Women of 
reproductive age have higher µ-opioid receptor binding values than men (Zubieta et al., 
1999). Reports on sex differences with respect to adverse effects are variable. Some studies 
report that women experience a significantly greater number of side effects than men, such as 
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nausea and emesis (Fillingim et al., 2005) and feeling “spaced out”, “sluggish” and “dry 
mouth” (Zacny, 2001). Others, like Gupta et al. (2014) found that sex differences did not 
significantly affect the likelihood of experiencing side effects with morphine. 
Dopamine agonist. As exogenous DA cannot cross the blood-brain barrier, the 
physiological precursor, Levodopa (L-DOPA), was administered. Once it crosses the hemato- 
meningeal barrier, L-DOPA is transformed into DA by dopa-decarboxylase. Madopar is the 
trade name for L-DOPA used in this study. Madopar contains L-DOPA (200-mg) and 
Benserazide (50-mg). L-DOPA acts on both D1 and D2 receptors (Schapira et al., 2006). 
Benserazide is a peripheral inhibitor of DOPA decarboxylase that prevents DOPA from being 
metabolized to DA in the blood (Rihet, Possama, Micallef-Roll, Blin, & Hasbroucq, 2002). 
The dose of 200-mg L-DOPA and 50-mg benserazide used in this study has been shown to 
have significant behavioural effects in healthy subjects (Hitz et al., 2012; Keller et al., 2011; 
Micallef-Roll, Rihet, Hasbroucq, Possamai, & Blin, 2001; Rihet et al., 2002). The 
experimental sessions started 60 minutes after oral intake of Madopar - a time that has been 
demonstrated to reflect peak plasma concentrations of the drug (Eisenegger et al., 2010; Flöel 
et al., 2005). 
Common side effects of L-DOPA are drowsiness and nausea (Koller, Hutton, Tolosa, 
& Capilldeo, 1999; Rihet et al., 2002), vomiting, dizziness, fatigue (Buhmann et al., 2003; 
Liggins, Pihl, Benkelfat, & Leyton, 2012) and dyskinesia (Koller et al., 1999). Side-effects in 
healthy volunteers on doses of Madopar identical to the ones used in the current study are 
mild tiredness, headache (Gasser, Crevoisier, Ouwerkerk, Lankhaar, & Dingemanse,1998) 
and nausea (Gasser et al., 1998; Haslinger et al., 2001). 
Once again, reports on the effects of food consumption on L-DOPA are variable and 
illustrate the unpredictability of drug-food interactions (Gillespie, Mena, Cotzias, & Bell, 
1973). High protein meals have been shown to have a negative impact on the clinical 
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response to levodopa in Parkinson’s patients (Tsui et al., 1989). On the other hand, it has also 
been shown that there is poor bioavailability of L-DOPA following low-protein meals when 
compared to fasting (Robertson et al., 1991). Other studies have described reduced absorption 
following a standard meal in Parkinson patients (Roos, Tijssen, Van der Velde, & Breimer, 
1993) and increased absorption following a light breakfast in healthy volunteers (Wilding et 
al., 1991). Crevoisier, Zerr, Calvi-Gries, and Nilsend (2003) reported that although food 
decreased the rate of L-DOPA absorption, it had no effect on the systemic exposure to 
levodopa. Similar results have previously been reported by Robertson et al. (1991) who found 
that initial peak and maximum plasma drug concentrations of L-DOPA were not affected by 
food. In the present study, participants were not dissuaded from consuming a meal with their 
medication–a practice followed in several studies examining various aspects of levodopa in 
healthy volunteers (Barthelmebs, Mbou, Stephan, Grima, & Imbs,1993; Linssen, Sambeth, 
Vuurman, & Riedel, 2014; Morris, Parsons, Trounce, & Groves, 1976). The main purpose of 
allowing food consumption with the medication was to minimize the side effect of vomiting. 
Dopamine antagonist. Haloperidol (Sandoz Haloperidol), is a prototypic 
butyrophenone antipsychotic with a high affinity to D2 receptors. It is extensively 
metabolized in humans and this could account for the large individual variability in its 
pharmacokinetics (Kudo & Ishizaki, 1999). The average Tmax reported shows a wide 
variance among studies, from 1.7 to 6.1 hours (Kudo & Ishizaki, 1999; Lim et al., 2013). 
Participants in the current study were assessed three hours after drug administration. A dose 
of 5-mg of Haloperidol was administered in the present study–a dose commonly given to 
healthy subjects (Gasso et al., 2013; King, Burke, & Lucas, 1995; Mas et al., 2013; Midha et 
al., 1989; Saeedi, Remington, & Christensen, 2006; Vernaleken et al., 2006). 
Frequently reported adverse effects after Haloperidol administration are 
sedation/sleepiness (Anderson, Reker, & Cooper, 1981; King et al., 1995; Liem-Moolenaar et 
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al., 2010), dysphoria, agitation and akathisia (Anderson et al., 1981; King et al., 1995). There 
is considerable evidence linking the level of D2 occupancy with extrapyramidal symptoms 
(EPS), with the risk of EPS rising with D2 blockade of 80% (approximately 5-mg of 
Haloperidol) or higher (Kapur, Zipursky, Jones, Remington, & Houle, 2000). Furthermore, 
adverse effects in the domains of both affect and cognition can occur with D2 receptor 
occupancy in excess of approximately 70%-80% (between 3- to 5-mg) in healthy subjects: 
sustained attention (Saeedi et al., 2006; Vernaleken et al., 2006; Veselinovic et al., 2013), 
reaction time and impaired processing speed (Saeedi et al., 2006; Veselinovic et al., 2013). 
For affect, the most notable changes have been seen on measures of contentment, confusion, 
anger (Saeedi et al., 2006) and avolition, apathy (Mas et al., 2013), and decreased interest in 
surroundings and commitments (Veselinovic et al., 2013). A single dose of 5-mg 
Haloperidol has also been shown to produce negative symptoms in normal individuals, but it 
was argued that drowsiness was an important confounding factor in the assessment of 
negative symptoms (Artaloytia et al., 2006). Haloperidol can be consumed with or without 
food (McKim, 2007). 
Placebo. Folic acid (also known as folate) was used as the placebo substance for this 
study. A dosage of 5-mg was given to the participants. This placebo was taken one hour prior 
to the psychoanalytic sessions. Folic acid is a B vitamin. 
Antiemetic. Medication in the form of 50-mg of Adco-Cyclizine was provided to all 
the participants in this study. This was a precautionary measure in the event any participant 
experienced any nausea or vomiting while on any of the above-mentioned substances. Adco- 
Cyclizine is typically used to treat and prevent motion sickness. It is classed as an 




Scoring the measures and deriving outcome variables. As previously mentioned, 
the hypotheses of this study were investigated using both quantitative and qualitative 
approached. The quantitative approach refers to the use of psychometric measures completed 
by participants at both baseline and after each medication. The following sub-scales were 
used in the psychometric measures analyses and scored using standard procedures outlined in 
the relevant scoring manuals: 
(1) SEEKING and PANIC/GRIEF sub-scales of the ANPS. 
 
(2) PA and NA sub-scales of the PANAS, 
 
(3) MDI (specifically, the rating of the severity of depression scores), 
 
(4) Anxiety, Avoidance, and Security sub-scales of the SAAM, 
 
(5) Avoidance and Anxiety sub-scales of the ECR-(R). 
 
The qualitative approach refers to the use of informal psychological probes such as 
‘free associations’, ‘directed probes’ and recalling of ‘memories of loss’. This data was 
obtained during the psychodynamic interviews following each medication, and was 
comparatively more descriptive in nature, compared to the data obtained from the 
psychometric measures. Obtaining this kind of data was crucial as the psychological 
phenomena under investigation in this study were subtle and complex. Relying solely on 
crude psychometric measures would not have been sufficient as it was imperative to gain an 
understanding of the various phenomena from the perspective of the individual experience. 
Statistical and content analyses were performed on this data. 
‘Free-association’ refers to the part of the interview where participants were asked to 
describe in their own words how they felt after taking a particular medication. 
‘Directed probes’ refers to the part of the interview where participants were asked to 
qualitatively describe and then quantify/rate the change (from baseline) they experienced in 
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SEEKING and PANIC/GRIEF as a result of the medication taken. Participants had to rate, on 
a scale from 0 (no change) to 3 (the highest possible change) the change in increased 
SEEKING and decreased SEEKING. These scores were then subtracted to give an overall 
change in SEEKING. For example, if a participant rated the change in increased SEEKING 
as 0 (i.e., no change) and the change in decreased SEEKING as 1 (i.e., a mild change) then 
their overall change would be -1 (indicating an overall decrease in SEEKING). These scores 
were then categorised as follows: -1 (a decrease in SEEKING), 0 (no change in SEEKING), 1 
(increase in SEEKING). The aim was to compare whether the changes in SEEKING 
(decrease, no change or increase) were associated with the use of the dopamine agonist vs 
antagonist. The same method was used to quantify the change in PANIC/GRIEF, and the aim 
was to compare whether the changes in PANIC/GRIEF (decrease, no change or increase) 
were associated with the use of the opioid agonist vs antagonist. Fischer Exact Test analyses 
were performed on this data. Furthermore, Spearman’s Correlations were also run to see if 
there were any associations between the ‘directed probes’ and their psychometric counterpart 
(ANPS). 
‘Memories of loss’ refers to the part of the interview where participants were asked to 
recall their three memories of loss and then to describe and quantify the change in overall 
emotional intensity for each memory compared to baseline. Change in emotional intensity 
was rated on a scale of 0 (no change) to 3 (the highest possible change in intensity) for each 
memory, and the scores summed to provide an overall change in emotional intensity score. 
Therefore, the overall score could range from 0 to 9. The overall scores were then categorised 
as follows: 0 = category 0 [no emotional intensity change]; 1-3 = category 1 [mild emotional 
intensity change]; 4-6 = category 2 [moderate emotional intensity change] and 7-9 = category 
3 [extreme emotional intensity change]. The aim was to compare these counts between each 
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of the medications to establish if there was an association between medication type and 
emotional intensity change. Fischer Exact Test analyses were performed on this data. 
As previously mentioned, a conventional content analysis of all the psychological 
probes data was undertaken. The purpose of a conventional content analysis is to describe a 
phenomenon (Hsieh & Shannon, 2005), which in this study was the affective responses of 
participants to the medications. This approach was chosen for three reasons. Firstly, it is 
suitable for exploratory research as it allows for the reporting of common issues in the data 
(Green & Thorogood, 2004), secondly, data can be quantified (i.e. number of counts) or 
weighted (Gbrich, 2007) and thirdly, the approach to coding of the data is more descriptive 
than interpretive (Morgan, 1993). 
Power analysis. For the whole sample analysis, an a priori power analysis suggested 
that the sample size be set at N = 47 to achieve a statistical power > .90 using a Wilcoxon 
signed-rank test for matched pairs given a medium effect size. However, only 16 participants 
completed the current study. This sample size generated statistical power of .59. 
For the split-sample analysis, a power analysis suggested that the sample size be set at 
N = 106 (n = 53 per group) to achieve a statistical power > .80 using a Mann-Whitney U test 
for independent between-group analyses given a medium effect size. However, only 16 
participants were enrolled in the current study (N = 8 per group). This sample size generated 
statistical power of .24. The small sample size of the current study is a serious limitation and 
is discussed in detail under the limitations section. 
Inferential statistical analyses. All analyses were conducted using SPSS version 23 
and R (the Exact package). Due to the number of individual tests run, inflated Type 1 
familywise error was an issue. However, correcting the p-value would have resulted in a 
significance value that was too stringent, especially considering that the research was 
exploratory, the analyses preliminary and the sample size small. It was considered more 
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important to try and establish what differences may exist for potential follow up studies. For 
this reason, the significance value was kept at .05 for all the analyses, with the knowledge 
that some of the significant results may be false-positives. For each of the analyses described 
below, the appropriate effect size estimate was calculated, and interpreted following 
convention. Cohen’s (1988) guidelines for r for Wilcoxon nonparametric tests (using the z 
value to calculate effect size) are: large effect is .5, medium effect is .3, and a small effect is 
.1. For Cramer’s V, a small effect is 0.1, a medium effect is 0.3 and a large effect is 0.5. All 
inferential statistical tests were non-parametric given the small sample size and the data was 
not normally distributed. 
For the psychometric measures, the analyses proceeded across three stages. First, a 
series of Wilcoxon signed-rank tests (non-parametric test for related samples) were used to 
analyse differences in the five outcome variables (SEEKING, PANIC/GRIEF, PA, NA and 
MDI) as a function of medication for the whole sample. These analyses aimed to investigate 
differences on these specific measures between pre-medication (i.e., baseline) and post- 
medication. Specifically, these analyses assessed: (1) the effect of the DA agonist (Madopar) 
on SEEKING, PA and MDI; (2) the effect of the DA antagonist (Haloperidol) on SEEKING, 
NA and MDI; (3) the effect of the opioid agonist (Morphine) on PANIC/GRIEF, PA and 
MDI and (4) the effect of the opioid antagonist (Naltrexone) on PANIC/GRIEF, NA and 
MDI. All these analyses were directional (one-tailed) and undertaken in relation to 
hypotheses one to four. 
The attachment measure SAAM was not administered at baseline and could therefore 
not be included in the aforementioned analysis. To investigate medication effects on the 
SAAM specifically, a series of Wilcoxon signed-rank tests analysed the relative effects of the 
opioid medications on the three SAAM sub-scales. Participant’s scores on each of the three 
sub-scales were compared post-opioid agonist versus post-opioid antagonist. Only the opioid 
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based medications were investigated considering the prominent role that opioids play in 
mediating social bonds. 
The specific constructs of ‘despair’ and ‘protest’ were then investigated separately. 
 
The ‘despair’ construct was investigated by splitting the sample into two groups according to 
MDI-baseline scores, with one group comprising the lower set of scores and the other the 
higher set of scores. The High and Low depression groups therefore represented high and low 
‘despair’ respectively. Prior to the split, the baseline range of scores for the entire sample on 
the MDI was 2-15, indicating that depression was not present in the sample. Naturally, after 
the split, the means for the High-MDI (M = 11.00) and Low-MDI (M = 5.50) groups 
remained within the ‘no or doubtful depression’ range. The prediction was that those with 
higher MDI-baseline scores (i.e., high ‘despair’ group) would respond differently to the 
medications compared to those with lower MDI-baseline scores (i.e., low ‘despair’ group). A 
series of Mann-Whitney U tests were used to assess the magnitude of change (from baseline 
to medication) between the Low- and High-MDI groups by comparing their scores on the five 
outcome variables. These analyses were non-directional (i.e., two-tailed) and were 
undertaken in relation to hypothesis five. 
The sample was again split into two groups according to ECR-Avoidance and Anxiety 
baseline scores, with one group comprising the lower set of scores and the other the higher 
set of scores. This analysis was conducted as attachment is central to the study’s central 
hypothesis that depression may be an abnormal variant of the normal mammalian separation 
response. The High and Low Avoidance and Anxiety groups thus represented high and low 
‘protest’ respectively. Prior to the split, the baseline median score for ECR-anxiety was 5.47, 
and for ECR-avoidance was 5.64. The prediction was that those with higher baseline 
avoidant/anxiety scores (i.e., high ‘protest’) would respond differently to the medications 
than those with lower baseline avoidance/anxiety scores (i.e., low ‘protest’). A series of 
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Mann-Whitney U tests were used to assess the magnitude of change (from baseline to 
treatment) between the Low- and High-ECR groups by comparing their scores on the five 
outcome variables. These analyses were non-directional (i.e., two-tailed) and were 
undertaken in relation to hypothesis six. 
As previously mentioned, statistical analyses were also carried out on some of the 
psychological probes data. The analyses proceeded across three stages. First, in relation to the 
‘directed probes’, a series of Fisher’s Exact tests (because > than 20% of observed counts 
were less than 5) assessed whether self-reported changes in SEEKING were associated with 
the DA medications, and whether self-reported changes in PANIC/GRIEF were associated 
with the opioid medications. Second, in relation to the ‘memories of loss’, a Fisher’s exact 
test assessed whether there was an association between change in emotional intensity for the 
re-experiencing of the three memories of emotional loss and the different medications. All the 
Fischer’s analyses for the psychological probes were directional (i.e., one-tailed) for the 
whole sample analyses but non-directional (i.e., two-tailed) for the split-sample analyses. 
Lastly, and in relation to the ‘directed probes’, a series of Spearman’s Rank-Order correlation 
analyses assessed whether self-reported changes in SEEKING and PANIC/GRIEF were 
associated with psychometric changes in SEEKING and PANIC/GRIEF (this change was 
calculated as the difference in SEEKING and PANIC/GRIEF scores on the ANPS from 
baseline to medication). The psychometric changes in SEEKING and PANIC/GREIF were 
then coded to match the coding of the directed probes as follows: -1 (a decrease), 0 (no 
change), and 1 (an increase). All the correlation analyses were performed on the sets of coded 
data, and all were directional (i.e., one-tailed). 
Content analysis of psychological probes data. Transcripts of the psychological 
probes data, which included ‘free associations’, ‘directed probes’ and recalling of ‘memories 
of loss’, were given to two independent coders (coders A), who were provided with a brief 
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rationale of the study, but who were not aware of the study’s hypotheses. The coders 
conducted their initial analysis of the transcripts independently. They each began with a type 
of “in vivo” coding exercise (Smith & Davies, 2010) searching for words or phrases in the 
transcripts that stood out and using the participant’s exact words/phrase as a code. This was 
followed by a more focused coding exercise which entailed identifying the most frequent 
codes and developing prominent categories of affective responses, as described in Saldaña 
(2013). Each category was then weighted as ‘x/16 participants had this similar affective 
response to this particular medication’. The various categories were then ordered according to 
their respective weighting. Thereafter, the two coders met to compare their respective 
analyses and to agree on the most frequently occurring affective categories for each 
medication. A final list of 13 categories of affective responses was compiled, with each 
category being assigned a descriptor code depicting words or phrases used by participants. Of 
the 13, seven affective responses on the list were regarded as prominent because these affects 
were identified in at least half of the participants on a particular medication (they were: 
positively stimulated, negatively stimulated, lowered drive, relaxed, detached, muted 
pain/detachment and connected). The balance of affective responses were regarded as less 
prominent because these affects were only identified in less than half of the participants (they 
were: happy, longing, compassion, acceptance, irritation/agitation and overwhelmed). 
The list of affective categories (without any reference to medication type) was then 
given to a further two independent coders (coders B). Coders B were instructed to identify 
which of the affects on the list, if any, were experienced by each participant. The purpose of 
this was to establish whether they could identify the same participants that coders A had 
originally identified who were experiencing a particular affect. These coders were unfamiliar 






Results are reported in the following order: 
 
- For the whole sample I report (1) physical side-effects of the medications, (2) 
psychobehavioural effects of the medications, (3) psychoanalyst’s ratings, (4) baseline 
descriptives prior to medication, (5) descriptives of the psychometric measures across 
medications, (6) psychological probes data: coding, ‘directed probes’, ‘memories of loss’ and 
(7) testing hypotheses 1 to 4. 
 
- For the split MDI sample, I report (1) psychobehavioural effects of the  medications, 
 
(2) baseline descriptives prior to medication, (3) descriptives of the psychometric measures 
across medications, and (4) testing hypothesis 5. 
- For the split ECR-Avoidance/Anxiety samples I report, (1) psychobehavioural effects 
of the medications, (2) baseline descriptives prior to medication, (3) descriptives of the 
psychometric measures across medications, and (4) testing hypothesis 6 
Results of Psychometric and Psychological Probes Data Analyses for the Whole Sample 
Physical side-effects of the medications. Table 1 reports the number of   participants 
that experienced each side-effect. The most severe side-effect was akathisia which four 
participants experienced on Haloperidol. Physical side-effects were reported least commonly 
with Placebo and Morphine and most often with Madopar, Haloperidol and Naltrexone (most 
commonly, elevated heart rate, feeling fuzzy/foggy, tiredness, and feeling jittery/shaky). 
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Table 1 
Physical Side-effects to the Medications 
 
Side-effects Madopar Haloperidol Morphine Naltrexone Placebo 
Elevated heart rate 6 1 3 1 1 
Jittery/Shaky/Buzzy 4 2 1 6 1 
Fuzzy/Foggy 3 7 3 3 2 
Nausea 5  1 2 3 
High 2   1  
Tiredness 1 7 4 4 1 















Subjective psychobehavioural effects of medications. Table 2 reports the number of 
participants that experienced each of the listed subjective changes in psychobehavioural state. 
The descriptors listed were used by the participants themselves. Positive effects were 
experienced with Madopar and Morphine more commonly than with Haloperidol, Naltrexone 
and Placebo. Although negative effects were experienced for all the medications, they were 
more commonly experienced with Haloperidol, Madopar and Naltrexone. 
108  
Table 2 
Psychobehavioural Effects of the Medications 
Type of effect Madopar Haloperidol Morphine Naltrexone Placebo 
Positive      
Safe/Secure 5 2 3 3 1 
Comfortable 1 3 2  1 
Hopeful 2  2 1 1 
Optimistic 2    1 
Confident 2  2 1  
Engaged 4  2  1 
Happy 4  3 1 1 
Positive   3  3 
Upbeat 3    1 
Nice 1     
Curious 1 1 1 1 1 
Calm 1 1 2 2  
Talkative 3     
Relaxed 2 3 6 2  
Euphoric 1   1  
Need for closeness 1  1   
Warm  1 2  1 
Attached  2   1 
Content  1 5 1  
Less concerned  1    
Humorous   1 1  
Stimulated   1  1 
Connected   2  1 
Disinhibited 1  2   
Enthusiastic   1  2 
Accepting    1 1 
Alert     1 
Energetic 1    1 
Negative      
Subdued 1 2 1 3 2 
Sad 2 2  2 1 
Anxious 7 2 1 3 2 
Rushed 1     
Difficulty Concentrating 4  3 4 1 
Withdrawn 2 3    
Angry     1 
Separated/Detached/Disconnected 6 8 7 8 4 
Less Happy 3   1  
Reluctant to engage 2 1 2 3 1 
Less secure 1     
Lonely 2 1 1   
Isolated 2   1  
Panicky 2 2    
Apathetic 1    1 
Less excited  1    
Indifferent  2  1 2 
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Irritable  1  2 1 
Less motivated  3 1 2  
Less interested  2 3 4 1 
Despondent    1  
Hopeless    1  
None 1 2 1 3 5 
 
 
Psychoanalyst’s ratings. As previously mentioned, the psychoanalyst was required to 
make a prediction as to what medication he thought each participant had taken after each 
experimental session. The success of his predictions was as follows: 50% in the case of 
Morphine, 6.25% in the case of Naltrexone, 18.75% in the case of Madopar, 25% in the case 
of Haloperidol and 43.75% for Placebo. Six participants spontaneously and correctly identified 
when they had been given Placebo.1
Baseline descriptives prior to medication. Table 3 shows the means, standard 
deviations, and ranges of all four psychometric measures completed prior to medication. 
 
Table 3 
Baseline Descriptive Statistics for Psychometric Measures for the Whole Sample 
 SEEKING PANIC/GRIEF PA NA MDI E_Av E_Anx 
Mean 30.63 21.38 34.19 13.19 8.25 5.59 5.40 
SD 3.93 4.67 4.79 2.71 3.50 0.94 0.80 
Range 25 - 39 8 - 29 25 - 41 10 - 21 2 – 15 3 - 7 3.66 – 6.50 
Note. SEEKING = ANPS seeking sub-scale; PANIC/GRIEF = ANPS panic/grief subscale; PA = 
PANAS positive sub-scale; NA = PANAS negative sub-scale; E_Anx = ECR attachment-related 
anxiety sub-scale; E_Av = ECR attachment-related avoidance sub-scale; MDI = total severity of 
depression score. 
 
The mean for SEEKING was 30.63 (SD = 3.93) and the mean for PANIC/GRIEF was 
 
21.83 (SD = 4.67). Davis et al. (2003) provided norms for the ANPS derived from two 
population groups, undergraduate students (N = 171; Mage = 20.3±3.5 years) and job 
applicants (N = 598; Mage = 41.9±10.3 years). I chose to compare sample means with the job 
applicant population rather than the student population group since the mean age of the 
                                                     
5 If there is any doubt that Placebo could be identified by participants by the absence of side-effects is covered by the fact that 5 of 
the 16 participants experienced side effects on Placebo. 
110  
former was relatively closer to the mean age of the current sample (Mage = 35). Unfortunately, 
the norms provided by Davis and colleagues were not for the entire sample but were reported 
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for each gender (SEEKING M for males = 28.07, SEEKING M for females = 28.52; 
PANIC/GRIEF M for males = 15.58, PANIC/GRIEF M for females = 16.52). The current 
sample was too small to separate out gender effects, but the sample means for SEEKING and 
PANIC/GRIEF were in keeping with the means for both genders. The means for PA and NA 
were 34.19 (SD = 4.79) and 13.19 (SD = 2.71) respectively. According to Watson et al., 
(1988), the normal population will have a mean PA score of 29.7 (SD = 7.9) and a mean NA 
score of 14.8 (SD = 5.4). Current sample means conformed to these suggested norms. The 
mean ‘severity of depression’ score for the current sample was 8.25 which fell within the ‘no 
or doubtful depression’ range (a score between 0 and 20) of the MDI (Bech et al., 2015). The 
means for avoidance and anxiety on the ECR-R were 5.59 (SD = 0.94) and 5.40 (SD = 0.80) 
respectively. The ECR-R is generally utilised with continuous data and there are as such no 
standardised norms (personal communication; Fraley, 2015). However, some norms were 
provided by Fraley (2015) based on a sample of 17 000 (Mage = 27±10 years). The mean for 
the avoidance and anxiety ECR subscales were 2.92 (SD = 1.19) and 3.56 (SD = 1.12) 
respectively (Fraley, 2012). Current sample means were comparatively higher. Single sample 
t-tests (non-directional) showed that the mean difference for ECR-avoidance between the 
current sample and the published means (mean difference = 2.67) was significant, t(15) = 
11.31, p < .001, as was the mean difference for ECR-anxiety between the current sample and 
the published means (mean difference = 1.83), t(15) = 9.20, p < .001. 
In summary, the descriptive data at baseline showed that the current sample was not 
clinically depressed, did not display higher than normal PA or NA, and both SEEKING, and 
PANIC/GRIEF were in keeping with published norms. With regards to the ECR, it would 
appear that the current sample was more avoidant and anxious compared to available norms. 
This claim however is made with reservation as the current sample and the normed sample 
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were not entirely comparable. For example, the mean age of the normed sample was Mage = 
27±10 years, compared to the mean age of the current sample of Mage = 35±11.84 years. 
Descriptives for psychometric measures following medication. Table 4 presents the 
means, standard deviations, and ranges for each of the psychometric measures as a function of 
medication. PA was decreased from baseline (M = 34.19) and NA was decreased from baseline 
(M = 13.19) on all medications except for Madopar (M = 15.81), where NA increased from 
baseline. MDI scores increased from baseline (M = 8.25) on all medications, except for Placebo 
(M = 7.31), where depression scores decreased from baseline. Despite this increase, the means 
for all the MDI scores on the different medications remained within the ‘no depression’ range 
(that is, below 20). On the ANPS, the means for SEEKING and PANIC/GRIEF decreased from 
baseline (M = 30.63 and 21.28 respectively) across all medications. The SAAM (a state 










PA NA MDI S_Anx S_Av S_Sec 
Morphine 21.63 (5.41) 17.44 (0.70) 23.81 (7.92) 11.88 (2.53) 9.19 (8.19) 3.44 (0.95) 2.53 (0.32) 5.55 (0.98) 
 10 – 31 12 - 23 11 - 36 10 - 17 0 - 29 1.29 – 5.14 1.14 – 5.14 3.14 – 6.71 
Naltrexone 20.19 ( 6.33) 19.50 (2.19) 21.69 (8.42) 12.75 (3.12) 12.06 (9.46) 3.60 (0.87) 3.15 (1.26) 5.30 (1.07) 
 6 – 29 13 - 22 10 - 37 10 - 18 0 - 31 1.71 – 4.86 1.71 – 5.29 3.29 – 6.86 
Haloperidol 22.69 (8.00) 18.81 (3.41) 25.88 (8.68) 12.25 (3.44) 11.50 (9.78) 3.74 (1.04) 2.23 (1.21) 5.88 (0.74) 
 5 – 35 12 - 25 13 - 38 10 - 22 0 - 33 1.86 – 6.57 1.00 – 5.29 4.71 – 7.00 
Madopar 21.94 (8.06) 19.88 (5.44) 28.13 (10.93) 15.81 (5.62) 12.06 (10.98) 3.54 (1.10) 2.81 (1.59) 5.41 (1.13) 
 6 – 31 11 - 30 11 - 47 10 - 28 0 - 32 2.14 – 6.00 1.00 – 5.57 3.14 – 7.00 
Placebo 23.31 (6.01) 18.19 (3.75) 30.75 (8.55) 12.50 (2.83) 7.31 (8.35) 3.70 (0.73) 2.18 (1.03) 5.90 (0.56) 
 12 – 36 11 - 27 15 - 45 10 - 19 0 - 31 2.14 – 5.14 1.00 – 4.57 4.86 – 6.71 
Note. On the first row of each medication condition, means are presented with standard deviations in parentheses, and on the 
second row, the range of scores. SEEKING = ANPS seeking sub-scale; PANIC/GRIEF = ANPS panic/grief subscale; PA = PANAS positive sub-scale; NA= 















Psychological probes data. 
 
Coding. As previously mentioned, coders A identified a total of 13 affective 
responses across the five medications in the psychological probes data (‘free associations’, 
‘directed probes’ and ‘memories of loss’). The first seven were considered prominent as they 
were identified in at least 50% of participants. They were: 
1. Feeling positively stimulated. Many participants had some form of physiological 
reaction (such as elevated heartrate, jittery, fidgety, shaky, rush of adrenaline, 
butterflies in my tummy) to all the medications but especially Madopar. Half of 
the participants felt stimulated by these physiological reactions and interpreted 
these reactions in a positive manner. They reported feeling happy, excited, upbeat, 
engaged, secure or confident. 
2. Feeling negatively stimulated. Other participants however did not respond well to 
the physiological reactions and felt quite distressed by them.  They reported 
feeling anxious, restless, detached, had difficulty concentrating and were reluctant 
to engage. This was seen on Naltrexone and Haloperidol, but especially Madopar. 
3. Low drive. Almost all participants experienced a physiological and mental 
‘slowing down’, to varying degrees, on one or more of the medications but 
especially on Haloperidol and Naltrexone. This reduction in drive was 
characterised by a loss of energy, interest, motivation or wanting to withdraw. 
4. Relaxed. Many participants reported that some of the medications made them feel 
quite relaxed, especially Morphine and Haloperidol. There was a clear absence of 
negative affect and a sense of well-being. Relaxation in this context was 
characterised by descriptions of feeling comfortable, calm, at ease, mellow, 
content or secure. 
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5. Detached. A very common affect, especially on Haloperidol, Naltrexone and 
Morphine, were feelings of detachment (or separation, disconnection and 
indifference), which were particularly evident when participants were recalling 
their memories of loss, and related to feeling distanced from their emotions, the 
actual memory or from other people. 
6. Muted pain/detachment. There was a close overlap between this affect and the one 
above in the sense that in both instances participants expressed feeling distanced 
from their memories. However, in the case of feeling a ‘muted sense of 
pain/detachment’, participants felt removed not only from the memory itself but 
specifically referred to feeling removed or distanced from the sadness and pain 
associated with their memories. This was seen on Madopar and Haloperidol, but 
especially Morphine. 
7. Connected. This referred to participant’s sense of interpersonal connection with 
others or a connection to positive images of the individuals in their memories. 
With regards to lost loved ones, the connection that they used to have was 
foregrounded and looked upon with fond remembrance. Some participants also 
regarded their connection with loved ones as less damaged as they previously 
thought. This was particularly common on Morphine. 
 
 
Less prominent were: 
 
 
8. Happy. This particular affect closely missed being classified as prominent. It 
featured quite strongly in Morphine and Madopar. It was not merely the absence 
of negative feelings but referred to a sense of hope, optimism and positivity. 
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9. Longing. A few participants expressed a desire or longing for closeness or contact 
with loved ones or felt lonely because they were really missing something or 
someone they had lost. This affect was mostly identified on Haloperidol, 
Naltrexone and Morphine. 
10. Compassion. Participants expressed sympathy for or a greater understanding of 
the actions of persons who had caused them pain in the past, but more often the 
sympathy was directed towards themselves. Reflecting on the nature of and the 
reaction to their loss, some participants reported that they felt sorry for the person 
they were then and that they felt less critical about themselves now. This was seen 
especially on Madopar. 
11. Acceptance. Some participants described feeling a sort of coming to terms with or 
acceptance of their loss. They were able to rationalise and think through their loss 
in a less emotive manner and in some cases consider it resolved. Interestingly, this 
affect was relatively common on Placebo. 
12. Irritation/Agitation. There were several participants were felt particularly irritated 
or agitated either with friends or the people in their memories, but more often, 
they simply felt agitated at being at the session and could not relax and expressed 
a desire to distract themselves from their current situation. This was evident across 
all medications except for Morphine. 
13. Overwhelmed. There were several participants who felt panicky or out of control 
in relation to the somatic effects of the medications, especially Madopar. This 
affect is quite similar to feeling ‘negatively stimulated’, but in this case, the 
difference was that there was an added component of panic, which made patients 
feel overwhelmed. 
There was complete agreement between coders A and B as to which affects 
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featured prominently (1-7) and which did not feature prominently (8-13). 
 
‘Directed probes’. These refer to participant’s self-reported changes during the 
‘directed probes’ part of the interview, when they were asked whether or not they had 
experienced any change in SEEKING and PANIC/GRIEF after each medication and if so, to 
qualify the degree of this change. 
On Madopar, nine participants reported a mild to moderate increase in SEEKING. On 
Haloperidol, eight participants reported a mild to extreme decrease in SEEKING. Half of the 
participants reported a decrease in PANIC/GRIEF on Morphine, with the intensity of the 
change being equally allocated between mild and moderate. On Naltrexone, nine participants 
reported no change in PANIC/GRIEF. Lastly, on Placebo most participants reported no 
changes with respect to SEEKING and PANIC/GRIEF. 
‘Memories of loss’. Participants were instructed prior to the experimental phase of the 
study to describe three autobiographical events associated with a significant personal loss. A 
total of 48 memories were recorded for the whole sample and allocated into the following 
categories: romantic disappointments (15), death of a parent, relative or friend (11), near- 
death of parent, relative or friend (4), death of a pet (4), parental divorce (2), relocating to 
another town or country (3), and existential loss, like loss of previous status (9). After 
participants recalled their three memories of loss on each medication, they had to describe 
and quantify the change in emotional intensity. These changes were then coded as either no 
change, mild, moderate and extreme changes in emotional intensity. To determine whether 
there was an association between type of medication and change in emotional intensity (from 
baseline), a Fischer’s Exact test compared the counts of the coded data across the various 
medications. The analysis detected a significant association between change in emotional 
intensity and drug trial type, p = .035, V =.28, in the whole sample, indicating that certain 
medications were more likely than others to result in a change in emotional intensity. To 
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explore this overall association further, a series of Fischer’s Exact Tests were again 
conducted to assess specific differences between medication types. Change in emotional 
intensity was significantly associated with each of the medications when compared to the 
Placebo trial (all ps < .014), except for Haloperidol, p = .067. When each medication was 
compared against the Placebo, change in emotional intensity was significantly greater when 
participants were taking the medications compared to the Placebo. There were no significant 
associations when each medication was compared with each another (all ps > .340), 
indicating that there were no significant differences in change in emotional intensity when 
participants were taking either the Dopamine or Opioid medications. Although participants 
were asked to rate the change in emotional intensity, they were unfortunately not specifically 
asked to rate whether this change meant that they re-experienced their loss with greater or 
lesser sadness/pain. This association could thus not be investigated statistically, only 
qualitatively. The breakdown of change in emotional intensity for ‘memories of loss’ across 
the five medications is shown in Table 5. Across all the medications, there were participants 
who reported no change in emotional intensity; the most being on Placebo. There was no 
dramatic difference between Madopar and Haloperidol with respect to the number of 
participants who reported ‘no change’, ‘mild change’, ‘moderate change’ and ‘extreme 
change’ in emotional intensity. Likewise, for Morphine versus Naltrexone. More participants 
reported a moderate change in emotional intensity on Morphine compared to the other 
medications and Madopar resulted in more extreme changes in emotional intensity compared 
to the other medications. 
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Table 5 
Degree of Change in Emotional Intensity of Memories of Loss 
 Madopar Haloperidol Morphine Naltrexone Placebo 
No change 4 5 3 5 6 
Mild change 3 5 3 3 7 
Moderate change 5 4 8 6 0 
Extreme change 4 2 2 2 3 
 
 
Testing hypothesis 1. Madopar will significantly increase SEEKING and PA and 
significantly improve depressive mood, from baseline, on the quantitative measures. Madopar 
will also increase SEEKING and improve affective valence and mood as qualitatively 
described in the ‘directed probes’, ‘memories of loss’ and ‘free association’, paradigms. 
A series of Wilcoxon tests were conducted to determine whether, compared to 
baseline, Madopar would significantly increase SEEKING and PA and significantly improve 
mood (see Table 6). The comparison for SEEKING on the ANPS was significant, z = -3.35, p 
= .001, but in the opposite direction to that predicted. Instead of increasing SEEKING as 
expected, Madopar reduced SEEKING in N=14. The comparison for PA was likewise 
significant, z = -2.11, p = .018, but once again, in the opposite direction to what was 
predicted. Instead of increasing PA, Madopar reduced PA in N=11. The comparison for 
mood on the MDI was not significant, z = -0.60, p = .275. 
A series of Spearman’s Rank-Order correlation analyses were run to assess whether 
there was any association between the changes in SEEKING as measured by the 
psychometric ANPS and the changes in SEEKING as measured by the qualitative ‘directed 
probes’. The analyses detected no significant associations for Madopar (rs = .32, p = .112), 
indicating that the psychometric and qualitative measures were not consistent with one 
another.  On the psychometric ANPS, participants reported that Madopar generally reduced 
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SEEKING, whereas on the qualitative ‘directed probes’, they generally reported an increase 
in SEEKING (explaining why the analysis indicated no association). 
On ‘memories of loss’, change in emotional intensity was significantly greater on 
Madopar, but only when compared to Placebo, and not to any of the other medications. Most 
participants reported some degree of change in emotional intensity on Madopar while re- 
experiencing their loss compared to only four who experienced no change. Qualitatively, of 
the 12 participants who reported a change, only two described an increase in sadness when 
re-experiencing their loss, as reflected in these statements “I feel the feelings stronger, 
stronger sadness and worried feelings” and “There’s sadness and feeling alone”. The other 
ten participant’s experience of recalling their loss was generally positive. There were some 
who experienced a decrease in the sadness and pain related to their memories, and others 
who felt distanced from the loss. These feelings are clearly depicted in the following 
examples: “The sadness is significantly less” , “Not as painful to think about it”, “Those 
feelings feel less intense now”, “I think the sense of loss is a bit more than normal, but not in 
a terrible way, just kind of a sad way, but more happy”, “I feel less of the self-esteem 
wound”,  “I find it hard to even connect to that sadness”, “It seems less significant now”, 
“I’m much more able to hold contrasting feelings and think it through” and “It doesn’t evoke 
any negative emotions”. 
A Fischer’s Exact test was used to compare changes in SEEKING on Madopar to 
changes in SEEKING on Haloperidol on the ‘directed probes’ specifically. There was a trend 
towards significance, p = .061, V =.39, with a medium effect size, for both dopamine 
medications. For Madopar, N=9 reported an increase in SEEKING, consistent with its 
predicted effects. For Haloperidol, N=8 reported a decrease in SEEKING, consistent with its 
predicted effects. These results indicate that participants qualitatively reported feeling 
increased SEEKING on Madopar and decreased SEEKING on Haloperidol. 
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On all the psychological probes data together, that is, ‘directed probes’, ‘memories of 
loss’ and ‘free association’, two prominent affects were identified by coders A for Madopar: 
• Feeling positively stimulated: Several participants interpreted their physiological reactions to 
Madopar in a positive manner. Coders A identified this affect in eight participants. The 
following are examples of how these participants felt on Madopar: “I feel a buzz. A happy 
feeling”, “Slightly euphoric. Happy. I’m in a good mood”, “I’m moving from happiness to a 
more physiological activation. It’s not unpleasant’, “I actually feel quite good”, “I feel quite 
upbeat”, “It almost feels like a bit of a stimulant” and “I do feel optimistic though. I’m 
feeling pretty happy”. Some felt more confident, evident in examples like, “I do feel more 
confident. I do feel that with greater confidence, I could engage with social situations “or “I 
feel emotionally bold”. Other participants felt more connected or engaged, illustrated in the 
following examples “I feel I was more engaging, sort of feeling more excited about the 
connections that could possibly be made”, “I’m aware of feeling very safe here”, “I kind of 
feel like I could curl into a little ball and be taken care of” and “I feel upbeat. I feel engaged 
with everyone”. Some participants only experienced the expected effects of Madopar much 
later in the day, after they had left the session. One participant expressly felt disinhibited after 
leaving the interview session. She reported that she had “A little disinhibited engagement 
with Ross (the designated driver used in this study) in the car”. Another participant reported 
that after leaving the session she “I had the experience of meeting somebody and feeling 
instantly attracted to them”. And yet another participant’s description of how she felt later in 
the day is stereotypical of the effects of a dopamine agonist. She reported that “I felt 
unusually good. I felt on a high. I felt like I could run up on any mountain. I felt manic, very 
energetic”. Coders B identified this affect in the same eight participants coders A had 
originally identified. There was thus complete agreement between coders A and B. 
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• Feeling negatively stimulated: The balance of participants interpreted their physiological 
reactions to Madopar in a negative manner. Coders A also identified this affect in eight 
participants. They felt anxious, evident in examples like “I feel very anxious. It feels as if 
someone is sitting on my chest”, “I’m more anxious…like stressing out quite a bit more than 
I think I normally would have” and “I’m definitely jittery and a bit anxious”. Others felt 
detached, evident in examples such as “The feelings are out of reach. Something else is 
overriding my feelings”, “It just feels as though I’m further away from it” or “I do feel a bit 
cut off from it though”. Some felt isolated and sad, illustrated in statements such as “I feel 
lonely. I feel left out”, “The lense that I’m looking at this memory through feels much more 
isolated”, “My sense of people’s attachment to me is more fragile right now. Easier to let me 
go and that feels quite sad”, “The thought of losing the people I love is much more 
distressing” and “I can feel a sense of longing. I do feel a sense of losing something that I 
want to have”. Coders B identified this affect in six of the eight participants originally 
identified by coders A. There was thus 75% agreement between coders A and B. 
Based on the psychological probes data, it appears that Madopar did produce some 
effects more in keeping with predictions. Eight participants felt positively stimulated (both 
coders A and B were in complete agreement). Nine participants reported an increase in 
SEEKING on the ‘directed probes’ and 10 participants reflected on their ‘memories of loss’ 
in a more positive manner. 
Testing hypothesis 2. Haloperidol will significantly decrease SEEKING, increase 
NA and significantly worsen depressive mood, from baseline, on the quantitative measures. 
Haloperidol will also decrease SEEKING and worsen affective valence and mood as 
qualitatively described in the ‘directed probes’, ‘memories of loss’ and ‘free association’, 
paradigms. 
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A series of Wilcoxon tests were conducted to determine whether, compared to 
baseline, Haloperidol would significantly decrease SEEKING, increase NA and significantly 
worsen mood (see Table 6). The comparison for SEEKING on the ANPS was significant, z = 
-2.86, p = .002, and in the direction predicted. Haloperidol reduced SEEKING in N=11. 
According to Cohen’s guidelines, the effect size of this comparison was large. Haloperidol 
also reduced NA in N=11, but the comparison did not reach significance, z = -1.52, p = .064, 
and had no significant effect on mood, z = -0.73, p = .235, on the MDI. 
 
Table 6 













Dopamine Agonist      
SEEKING 1.00 8.50 -3.35 <.001 -0.59 
PA 6.33 7.82 -2.11 .018 -0.37 
MDI 10.07 6.19 -0.60 .275 -0.11 
Dopamine Antagonist     
SEEKING 2.33 8.91 -2.86 .002 -0.51 
NA 9.50 6.95 -1.52 .064 -0.27 
MDI 10.25 6.75 -0.73 .235 -0.13 
Note. Dopamine Agonist = Madopar. Dopamine Antagonist = Haloperidol. 
 
 
A series of Spearman’s Rank-Order correlation analyses were run to assess whether 
there was any association between the changes in SEEKING as measured by the 
psychometric ANPS and the changes in SEEKING as measured by the qualitative ‘directed 
probes’. The analyses detected a trend towards significance for Haloperidol (rs = .41, p = 
.059). According to Cohen’s guidelines, the effect size of this comparison is medium, 
indicating some degree of association between the psychometric and qualitative measures. 
This is reasonable given that 11 participants reported a decrease in SEEKING on the ANPS 
and eight reported a decrease on the ‘directed probes’. 
On ‘memories of loss’, there were no statistically significant differences in change in 
emotional intensity on Haloperidol. The majority of participants reported some degree of 
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change in emotional intensity on Haloperidol, compared to only five who experienced no 
change. Qualitatively, of the 11 participants who reported a change, only one described an 
increase in sadness when re-experiencing their loss. This participant felt “A bit more sad, 
more regret, a little bit of guilt”. The other 10 participants described varying degrees of 
emotional numbness as illustrated in these examples: “I still feel the pain, but maybe more 
dulled”, “It doesn’t feel as though it has the same unmanageable sadness attached to it”, “A 
bit less emotionally charged”, “I feel emotionally numb or buffered”, “I feel detached from 
the emotion”, “No feelings of loss or sadness”, “I’m not traumatised by the thought of it”, “I 
remember how I feel but I can’t quite feel it” and “It’s not that I’m more sad, but I want 
reassurances that things are okay”. 
On all the psychological probes data together, that is, ‘directed probes’, ‘memories of 
loss’ and ‘free association’, three prominent affects were identified by coders A for 
Haloperidol: 
• Low drive: Coders A identified eight participants who reported lowered 
energy, motivation, interest and feeling withdrawn, described in statements like 
“I think it’s more a decrease in energy, decrease in interest, in wanting to do 
things”, “Hmm, maybe the drive is missing a little bit”, “I feel not very 
interested in anything”, “I’m not feeling motivated to do anything 
challenging”, “So it’s kind of like I think…yes, that’s a very good idea, can we 
do it tomorrow”, “I feel very, very tired. Less interested and less excited. I feel 
low-spirited” and “There is a pure dampening of my motivation”. Others 
reported that it was a huge effort to think about their losses and that they 
simply did not care to do so. Some felt quite withdrawn, expressed in 
statements such as “I think it’s a bit of a withdrawal from the world”, “I just 
feel like withdrawing and closing my eyes” and “I feel an inner sense of 
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withdrawing into myself”. After leaving the interview sessions, some 
participants continued to experience the typical effects of Haloperidol, 
reporting that “I was really low on energy” and “Emotionally, I was just really 
tired.” Coders B identified this affect in six of the eight participants coders A 
had originally identified. There was thus 75% agreement between coders A and 
B. 
• Relaxed: Not all participants interpreted reduced drive in a negative manner, 
but rather as a kind of relaxation, which encompassed feeling calm, 
comfortable, secure, at ease, subdued, content and tired or sleepy. Coders A 
identified eight participants who described this relaxed feeling in statements 
like “Actually, in the moment, I feel quite relaxed, quite nice even”, “I feel at 
ease. Interestingly, in this session, comfortable”, “I feel very relaxed…not a lot 
of anxiety at all”, “I feel less concerned about the situation, so maybe a slight 
positive improvement in mood”, “A little more comfortable, more secure, more 
attached”, “I feel quite content in the way you just described”, “I have felt very 
calm today” and “I’m still very tired but I feel more in a relaxed way tired”. 
Coders B however only identified this affect in three of the eight participants 
originally identified by coders A. There was thus only a 37.5% agreement 
between coders A and B. 
• Detached: Coders A identified eight participants who felt detached from their 
emotions, their memories or from other people. These feelings were evident in 
statements like “I don’t feel attached to my loved ones, but I know I can rely 
on them”, “I feel detached from the emotion. Too much effort to think about 
it”, “My feeling of caring is diminished. I feel buffered”, “I feel indifferent. 
There’s a lack of feeling of loss really”, “I feel separated from my feelings. 
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The thought is completely separated from any emotion” and “I wouldn’t say 
there is no affect, but there is a diminished feeling”. Coders B identified this 
affect in the same eight participants originally identified by coders A. There 
was thus complete agreement between coders A and B. 
 
 
Based on the psychological probes data, Haloperidol did produce some effects in 
keeping with predictions. Eight participants felt detached and six reported a reduction in drive 
(coders A and B were in strong agreement). Eight participants reported a decrease in 
SEEKING on the ‘directed probes’ and 10 participants described feeling emotionally numb 
when recalling their ‘memories of loss’.  Moreover, there was corroborating evidence from 
the psychometric data, confirming a decrease in SEEKING on the ANPS. Lastly, there was a 
trend towards significance indicating some degree of association between the psychometric 
and qualitative measures of reduced SEEKING. 
Testing hypothesis 3. Morphine will significantly decrease PANIC/GRIEF, increase 
PA and significantly improve depressive mood, from baseline, on the quantitative measures. 
Morphine will reduce PANIC/GRIEF and improve affective valence and mood as 
qualitatively described in the ‘directed probes’, ‘memories of loss’ and ‘free association’, 
paradigms. 
A series of Wilcoxon tests were conducted to determine whether, compared to 
baseline, Morphine would significantly reduce PANIC/GRIEF, increase PA and significantly 
improve mood (see Table 7). The comparison for PANIC/GRIEF was significant, z = -2.46, p 
= .007, and in the direction predicted. Morphine reduced PANIC/GRIEF in N=13. According 
to Cohen’s guidelines, the effect size of this comparison is medium. The comparison for PA 
was significant, z = -2.95, p = .002, but in the opposite direction to that predicated. Instead of 
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increasing PA, Morphine reduced PA in N=13. Although Morphine did not have a significant 
effect on mood, z = -0.23, p = .410, MDI scores were lower than baseline in N=10. 
A series of Spearman’s Rank-Order correlation analyses were run to assess whether 
there was any association between the changes in PANIC/GRIEF as measured by the 
psychometric ANPS and the changes in PANIC/GRIEF as measured by the qualitative 
‘directed probes’. The analyses detected no significant associations for Morphine (rs = -.19, p 
= .239), indicating that the psychometric and qualitative measures were not consistent with 
one another. On the ANPS, N=13 reported a decrease in PANIC/GRIEF, whereas on the 
‘directed probes’, N=6 reported no change in PANIC/GRIEF (explaining why the correlation 
indicated no association). 
On ‘memories of loss’, change in emotional intensity was significantly greater on 
Morphine, but only when compared to Placebo, and not to any of the other medications. 
Only three participants reported no change in emotional intensity on Morphine when re- 
experiencing their memories. Qualitatively, several participants felt less pain and sadness, 
described as “I feel less negative emotion”, “When I think about it, I don’t feel any pain 
around it”, “I’m not feeling tearful, I’m not feeling sadness” and “The sadness feels 
peripheral at this moment”. Others described feeling removed from the emotion connected 
to it. Examples of such feelings were: “The whole memory feels suspended”, “I feel distant 
from the emotion, it doesn’t feel distressing”, “I can’t detect any emotions really”, “Hard to 
connect with the way I was feeling” and “It doesn’t carry any emotional weight thinking 
about that now”. 
A Fischer’s Exact test was used to compare changes in PANIC/GRIEF on Morphine 
to changes in PANIC/GRIEF on Naltrexone on the ‘directed probes’ specifically. There were 
no significant associations between changes in PANIC/GRIEF and the opioid-based 
medication, p = .208, V =.26. This is understandable given that eight participants qualitatively 
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reported a decrease in PANIC/GRIEF on Morphine, but only three qualitatively reported an 
increase in PANIC/GRIEF on Naltrexone. 
On all the psychological probes data together, that is, ‘directed probes’, ‘memories of 
loss’ and ‘free association’, three prominent affects were identified by coders A for 
Morphine: 
• Relaxed: Coders A identified eight participants who reported feeling 
relaxed/content, described variously as calm, comfortable, secure, at ease, 
subdued, content, tired or sleepy and less anxious. Examples of the kinds of 
positive sentiments that participants expressed were: “I felt this kind of 
relaxation, it felt like a calming relaxation, and then it kind of turned into a 
slight happiness”, “I feel physically relaxed”, “It’s kind of a warm, comfort, 
almost slightly numb sensation”, “I feel lighter and happier and more hopeful”, 
“I have a warm fuzzy feeling”, “I feel content and energised”, “I have an 
overall positive affect. I feel happy” and “I think the anxiety has decreased. I’m 
actually feeling quite calm”. Some participants continued to feel the effects of 
Morphine after they had left the interview session. They reported that they 
continued to feel quite positive, relaxed and content, for example, “I was very 
relaxed”, “The main thing was a sense of contentment with whatever I was 
doing” and “I had a “can-do” feeling. It persisted for the rest of the day”. 
Coders B identified this affect in seven of the eight participants originally 
identified by coders A. There was thus an 87.5% agreement between coders A 
and B. 
• Muted pain/detachment: Coders A identified ten participants who reported a 
detachment from the negative aspects, pain and/or sadness of their memories, 
that is, the pain associated with their respective loss was reduced or muted. 
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Examples of feelings of detachment were “I feel distant from the loss 
experience”, “I feel indifferent to the loss situation”, “I’m feeling more 
detached from the negative emotions of that experience”, “I am separated from 
the feelings around receiving bad news”, “I don’t feel as upset as I normally 
do”, “I’m not feeling it, and I’m not feeling tearful, I’m not feeling sadness”, “I 
almost feel less negative emotion than I recall from describing it the first time”, 
“There’s something more contained about it, it doesn’t feel so horrible”, “I’m 
remembering the good times”, “What’s coming to mind is enjoyable events 
with her, not the actual split”, “I feel sadness, but not the severe aching sadness 
I felt the last time. It feels peripheral at this moment”, “I feel a little annoyed 
actually, no sadness or pain. Not annoyance at myself, but at him” and “I feel 
slightly hurt when remembering the loss but the hurt is muted”. Again, some of 
the effects of Morphine lingered for certain participants. Two participants 
reported how they continued to feel quite detached, evident in these examples, 
“An effort was required to engage with what’s out there” and “Towards the 
evening, I was struck by a feeling of being very very unenthused. Surprising in 
the circumstances. Interesting live music, but I had no interest or wish to 
participate. I was noticeably bland”. Coders B identified this affect in seven of 
the ten participants originally identified by coders A. There was thus a 70% 
agreement between coders A and B. 
• Connected: Coders A identified this affect in eight participants, who either 
reported feeling an increased desire to be around loved ones or they were more 
focused on and connected to the positive aspects of their memories 
Participants described this increased connectedness as “There is pleasure in 
relating to others”, “I feel relaxed and comfortable in terms of the people that 
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are close to me, and interacting with people”, “I do feel relaxed and 
comfortable in relation to people close to me”, “I feel like I could call someone 
and they would want to do something with me – they wouldn’t be busy”, “I 
would like to be around the people I feel safest with”, “I have a desire to be 
around the people I feel safest with”, “What is right at the forefront is just the 
experience of the connection, and the leaving part is sort of diminished”, “It 
doesn’t evoke any negative emotions, aside from the latent warmth about him” 
and “I feel a fond sense of remembrance”.  Coders B identified this affect in 
five of the eight participants originally identified by coders A. There was thus a 
62.5% agreement between coders A and B. 
 
 
Based on the psychological probes data, it would appear that Morphine did produce 
some effects in keeping with predictions. Seven participants felt relaxed and seven reported 
that the pain associated with their loss was muted (relatively strong agreement between 
coders A and B). Eight participants reported a decrease in PANIC/GRIEF on the ‘directed 
probes’ and 11 participants described feeling emotionally removed when recalling their 
‘memories of loss’. Furthermore, there was corroborating evidence from the psychometric 
data, confirming the decrease in PANIC/GRIEF on the ANPS. 
Testing hypothesis 4. Naltrexone will significantly increase PANIC/GRIEF and NA 
and significantly worsen depressive mood, from baseline, on the quantitative measures. 
Naltrexone will increase PANIC/GRIEF and worsen affective valence and mood as 
qualitatively described in the ‘directed probes’, ‘memories of loss’ and ‘free association’, 
paradigms. 
A series of Wilcoxon tests were conducted to determine whether, compared to 
baseline, Naltrexone would significantly increase PANIC/GRIEF and NA, and significantly 
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worsen mood (see Table 7). The comparison for PANIC/GRIEF on the ANPS was 
significant, z = -1.69, p = .046, but in the opposite direction to that predicted. Naltrexone only 
increased PANIC/GRIEF in N=5. Naltrexone did not significantly increase NA as predicted, 
z = -0.49, p = .314, but only increased NA in N=6. Lastly, Naltrexone did not significantly 


















Opioid Agonist      
PANIC/ 
GRIEF 
6.83 8.88 -2.46 .007 -0.43 
PA 3.67 9.62 -2.95 .002 -0.52 
MDI 11.20 6.40 -0.23 .410 -0.04 
Opioid Antagonist      
PANIC/ 
GRIEF 
7.10 9.14 -1.69 .046 -0.30 
NA 8.58 7.61 -0.49 .314 -0.09 
MDI 9.13 5.33 -1.29 .098 -0.23 
Note. Opioid Agonist = Morphine. Opioid Antagonist = Naltrexone. 
 
 
A series of Spearman’s Rank-Order correlation analyses were run to assess whether 
there was any association between the changes in PANIC/GRIEF as measured by the 
psychometric ANPS and the changes in PANIC/GRIEF as measured by the qualitative 
‘directed probes’. The analyses detected no significant associations for Naltrexone (rs = .07, 
p = .405), indicating that the psychometric and qualitative measures were not consistent with 
one another. On the ANPS, N=11 reported a decrease in PANIC/GRIEF, whereas on the 
‘directed probes’, N=9 reported no change in PANIC/GRIEF (explaining why the correlation 
analysis indicated no association). 
On ‘memories of loss’, change in emotional intensity was significantly greater on 
Naltrexone, but only when compared to Placebo, and not to any of the other medications. 
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The majority of participants once again reported some degree of change in emotional 
intensity on Naltrexone compared to only five who experienced no change. Qualitatively, 
two participants felt an increase in sadness when re-experiencing their loss and described it 
as “Again those feelings, me causing all the heartache, they’re stronger” and “I feel more 
sadness”. Generally, however, participants mostly described having difficulty connecting 
with the memory and there was very little reference to any specific emotion relating to the 
memory. They described how “It’s hard to actually feel anything”, “I can’t grasp the 
feeling”, “It doesn’t feel like I’m emotionally really attached to those memories”, “I just 
don’t feel like I’m easily getting involved in thinking about these different things” and “The 
thought is there but not attached to any emotions”. 
More so than the other medications, Naltrexone produced a range of relatively 
extreme affects; two participants were severely depressed – in fact, the interviewer had made 
a particular reference to this – while three participants had very pleasurable responses to 
Naltrexone, which is highly unusual. Here are some examples of positive reactions: “What is 
diminished is my desire, but not my sense of pleasure. I feel a pleasurable not caring about 
things. Eat drink and be merry”, “I’m definitely feeling a relaxed feeling, physically and 
emotionally” and “I would definitely say there’s a sense of contentedness. I’m feeling secure, 
secure within my body.” Two of these participants continued to feel these positive effects for 
several hours after the session, reporting that “I sat at the cricket in the sun thinking this is 
Nirvana” and “I felt ‘flippen’ (a colloquial term for the word very) fantastic the whole day”. 
As mentioned above, two participants were notably feeling depressed, which is evident in 
their statements “Something is going to go wrong”; “The feelings are stronger. I feel more 
hopeless about it and that sort of thing” and “I’m despondent, but that despondency has 
increased. Greater sadness. There’s a greater feeling of that kind, more than baseline and 
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more than last time. I feel the world wants something from me that I’m not willing to give. 
Anxiety, yes.” 
On all the psychological probes data together, that is, ‘directed probes’, ‘memories of loss’ 
and ‘free association’, two prominent affects were identified by coders A for Naltrexone. 
• Detached: With regards to the feelings of detachment, there was a general 
absence of affect; some participants only remembered factual information, 
while others felt like an outside observer. Some said that their memories felt 
abstract and that they were struggling to bring the memory to mind entirely. 
Coders A identified nine participants who reported feeling detached either 
from other people or their memories. These feelings of detachment are clearly 
illustrated in statement such as “This time, it’s detached and distant”, “I feel 
minimally removed, but not uncomfortably. It’s there as a factual memory but 
not as an emotional one,” “I can’t get a clear memory. It’s like all the edges 
have been blurred around it”, “I need to access the memory to access the 
feeling but I can’t access the memory”, “It’s almost like there is a distance, 
almost like I’m an outsider, an observer”, “The thought is there, but not 
attached to any emotions”, “Ok, so I’ve got the memory back but the feeling is 
not there”, “Mostly I feel third person-ish about it”, “The memory has no 
affective tone. It feels blunted”, “So I feel safe, but I do not feel like cared 
about or bonded to. Not at all mindful of the people in my life”, “Not that 
phased about other people” and “Maybe I’m less willing to be here. I don’t 
want to engage.” Coders B identified this affect in seven of the nine 
participants originally identified by coders A. There was thus a 78% agreement 
between coders A and B. 
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• Low drive: Coders A identified eight participants who experienced a decrease 
in drive which mainly encompassed lowered motivation, interest and energy. 
Some illustrative examples of this are “It’s like a more solemn feeling in 
general”, “I’m slowly starting to feel less energetic”, “I can’t crank up the 
energy when I don’t really have it”, “I feel subdued. A general loss of interest”, 
“Definitely a lack of interest”, “I feel a bit more subdued”, “I don’t really 
experience the need to go out into the world right now”, “I do feel a decreased 
need to go out and find anything”, “A state of nothingness really” and “It’s a 
chore to have thoughts”. Coders B identified this affect in four of the eight 
participants originally identified by coders A. There was thus only a 50% 
agreement between coders A and B. 
 
 
The psychological probes showed that Naltrexone did not increase PANIC/GRIEF or 
NA, reflected in the lack of references by participants to increases in mental pain caused by 
separation or loss. This was also corroborated by the psychometric data. Instead, what was 
most notable was the strong feelings of detachment described by participants, with little 
reference to any negative emotion. The trend for Naltrexone to worsen mood was in keeping 
with the study’s predictions. 
A series of Wilcoxon tests were conducted to determine whether, compared to 
Naltrexone, Morphine would significantly decrease avoidance and anxiety and increase 
security on the SAAM (see Table 8). As predicted, avoidance on Morphine was significantly 
less than avoidance on Naltrexone in N=11, z = -1.88, p = .031. According to Cohen’s 
guidelines, the effect size of this comparison is medium. There was no significant difference 
on anxiety between the opioid-based medications, z = -0.63, p = .265; anxiety scores were 
only lower on Morphine compared to Naltrexone in N=6. Similarly, there was no significant 
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difference on security between the opioid-based medications, z = -0.88, p = .189, even though 
security scores on Morphine were greater compared to Naltrexone in N=10. 
 
Table 8 













Avoidance 8.45 6.75 -1.88 .031 -0.33 
Anxiety 7.81 7.08 -0.63 .265 -0.11 
Security 8.50 8.50 -0.88 .189 -0.16 
 
Lastly, Placebo significantly reduced SEEKING for N=13, z = -3.16, p = .002, (two- 
tailed as no effect was predicted). There was also a trend for PA to be reduced by Placebo 
for N=11, z = -1.89, p = .059. On ‘memories of loss’, change in emotional intensity was 
significantly associated with each of the medications when compared to Placebo, except for 
Haloperidol. Six participants reported no change in emotional intensity on Placebo when re- 
experiencing their memories. Of the ten who did experience a change, seven described the 
change in emotional intensity as mild. These descriptions were quite varied, and some 
participants had a relatively positive re-experiencing of their loss, reporting that “It feels a 
bit easier to speak about than usual”, “I’m feeling a bit more positive” and “I’m feeling more 
positive”. Others found that their re-experiencing of loss was quite negative, describing that 
“That’s a much stronger feeling. I have the panic you describe”, “I feel more judgement of 
myself” and “Separation anxiety is heightened”. On all the psychological probes data 
together, that is, ‘directed probes’, ‘memories of loss’ and ‘free association’, coders A and B 
identified a wide range of affects on Placebo, but none were prominent. Some participants 
experienced positive feelings such as feeling happy, enthusiastic and more interestingly, a 
sense of acceptance (especially in terms of their memories). Five of the participants reported 
feeling a kind of coming to terms with or acceptance of their loss – almost nostalgic - 
described in statements such as “The mind frame I’m in is allowing me to pack the memory 
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away”, “I feel less sad, I feel like smiling about him today. A fond remembrance”, “I am 
maybe feeling a bit more resolved, perhaps”, “I feel a bit better about it. I really got over it 
and left it behind” and “I suppose, if anything, I’m feeling better about it now than I usually 
would”. Others experienced negative feelings like anxiety, evident in statements like “I’m a 
bit jittery” and “I do feel a slightly elevated anxiety”; panic, described as “The sadness is a 
little less and the shock, the panic of it, is a bit more”, “I feel a sense of vulnerability, a fear 
of loss again” and “The separation-anxiety is heightened” and one participant experienced a 
reduction in drive, stating that “I feel quite down, subdued, not interested”. Also, as 
previously mentioned, six participants correctly identified that they were on Placebo. 
Summary of results for the whole sample. Dopamine medications (Hypothesis 1 & 
2): Contrary to my hypotheses, Madopar decreased SEEKING and PA and had no effect on 
mood. In line with predictions, Haloperidol decreased SEEKING, although it had no effect on 
NA and mood. There was a trend towards significance between changes in SEEKING and both 
DA medications on ‘directed probes’. There were no significant associations between changes 
in SEEKING as measured by the psychometric ANPS and changes in SEEKING as measured 
by the qualitative ‘directed probes’ for Madopar but a trend towards significance for 
Haloperidol. On ‘memories of loss’, there were no statistically significant differences in change 
in emotional intensity when participants were taking Haloperidol, but there were significant 
differences on Madopar, but only when compared to Placebo. Prominent affects on Madopar 
were ‘positively stimulated’ (100% agreement between coders A and B) and ‘negatively 
stimulated’ (75% agreement between coders A and B). Prominent affects for Haloperidol were 
‘low drive’ (75% agreement between coders A and B), ‘detached’ (100% agreement between 
coders A and B) and ‘relaxed’ (37.5% agreement between coders A and B). 
Opioid medications (Hypothesis 3 & 4): In line with predictions, Morphine decreased 
PANIC/GRIEF, although contrary to hypotheses it decreased PA and had no effect on mood. 
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Again, contrary to hypotheses, Naltrexone decreased PANIC/GRIEF, had no effect on NA 
and there was a trend towards worsening of mood. There were no significant associations 
between changes in PANIC/GRIEF and the opioid-based medication on ‘directed probes’. 
There were no significant associations between changes in PANIC/GRIEF as measured by 
the psychometric ANPS and changes in PANIC/GRIEF as measured by the qualitative 
‘directed probes’ for Morphine or Naltrexone. On the ‘memories of loss’, there were 
significant differences in change in emotional intensity when participants were taking the 
Opioid medications, but only when compared to Placebo. Prominent affects on Morphine 
were ‘relaxed’ (87.5% agreement between coders A and B), ‘muted pain/detachment’ (70% 
agreement between coders A and B) and ‘connected’ (62.5% agreement between coders A 
and B). Prominent affects for Naltrexone were ‘detached’ (78% agreement between coders A 
and B) and ‘low drive’ (50% agreement between coders A and B). Morphine significantly 
reduced Avoidance on the SAAM compared to Naltrexone. No significant differences were 
found for Anxiety and Security between the Opioid-based medications. 
Placebo: Placebo significantly reduced SEEKING and there was a trend for PA to be 
reduced. On ‘memories of loss’, change in emotional intensity was significantly associated 
with each of the medications when compared to the Placebo trial, except for Haloperidol. 
There were no prominent affects identified by coders A and B. 
 
Results of Psychometric and Psychological Probes Data Analyses for the Split MDI 
Sample 
Subjective psychobehavioural effects of medications. There were no substantial 
differences between the two groups with respect to the number of positive and negative 
psychobehavioural effects reported on Madopar, Naltrexone and Placebo. There were however 
differences between the groups for Haloperidol and Morphine. On Haloperidol, the Low-MDI 
group reported more than double the number of negative effects compared to    the High-MDI 
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group. It would appear that the Low-MDI group was more responsive to the DA antagonist 
than the High-MDI group. On Morphine, the High-MDI group experienced double the number 
of positive effects compared to the Low-MDI group. It would appear that the High-MDI group 
was more responsive to the opioid agonist compared to the Low-MDI. 
Baseline descriptives prior to medication. All results reported under this section refer 
to a split sample, which was based on the MDI scores. Table 9 presents the means and standard 
deviations of all four psychometric measures at baseline. The High-MDI group had 
significantly higher baseline MDI scores compared to the Low-MDI group, U = 0.50, p <.001. 








n = 8 
High-MDI 









SEEKING 31.38 (3.58) 29.88 (4.36) 32.00 28.00 21.50 .14 
PANIC/GRIEF 21.38 (6.35) 21.38 (2.56) 23.00 22.00 26.50 .30 
PA 35.50 (3.93) 32,88 (5.46) 35.5 32.00 21.50 .14 
NA 13.13 (1.64) 13.25 (3.62) 13.50 12.50 27.00 32 
MDI 5.50 (1.92) 11.00 (2.27) 5.50 10.50 0.50 <.001* 
ECR_Avoidance 5.42 (0.97) 5.76 (0.95) 5.64 6.00 25.50 .26 
ECR_Anxiety 5.33 (0.72) 5,47 (0.92) 5.47 5.53 27.00 .30 
Note. Means are presented with standard deviations in parentheses. All statistical tests 
reported were 1 tailed. 
 
 
At baseline, no participant in either the Low- or High-MDI group met the criteria for 
clinical depression according to the cut-offs score of 26 for a diagnosis of major depression on 
the MDI (see Table 10). After taking Haloperidol, two participants in the Low-MDI group 
scored more than 26 on the MDI. The opposite effect occurred in the High-MDI group; it was 
Madopar that caused two participants to score more than 26 on the MDI. 
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Table 10 
Descriptive Statistics for MDI in the Low and High MDI-Groups for all Medication Conditions 
 Low MDI   High MDI  
Medication Condition Count > 26 Percentage Range Count > 26 Percentage Range 
Baseline 0 0 2 – 8 0 0 8 – 15 
Morphine 0 0 0 – 21 1 12.5 4 – 29 
Naltrexone 1 12.5 0 – 31 1 12.5 8 – 26 
Haloperidol 2 25 5 – 33 0 0 0 – 14 
Madopar 1 12.5 0 – 30 2 25 5 – 32 
Placebo 0 0 0 – 20 1 12.5 0 – 31 
 
 
Descriptives of the psychometric measures across medications. The means and 
standard deviations of the psychometric measures across medication conditions for the split 




Descriptives for Psychometric Measures Across Medication Conditions for the Split MDI-Groups 
 SEEKING PANIC/GRIEF PA NA MDI S_Anx S_Av S_Sec 
Low-MDI         
Baseline 31.38 (3.58) 21.38 (6.35) 35.50 (3.93) 13.13 (1.64) 5.50 (1.93) - - - 
Morphine 21.13 (3.18) 18.13 (2.36) 22.88 (6.99) 11.63 (2.56) 8.13 (7.22) 3.55 (1.21) 2.11 (0.99) 6.05 (0.65) 
Naltrexone 23.25 (5.23) 19.25 (1.28) 24.63 (8.53) 11.75 (3.28) 7.50 (9.87) 3.81 (0.76) 2.43 (0.93) 6.00 (0.51) 
Haloperidol 18.50 (8.78) 21.25 (2.31) 21.25 (9.08) 13.88 (4.32) 17.13 (10.37) 3.98 (1.07) 2.73 (1.54) 5.93 (0.82) 
Madopar 22.88 (7.12) 19.25 (4.06) 31.25 (11.09) 14.50 (3.66) 8.50 (1.00) 3.58 (1.36) 2.50 (1.45) 5.80 (0.93) 
Placebo 24.86 (5.54) 18.13 (2.03) 31.38 (8.33) 11.88 (2.47) 6.38 (6.89) 3.68 (0.79) 1.96 (1.04) 6.09 (0.57) 
M (SD) 23.00 (6.97) 17.60 (3.57) 25.67 (9.43) 11.24 (3.16) 11.71 (8.71) 4.16 (1.02) 2.62 (1.19) 9.00 (0.68) 
High-MDI         
Baseline 29.88 (4.36) 21.37 (2.56) 32.88 (5.46) 13.25 (3.62) 11.00 (2.27) - - - 
Morphine 22.13 (7.22) 16.75 (3.11) 24.75 (9.13) 12.13 (2.64) 10.25 (9.44) 3.32 (0.66) 2.95 (1.45) 5.05 (1.03) 
Naltrexone 17.13 (6.08) 19.75 (2.92) 18.75 (7.70) 13.75 (2.76) 16.63 (6.84) 3.39 (0.98) 3.88 (1.16) 4.61 (1.04) 
Haloperidol 26.88 (4.45) 16.38 (2.45) 30.50 (5.48) 10.63 (0.74) 5.88 (5.03) 3.50 (1.02) 1.73 (0.43) 5.82 (0.71) 
Madopar 21.00 (8.82) 20.50 (6.78) 25.00 (10.52) 17.13 (7.10) 15.63 (11.38) 3.50 (0.87) 3.12 (1.76) 5.02 (1.23) 
Placebo 21.75 (6.41) 18.25 (5.09) 30.13 (9.30) 13.13 (3.18) 8.25 (9.99) 3.71 (0.72) 2.39 (1.04) 5.71 (0.52) 
M (SD) 23.13 (7.44) 18.83 (6.78) 27.00 (9.69) 13.33 (5.74) 11.27 (10.82) 3.49 (1.22) 2.81 (1.37) 5.24 (4.04) 
Note: SEEKING = ANPS seeking sub-scale; PANIC/GRIEF = ANPS panic/grief subscale; POS = PANAS positive sub-scale; NEG= PANAS 
negative sub-scale; S_Anx = SAAM anxiety sub-scale; S_Av = SAAM avoidance sub-scale; S_Sec = SAAM security sub-scale; MDI = total 













Splitting the sample revealed that the two MDI groups had different responses to the 
medications. In the Low-MDI group, SEEKING and PA were reduced mostly by the DA 
antagonist whereas in the High-MDI group, the biggest reductions in SEEKING and PA were 
caused by the opioid antagonist. Similarly, the DA antagonist caused the biggest increase in 
MDI scores in the Low-MDI group but the largest decrease in MDI scores in the High-MDI 
group. Once again, in the High-MDI group, the opioid antagonist caused the largest increase 
in MDI scores. Thus, in 3 of the 5 psychometric measures (SEEKING, PA and MDI), the 
Low-MDI group appeared to be more responsive to the DA antagonist, whereas the High- 
MDI group was more responsive to the opioid antagonist. Lastly, the low-MDI group’s more 
pronounced response to the DA-based medications was once again reflected in their NA 
scores; both Haloperidol and Madopar accounted for the largest increases in NA for this 
group.  In the High-MDI group, although the opioid antagonist did result in a slight increase 
in NA, the largest increase was caused by the DA agonist. 
Testing hypothesis 5. The magnitude of change for SEEKING, PANAS and MDI on 
the dopamine-based medications will be significantly different between the low and high 
baseline-MDI groups (i.e. high and low baseline ‘despair’). The groups will likewise differ in 
relation to their ‘directed probes’, ‘memories of loss’ and ‘free associations’ on the 
Dopamine-based medications. 
A series of Mann-Whitney U tests were conducted to determine whether the 
magnitude of change for SEEKING, PANAS and MDI on the DA-based medications was 
significantly different between the Low and High-MDI groups (see Table 12). There were no 
significant differences in the magnitude of change between the Low and High-MDI groups 
for SEEKING, affect or mood on the DA agonist. There were however some significant 
differences between the groups on the DA antagonist. The change from baseline in 
SEEKING on Haloperidol was significantly different between the two groups, U = 11.00, p = 
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.027, (according to Cohen’s guidelines, the effect size of this comparison was large), with the 
Low-MDI group experiencing a significantly larger reduction in SEEKING. The change in 
MDI from baseline on Haloperidol was significantly different between the two groups, U = 
6.00, p = .006, (large effect size), with the Low-MDI group experiencing an increase in 
depressive mood but the High-MDI group experiencing a reduction in depressive mood. The 
absolute change was larger in the Low-MDI group. The change in PA from baseline on 
Haloperidol was significantly different between the two groups, U = 13.00, p = .046, (large 
effect size), with the Low-MDI group experiencing a significantly larger reduction in PA. 
The change for NA was not significant. 
Table 12 
Results of Mann-Whitney U Tests for Dopamine Medications 
 Low-MDI High-MDI     
Variable M Rank M Rank Z U p r 
Dopamine Agonist       
SEEKING 8.25 8.75 -0.21 30.00 .833 0.05 
MDI 8.63 8.38 -0.11 31.00 .916 0.03 
PA 7.56 9.44 -0.79 24.50 .430 0.20 
NA 8.75 8.25 -0.21 30.00 .833 0.05 
Dopamine Antagonist       
SEEKING 11.13 5.88 -2.21 11.00 .027 0.55 
MDI 5.25 11.75 -2.74 6.00 .006 0.69 
PA 10.88 6.13 -2.00 13.00 .046 0.50 
NA 7.25 9.75 -1.07 22.00 .285 0.27 
Note. Dopamine Agonist = Madopar. Dopamine Antagonist = Haloperidol. 
 
 
As to the association between the changes in SEEKING as measured by the ANPS 
and the changes in SEEKING as measured by the ‘directed probes’, there was no significant 
association for Madopar in the Low-MDI group, rs = .29, p = .247 or the High-MDI group, rs 
= .36, p = .190. In the Low-MDI group, N=7 reported a decrease in SEEKING on the ANPS 
but N=5 reported an increase in SEEKING on ‘directed probes’. In the High-MDI group, 
N=7 reported a decrease in SEEKING on the ANPS, but N=4 reported an increase in 
SEEKING on ‘directed probes’ (explaining why the correlation analysis indicated no 
association). But for Haloperidol, there was a significant association between the two 
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measures of reduced SEEKING in the Low-MDI group, rs = .66, p = .039, and with a strong 
effect size. This was a reasonable outcome given that N=7 reported a decrease in SEEKING 
on the ANPS and N=6 reported a decrease in SEEKING on ‘directed probes’. Within the 
High-MDI group, analyses detected no significant associations for Haloperidol, rs = .10, p = 
.411. The High-MDI group, N=4 reported a decrease in SEEKING on the ANPS but only 
N=2 reported a decrease in SEEKING on the ‘directed probes’. 
On ‘memories of loss’, there were no striking differences between the groups with 
regards to the types of personal loss experienced. The number of romantic disappointments, 
death of a parent, relative or friend, near-death of parent, relative or friend and relocating to 
another town or country were the same for both groups. Some minor differences were that the 
High-MDI group experienced more pet-related deaths. The Low-MDI experienced parental 
divorce whereas the High-MDI group did not and lastly, the Low-MDI experienced double 
the number of existential losses compared to the High-MDI group. Furthermore, there was a 
trend towards a statistically significant association between change in emotional intensity and 
medication, p = .072, V = .41, in the Low-MDI group, with a medium effect size. Change in 
emotional intensity was significantly associated with Madopar when compared to Placebo (p 
= .026), but not with any of the other medications (all ps > .076). For the association between 
Madopar and Placebo, change in emotional intensity was significantly greater when 
participants were taking Madopar. Of the eight participants in the Low-MDI group, only 2 
experienced no change in emotional intensity when re-experiencing their ‘memories of loss’ 
on Madopar. Two participants experienced a mild change, three a moderate change, and one 
an extreme change in emotional intensity. Of the six who experienced a change, five 
described feeling either less emotional pain or more positive when re-experiencing their 
memories of loss, for example, “I can bring it to mind, it is not as painful to think about it as 
previous times”, “So it feels like I don’t, I really don’t have a sad feeling about it right now”, 
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“I suppose I’m feeling more hopeful about it” and “The difference is noticing that I don’t feel 
personally wounded by it”. One patient’s recollection of their ‘memories of loss’ was more 
painful on Madopar and she described it as “I feel a bit more sad about it. It touches me more 
than it usually does”. Within the High-MDI group, the analysis detected no significant 
association between change in emotional intensity and Madopar, p = .132, V = .39. On 
Haloperidol, three participants in the Low-MDI group reported no change in emotional 
intensity compared to two in the High-MDI group. Furthermore, there were two notable 
difference between the groups. Firstly, two participants in the Low-MDI group reported 
extreme changes, described as “It’s too much effort to think about it. I feel separated from my 
feelings” and “It’s hard to access it. I can’t trigger the feeling”, compared to no participants 
reporting extreme changes in the High-MDI group. Secondly, one participant reported mild 
changes in the Low-MDI group compared to four participants in the High-MDI group. Some 
examples of mild to moderate changes in the High-MDI group are “It doesn’t seem to hold 
the seriousness that it did when I normally think about it”, “So it’s almost like looking back 
on a sad scene rather than being in it”, “It’s a bit more difficult to feel the emotions” and “I 
feel a bit more detached from the pain of how it was”. What is common in these examples is 
that participants in this group generally felt more distanced from their memories. This is 
consistent with the finding mentioned below that in the High-MDI group, a commonly 
experienced affect throughout all the psychological probes data, was feeling ‘detached’. 
There was a significant association between change in SEEKING and the DA 
medications, p = .032, V = .68, with a large effect size, in the Low-MDI group for ‘directed 
probes’ specifically. N=5 reported an increase in SEEKING when on Madopar and N=6 
reported a decrease in SEEKING on Haloperidol. These results indicate that the Low-MDI 
group qualitatively reported increases in SEEKING on Madopar and decreases in SEEKING 
on Haloperidol, and the direction of change was consistent with the predicted effects of 
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Madopar and Haloperidol on SEEKING. There was no significant association between 
change in SEEKING and the DA medications, p = .674, V = .29, in the High-MDI group. 
On all the psychological probes data together, that is, ‘directed probes’, ‘memories of 
loss’ and ‘free association’, in the Low-MDI group, five of the eight participants felt 
‘positively stimulated’ on Madopar while in the High-MDI group, five of the eight 
participants felt ‘negatively stimulated’. In the Low-MDI group, four of the eight participants 
experienced a ‘low drive’ on Haloperidol, while in the High-MDI group, only two 
participants experienced a reduction in drive. Only three participants in the High-MDI group 
reported feeling ‘relaxed’; no participants in the Low-MDI reported feeling relaxed on 
Haloperidol. Six of the eight participants in the High-MDI group reported feeling ‘detached’ 
compared to two in the Low-MDI group. 
Summary of results for the split MDI-sample. Dopamine medications. Madopar 
did not account for any differences between the groups on SEEKING, affect or mood. In 
contrast, Haloperidol resulted in the Low-MDI group experiencing relatively larger reduction 
in SEEKING and PA, and an increase in depressive mood, compared to the High-MDI group. 
On the ‘directed probes’, there was a significant association between change in SEEKING 
and the DA medications in the Low-MDI group only. There was no significant association 
between the ‘directed probes’ and the ANPS measures of increased SEEKING for Madopar, 
in both groups. There was a significant association between the measures for decreased 
SEEKING on Haloperidol in the low-MDI group, but not the High-MDI group. On the 
‘memories of loss’, there was a significance in change in emotional intensity on Madopar 
when compared to Placebo in the Low-MDI group. Lastly, with regards to prominent affects, 
the Low-MDI group was relatively more ‘positively stimulated’ on Madopar compared to the 
High-MDI group. In turn, the High-MDI group felt relatively more ‘detached’ on Haloperidol 
compared to the Low-MDI group. 
145  
Results of Psychometric and Psychological Probes Data Analyses for the Split ECR- 
Avoidance Sample 
Subjective psychobehavioural effects of medications. There were no substantial 
differences between the two groups with respect to the number of positive and negative 
psychobehavioural effects reported on Morphine, Naltrexone and Placebo. There were 
however differences between the High and Low-Avoidance groups for Madopar, with the 
Low-Avoidance group experiencing almost three times the number of positive effects 
compared to the High-Avoidance group. This is consistent with the Low-Avoidance group 
having significantly higher baseline SEEKING scores compared to the High-Avoidance 
group. On Haloperidol, the High-Avoidance group experienced three times the number of 
negative effects compared to the Low-Avoidance group. 
Baseline descriptives prior to medication. All results reported under this section 
refer to the split sample, which was based on ECR-Avoidance scores. Table 13 presents the 
means and standard deviations of all four psychometric measures at baseline. The High- 
Avoidance group had significantly higher baseline ECR-Avoidance scores compared to the 
Low-Avoidance group, U < 0.01, p = .001, providing validation for splitting the sample. The 
Low-Avoidance group had significantly higher baseline SEEKING scores compared to the 
High-Avoidance group, U = 15.50, p = .041. The two groups did not differ significantly on 








n = 8 
High Avoidance 









SEEKING 32.25 (4.17) 29.00 (3.12) 32.50 28.00 15.50 .041* 
PANIC/GRIEF 22.63 (2.26) 20.13 (6.17) 23.00 20.00 22.00 .142 
PA 35.50 (4.84) 32.88 (4.67) 36.50 32.00 20.50 .113 
NA 14.25 (3.24) 12.13 (1.64) 14.00 11.50 17.00 .056 
MDI 8.88 (4.19) 7.63 (2.77) 8.50 8.00 28.00 .337 
ECR_Avoidance 4.91 (0.81) 6.27 (0.43) 5.08 6.33 <0.01 <.001* 
ECR_Anxiety 4.99 (0.68) 5.80 (0.74) 5.05 5.99 10.50 .012* 



























Descriptives of the psychometric measures across medications. The means and 
standard deviations of the psychometric measures across medications for the split ECR- 
Avoidance sample are shown in Table 14. PA was reduced for both groups across all 
medications, compared to baseline. In the Low-Avoidance group, Morphine caused the 
greatest reduction in PA, followed by Naltrexone, whereas in the High-Avoidance group, 
Naltrexone caused the greatest decrease in PA, followed by Morphine. Compared to baseline, 
NA was reduced by all medications except for Madopar in the Low-Avoidance group, with 
Morphine causing the largest reduction. For the High-Avoidance group, NA was only 
reduced on Placebo, remained the same on Haloperidol, and increased on Morphine, 
Naltrexone and Madopar. PANIC/GRIEF was reduced in both groups across all medications, 
except for the High-Avoidance group who experienced an increased in PANIC/GRIEF on 
Madopar. In the Low-Avoidance group, Morphine and Madopar caused the largest decrease 
in PANIC/GRIEF. In the High-Avoidance group, the greatest decrease in PANIC/GRIEF was 
caused by Placebo, followed closely by Morphine. In the Low-Avoidance group, Haloperidol 
and Madopar caused an increase in depression scores compared to baseline but the biggest 
increase was caused by Madopar. All other medications caused a reduction in depression 
scores, with the biggest reduction caused by Morphine. In the High-Avoidance group, all 
medications except Placebo caused an increase in depression scores, with the biggest increase 
caused by Naltrexone, followed by Haloperidol. 
As previously mentioned, the SAAM was not administered at baseline, thus no baseline 
means were available for comparison. However, when comparing the group means for each 
sub-scale across all medications on this attachment measure, there was no noteworthy 











Descriptives for Psychometric Measures Across Medications for the Split ECR-Avoidance-Groups 
 SEEKING PANIC/GRIEF PA NA MDI S_Anx S_Av S_Sec 
Low Avoidance         
Baseline 32.25 (4.17) 22.63 (2.26) 35.50 (4.84) 14.25 (3.24) 8.88 (4.19) - - - 
Morphine 22.88 (3.80) 16.88 (1.64) 23.13 (7.49) 11.25 (1.83) 6.50 (6.39) 3.71 (0.93) 2.66 (1.34) 5.36 (0.84) 
Naltrexone 22.63 (4.21) 19.25 (2.82) 25.00 (9.32) 11.88 (2.95) 8.75 (7.32) 4.02 (0.72) 2.98 (1.17) 5.29 (0.97) 
Haloperidol 21.88 (8.98) 19.00 (4.07) 25.38 (8.25) 12.38 (2.97) 10.50 (11.60) 4.14 (1.03) 2.48 (1.58) 5.56 (0.43) 
Madopar 22.13 (9.85) 18.63 (5.88) 29.00 (11.64) 16.38 (5.76) 12.75 (11.41) 3.73 (1.40) 2.77 (1.47) 5.18 (1.04) 
Placebo 24.88 (6.56) 18.75 (2.82) 33.13 (8.36) 13.13 (3.04) 8.13 (9.91) 3.84 (0.54) 2.39 (1.41) 5.78 (0.59) 
M (SD) 24.21 (6.93) 18.86 (3.62) 27.75 (9.19) 12.93 (3.58) 8.86 (8.36) 3.54 (1.05) 2.58 (1.30) 5.55 (0.84) 
High Avoidance         
Baseline 29.00 (3.12) 20.13 (6.17) 32.88 (4.67) 12.13 (1.64) 7.63 (2.77) - - - 
Morphine 20.38 (6.70) 18.00 (3.59) 24.50 (8.78) 12.50 (3.07) 11.88 (9.30) 3.16 (0.95) 2.39 (1.28) 5.75 (1.12) 
Naltrexone 17.75 (7.38) 19.75 (1.49) 18.38 (6.32) 13.63 (3.20) 15.38 (10.64) 3.18 (0.84) 3.32 (1.41) 5.32 (1.23) 
Haloperidol 23.50 (7.41) 18.63 (2.88) 26.38 (9.64) 12.13 (4.05) 12.50 (8.26) 3.34 (0.95) 1.98 (0.71) 6.20 (0.87) 
Madopar 21.75 (6.50) 21.13 (5.03) 27.25 (10.90) 15.25 (5.82) 11.38 (11.27) 3.35 (0.75) 2.86 (1.80) 5.64 (1.24) 
Placebo 21.75 (5.37) 17.63 (4.63) 28.38 (8.60) 11.88 (2.64) 6.50 (7.05) 3.55 (0.89) 1.97 (0.42) 6.02 (0.55) 
M (SD) 22.07 (6.82) 19.04 (4.11) 26.04 (8.99) 12.86 (3.55) 11.02 (8.75) 3.66 (0.80) 2.58 (1.32) 5.67 (1.02) 
Note: SEEKING = ANPS seeking sub-scale; PANIC/GRIEF = ANPS panic/grief subscale; POS = PANAS positive sub-scale; NEG= PANAS 
negative sub-scale; S_Anx = SAAM anxiety sub-scale; S_Av = SAAM avoidance sub-scale; S_Sec = SAAM security sub-scale; MDI = total 













Testing hypothesis 6. The magnitude of change for PANIC/GRIEF, PANAS and 
MDI on the opioid-based medications will be significantly different between the low and 
high baseline ECR ‘anxious’ and ‘avoidant’ attachment groups (i.e., high and low baseline 
‘protest’). The groups will likewise differ in relation to their ‘directed probes’, ‘memories of 
loss’ and ‘free associations’ on opioid-based medications. 
For avoidant attachment, a series of Mann-Whitney U tests were conducted to 
determine whether the magnitude of change for PANIC/GRIEF, PANAS and MDI on the 
opioid-based medications would be significantly different between the Low and High- 
Avoidant groups (see Table 15). There were no significant differences in the magnitude of 
change between the Low and High-Avoidance groups for PANIC/GRIEF, PA or mood on the 
opioid-based medications. There were however some significant differences between the 
groups for NA on both opioid-based medications. The change from baseline in NA scores on 
Morphine was significantly different between the two groups, U = 12.50, p = .039 (large 
effect size), with the Low-Avoidance group experiencing a significantly larger reduction in 
NA. The Low-Avoidance group experienced a decrease in NA, whereas the High-Avoidance 
group experienced a slight increase in NA. The change from baseline in NA on Naltrexone 
was also significantly different between the two groups, U = 11.50, p = .030 (large effect 
size), with the Low-Avoidance group experiencing a significantly larger reduction in NA. 
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Table 15 





    
Variable M Rank M Rank z U p r 
Opioid Agonist       
PANIC/ 
GRIEF 
9.56 7.44 -0.90 23.50 .370 0.23 
MDI 10.19 6.81 -1.42 18.50 .155 0.36 
PA 9.31 7.69 -0.68 25.50 .494 0.17 
NA 10.94 6.06 -2.07 12.50 .039* 0.52 
Opioid Antagonist       
PANIC/ 
GRIEF 
9.75 7.25 -1.06 22.00 .291 0.27 
MDI 10.38 6.63 -1.58 17.00 .113 0.40 
PA 7.06 9.94 -1.22 20.50 .222 0.31 
NA 11.06 5.94 -2.17 11.50 .030* 0.54 
Note. Opioid Agonist = Morphine. Opioid Antagonist = Naltrexone. All statistical tests 
reported were 2 tailed. 
 
 
On ‘directed probes’, there was no significant association between change in 
PANIC/GRIEF and the opioid-based medications, p = .413, V = .41 and p = .293, V = .13 in 
both the Low-and- High- ECR-Avoidance groups respectively. On Morphine, N=4 in the 
Low-Avoidance group and N=4 in the High-Avoidance group reported a decrease in 
PANIC/GRIEF. On Naltrexone, N=2 in the Low-Avoidance group and N=1 in the High- 
Avoidance group reported an increase in PANIC/GRIEF. These results indicate that the same 
number of participants in both groups qualitatively reported decreases in PANIC/GRIEF on 
Morphine and very few participants in both groups qualitatively reported increases in 
PANIC/GRIEF on Naltrexone. 
As to the association between the changes in PANIC/GRIEF as measured by the 
ANPS and the changes in PANIC/GRIEF as measured by the ‘directed probes’, there was no 
significant association for Naltrexone, rs = -.10, p = .412 in the Low-ECR-Avoidance group. 
When on Naltrexone, most participants reported a decrease in PANIC/GRIEF on the ANPS, 
whereas more participants (N=5) reported no change in PANIC/GRIEF on the ‘directed 
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probes’. [No correlation could be run for Morphine because all participants reported 
experiencing a decrease in PANIC/GRIEF on the ANPS]. Within the High-ECR-Avoidance 
group, analyses detected no significant associations for Morphine (rs = -.31, p = .229) or 
Naltrexone (rs = .36, p = .192). On Morphine, N=5 reported a decrease in PANIC/GRIEF on 
the ANPS, and N=4 reported a decrease in PANIC/GRIEF on the ‘directed probes’, but N=3 
also reported ‘no change’. On Naltrexone, N=7 in the Low-Avoidance group and N=4 in the 
High-Avoidance group reported a decrease in PANIC/GRIEF on the ANPS, but N=5 in the 
Low-Avoidance group and N=4 in the High-Avoidance group responded with ‘no change’ on 
the ‘directed probes’ (explaining why the correlation indicated no association). 
On ‘memories of loss’, there were no striking differences between the High and Low 
ECR-Avoidance groups with respect to the types of personal loss experienced. Also, there 
were no statistically significant associations between change in emotional intensity during 
‘memories of loss’ recall and medication for the Low (p = .129, V = .39) and High (p = .665, 
V = .27) Avoidance groups. One participant in the Low-Avoidance group compared to two in 
the High-Avoidance group reported no change in emotional intensity on Morphine. There 
were four moderate and two mild changes in emotional intensity reported in the Low- 
Avoidance group, compared to three moderate and two mild changes in emotional intensity in 
the High-Avoidance group. Some examples of mild to moderate change in the Low- 
Avoidance group were “Less anxiety if I think about it now”, “Not as distressing as I found it 
the other times” and “The mental imagery is more positive than it would normally be”. In the 
High-Avoidance group, some examples of mild to moderate change were “There’s no 
particular feeling” and “It doesn’t have too much impact on me recalling that”. Qualitatively, 
there was less psychological pain when participants in the Low-Avoidance group re- 
experienced their loss compared to the High-Avoidance group who were relatively less 
engaged with the emotions attached to their loss. Lastly, there was one extreme change 
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reported in each of the Low and High-Avoidance groups, described as “This is very unusual 
for me, I feel it’s almost something very destructive” and “I can feel a memory of the feeling, 
but it’s not even that I can feel it. It’s like a memory of a feeling”, respectively. On 
Naltrexone, two participants in the Low-Avoidance group compared to three in the High- 
Avoidance group reported no change in emotional intensity. There were two notable 
differences between the groups on Naltrexone. Firstly, there were four moderate changes in 
emotional intensity reported in the Low-Avoidance group, compared to two in the High- 
Avoidance group. Some examples of moderate change in the Low-Avoidance group are “I 
think what strikes me is the fact that I feel very tranquil when I think about it”, “Sharp and 
clear in my mind but the feelings are more sad than angry”, “I feel more at peace with it|” and 
“The pain of loss is erased”. Also, two participants reported extreme changes in emotional 
intensity in the High-Avoidance group, described as “This one has aroused that 
uncomfortable, panicky feeling” and “I’m truly trying hard to access them, but I can’t break 
though something. I can’t get there”, compared to zero in the Low-Avoidance group. 
On all the psychological probes data together, that is, ‘directed probes’, ‘memories of 
loss’ and ‘free association’, four participants in the Low and three in the High-Avoidance 
group reported feeling ‘relaxed’, four participants in the Low and three in the High- 
Avoidance group reported feeling ‘muted pain/detachment’, and lastly, two participants in 
each group reported feeling ‘connected’ on Morphine. The Low and High-Avoidance group’s 
affective responses to Naltrexone were slightly more varied. Four participants in the Low and 
three in the High-Avoidance group reported feeling ‘detached’, while three participants 
experienced a reduction in drive in the High-Avoidance group compared to one in the Low- 
Avoidance group. 
Summary of results for the split ECR-Avoidance sample. Opioid Medications: 
 
Morphine and Naltrexone did not account for any significant differences between the groups 
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for PANIC/GRIEF, PA or mood. The Low-Avoidance group however experienced a 
significantly larger reduction in NA on Morphine and Naltrexone. There were no significant 
association between changes in PANIC/GRIEF and the opioid-based medications on 
‘directed probes’. There were no significant associations between the ‘directed probes’ and 
the ANPS measures for Naltrexone or Morphine. There were no statistically significant 
associations between change in emotional intensity and medication in both groups for 
‘memories of loss’. Lastly, there was little difference between the groups in terms of affects 
on Morphine. On Naltrexone, the groups varied slightly in that more participants in the High- 
Avoidance group experienced a reduction in drive compared to the Low-Avoidance group. 
Results of Psychometric and Psychological Probes Data Analyses for the Split ECR- 
Anxiety Sample 
Baseline descriptives prior to medication. All results reported under this section refer 
to the split sample, which was based on ECR-Anxiety scores. Table 16 presents the means and 
standard deviations of all four psychometric measures at baseline. The High-Anxiety group 
had significantly higher baseline ECR-Anxiety scores compared to the Low-Anxiety group, U 
= 10.00, p = .011 and U < 0.01, p < .001, once again justifying the split. The Low-Anxiety 
group had significantly higher baseline PANIC/GRIEF scores compared to the High-Anxiety 
group, U = 16.00, p = .043. (Although this is a counter-intuitive finding, it must be noted that 
in this instance, we are possibly seeing the effects of “extreme” values in a small sample. One 
participant in the Low-Anxiety group had a high PANIC/GRIEF score and one participant in 
the High-Anxiety group had a very low PANIC/GRIEF score). The two groups did not differ 








n = 8 
High Anxiety 









SEEKING 32.38 (4.07) 28.88 (3.09) 33.50 28.00 16.50 .051 
PANIC/GRIEF 23.38 (3.20) 19.38 (5.24) 23.00 20.00 16.00 .043* 
PA 35.25 (5.92) 33.13 (3.40) 37.00 33.50 21.00 .123 
NA 13.88 (3.40) 12.50 (1.77) 13.50 12.50 24.50 .213 
MDI 8.75 (4.53) 7.75 (2.25) 8.50 8.00 27.50 .318 
ECR_Avoidance 5.07 (0.95) 6.11 (0.61) 5.33 6.33 10.00 .011* 
ECR_Anxiety 4.79 (0.62) 6.01 (0.36) 4.94 5.99 <0.01 <.001* 



























Subjective psychobehavioural effects of medications. As for the split avoidance 
groups, there were likewise no substantial differences between the two anxiety groups with 
respect to the number of positive and negative psychobehavioural effects reported on 
Morphine, Naltrexone and Placebo. There were however differences between the High and 
Low-Anxiety groups for Madopar, with the Low-Anxiety group experiencing almost three 
times the number of positive effects compared to the High-Anxiety group; this is similar to 
the experience of the Low-Avoidance group on Madopar. The Low-Anxiety group also 
experienced double the number of negative effects on Haloperidol, compared to the High- 
Anxiety group. 
Descriptives of the psychometric measures across medications. The means and 
standard deviations of the psychometric measures across medications for the split ECR- 
Anxiety sample are shown in Table 17. Compared to baseline, PA was reduced for both groups 
across all medications. In both groups, Naltrexone and Morphine caused the greatest reductions 
in PA. Compared to baseline, NA was reduced on all medications except for Madopar in the 
Low-Anxiety group, with Morphine causing the largest reduction. In the High-Anxiety group, 
NA was reduced on all medications except for Naltrexone and Madopar, which increased NA. 
The largest increase in NA by far in this group was caused by Madopar. Interestingly, Madopar 
caused the biggest increase in NA in both Anxiety groups, as it did in both the MDI and 
Avoidance groups. PANIC/GRIEF was reduced in both groups across all medications, except 
for the High-Anxiety group who experienced an increase in PANIC/GRIEF on Madopar and 
Naltrexone. In the Low-Anxiety group, Morphine caused the largest decrease in 
PANIC/GRIEF. In the High-Anxiety group, Placebo caused the greatest decrease in 
PANIC/GRIEF followed by Morphine. In the Low-Anxiety group, Naltrexone, Haloperidol 
and Madopar caused an increase in depression scores compared to baseline with the biggest 
increase caused by Madopar. Morphine caused a reduction in depression scores in this group. 
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In the High-Anxiety group, all medications except Placebo caused an increase in depression 
scores. The biggest increase in depression scores compared to baseline was caused by 
Naltrexone, followed by Madopar. Lastly, as regards the SAAM, when comparing the group 
means for each sub-scale across all medications on this attachment measure, there was no 




Descriptives for Psychometric Measures Across Medications for the Split ECR-Anxiety-Groups 
 SEEKING PANIC/GRIEF PA NA MDI S_Anx S_Av S_Sec 
Low Anxiety         
Baseline 32.38 (4.07) 23.38 (3.20) 35.25 (5.92) 13.88 (3.40) 8.75 (4.53) - - - 
Morphine 21.38 (4.17) 16.63 (1.41) 21.50 (8.02) 11.63 (2.07) 8.25 (8.55) 3.27 (1.16) 2.57 (1.39) 5.69 (1.01) 
Naltrexone 21.13 (5.59) 19.00 (2.93) 21.38 (9.72) 12.88 (3.52) 11.50 (10.92) 3.77 (0.74) 2.86 (1.21) 5.48 (1.09) 
Haloperidol 22.13 (8.72) 18.88 (3.91) 23.38 (8.88) 13.13 (4.67) 10.75 (10.95) 4.13 (1.03) 2.04 (1.10) 5.93 (0.57) 
Madopar 22.38 (9.66) 17.88 (5.54) 29.25 (11.88) 15.25 (6.04) 11.75 (11.79) 3.07 (0.73) 2.77 (1.47) 5.34 (1.10) 
Placebo 24.13 (6.79) 18.50 (2.45) 30.63 (9.67) 13.25 (3.54) 8.13 (11.21) 3.68 (0.36) 2.39 (1.43) 5.93 (0.64) 
M (SD) 23.55 (7.22) 18.70 (3.75) 26.13 (9.99) 13.09 (3.82) 10.16 (9.26) 3.53 (0.94) 2.46 (1.33) 5.79 (0.84) 
High Anxiety         
Baseline 28.88 (3.09) 19.38 (5.24) 33.13 (3.40) 12.50 (1.77) 7.75 (2.25) - - - 
Morphine 21.88 (6.73) 18.25 (3.58) 26.13 (7.61) 12.13 (3.04) 8.25 (8.55) 3.61 (0.74) 2.48 (1.24) 5.41 (0.99) 
Naltrexone 19.25 (7.25) 20.00 (1.07) 22.00 (7.56) 12.63 (2.88) 12.63 (8.48) 3.43 (1.01) 3.45 (1.32) 5.13 (1.09) 
Haloperidol 23.25 (7.76) 18.75 (3.11) 28.38 (8.26) 11.38 (1.30) 12.25 (9.16) 3.36 (0.96) 2.43 (1.36) 5.82 (0.92) 
Madopar 21.50 (6.74) 21.88 (4.85) 27.00 (10.58) 16.38 (5.53) 12.38 (10.91) 4.01 (1.26) 2.86 (1.80) 5.48 (1.23) 
Placebo 22.50 (5.45) 17.88 (4.88) 30.88 (7.95) 11.75 (1.83) 6.50 (4.72) 3.71 (1.01) 1.97 (0.33) 5.87 (0.52) 
M (SD) 22.73 (6.66) 19.20 (3.98) 27.66 (8.11) 12.70 (3.29) 9.71 (7.94) 3.68 (0.93) 2.70 (1.28) 5.43 (0.99) 
Note: SEEKING = ANPS seeking sub-scale; PANIC/GRIEF = ANPS panic/grief subscale; POS = PANAS positive sub-scale; NEG= PANAS 
negative sub-scale; S_Anx = SAAM anxiety sub-scale; S_Av = SAAM avoidance sub-scale; S_Sec = SAAM security sub-scale; MDI = total 













Testing hypothesis 6. The magnitude of change for PANIC/GRIEF, PANAS and MDI 
on the opioid-based medications will be significantly different between the low and high 
baseline ECR ‘anxious’ and ‘avoidant’ attachment groups (i.e., high and low baseline 
‘protest’). The groups will likewise differ in relation to their ‘directed probes’, ‘memories of 
loss’ and ‘free associations’ on the Opioid-based medications. 
For anxious attachment, a series of Mann-Whitney U tests were conducted to determine 
whether the magnitude of change for PANIC/GRIEF, PANAS and MDI on the opioid-based 
medications would be significantly different between the Low and High-Anxiety attachment 
groups (see Table 18). There were no significant differences in the magnitude of change 
between the Low and High-Anxiety groups for PANIC/GRIEF, affect or mood on the opioid- 
based medications. Although not significant, there was a trend towards significance in the Low- 
Anxiety group for Morphine, which accounted for the largest decrease in PANIC/GRIEF on 
ANPS, with a medium effect size. 
 
Table 18 
Results of Mann-Whitney U Tests for Opioid Medications 
 Low Anxiety High Anxiety     
Variable M Rank M Rank z U p r 
Opioid Agonist       
PANIC/ 
GRIEF 
10.69 6.31 -1.85 14.50 .065 0.46 
MDI 8.81 8.19 -0.26 29.50 .792 0.07 
PA 10.25 6.75 -1.47 18.00 .141 0.37 
NA 9.31 7.69 -0.69 25.50 .491 0.17 
Opioid Antagonist       
PANIC/ 
GRIEF 
10.44 6.56 -1.64 16.50 .102 0.41 
MDI 9.56 7.44 -0.90 23.50 .370 0.23 
PA 9.75 7.25 -1.06 22.00 .228 0.27 
NA 9.19 7.81 -0.58 26.50 .561 0.15 
Note. Opioid Agonist = Morphine. Opioid Antagonist = Naltrexone. All statistical tests 
reported were 2 tailed. 
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On ‘directed probes’, there was no significant association between change in 
PANIC/GRIEF and the opioid-based medications, p = .431, V = .17 and p = .075, V = .41 for 
the Low- and- High-ECR-Anxiety groups, but there was a trend towards significance, with a 
medium effect size, in the High-Anxiety group for Morphine. N=2 reported a decrease in 
PANIC/GRIEF in the Low-Anxiety group but in the High-Anxiety group, N=6 reported a 
decrease in PANIC/GRIEF. This result indicates that more participants in the High-Anxiety 
group qualitatively reported a decrease in PANIC/GRIEF on Morphine, which is a reasonable 
finding. On Naltrexone, N=2 in the Low-Anxiety group and N=1 in the High-Anxiety group 
reported an increase in PANIC/GRIEF. This result indicates that very few participants in both 
groups qualitatively reported an increase in PANIC/GRIEF on Naltrexone. 
As to the association between the changes in SEEKING as measured by the ANPS 
and the changes in SEEKING as measured by the ‘directed probes’, there was no significant 
association for Naltrexone (rs = -.10, p = .412), within the Low-Anxiety group. When on 
Naltrexone, nearly all participants reported a decrease in PANIC/GRIEF on the ANPS, 
whereas more participants reported no change in PANIC/GRIEF on ‘directed probes’. [Once 
again, no correlation could be run for Morphine because all participants reported 
experiencing a decrease in PANIC/GRIEF on the ANPS]. Within the High-Anxiety group, 
analyses detected no significant associations for Morphine (rs = .15, p = .363) or Naltrexone 
(rs = .36, p = .192). For Morphine and Naltrexone, most participants reported an increase or 
decrease in PANIC/GRIEF on the ANPS, whereas on the ‘directed probes’, most participants 
reported no change or a decrease in PANIC/GRIEF (possibly explaining why the correlation 
indicated no association). 
On ‘memories of loss’, there were no striking differences between the High and Low- 
Anxiety groups with respect to the types of personal loss experienced. There were also no 
significant associations between change in emotional intensity during ‘memories of loss’ 
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recall and medication for the Low (p = .329, V = .33) and High (p = .619, V = .27) -Anxiety 
groups. Six participants in each group reported some change in emotional intensity on 
Morphine and the range of reported emotional changes was quite similar between the groups. 
In both groups, two participants reported no change in emotional intensity. Four participants 
reported a moderate change in the High-Anxiety group, described as “There’s no sense of 
panic that I don’t mean anything to him anymore”, “It feels like I can direct my thoughts 
quite clearly now and I can look into things” and “I can feel some of the memory of the 
distress, but it’s distant”, compared to three in the Low Anxiety group. In the Low-Anxiety 
group, some examples of moderate change are “The general affective tone is not very 
catastrophic”, “It feels somehow in a way slightly more out of my mental grasp” and “I’m 
unable to intensely experience that now”. There was also one participant who reported an 
extreme change in both the Low and High-Anxiety groups, described as “I can’t, I can’t grip 
it, it’s actually the strangest thing” and “I’m not feeling it. It’s so weird, such a weird thing. 
Anyway, I’m not feeling it”, respectively. In both groups, there was a lack of negative affect 
in general and difficultly accessing the loss when participants were re-experiencing their 
memories. The range of reported emotional changes was also quite similar between the 
groups on Naltrexone. In both groups, three participants reported no change in emotional 
intensity and three participants in each group reported a moderate change. In the Low- 
Anxiety group, some examples of moderate change in emotional intensity are “It doesn’t feel 
like I’m emotionally attached to those memories”, “The memory has no affective tone” and 
“Mostly, I feel third-personish about it”. In the High-Anxiety group, some examples of 
moderate change in emotional intensity are “It makes me feel like crying. The increase stress 
of anxiousness and sadness”, “I’m just so disconnected, I don’t feel so agitated” and “I don’t 
feel any pangs. I feel carefree. It doesn’t bother me”. Lastly, there was one participant who 
reported an extreme change in both the Low and High-Anxiety groups, described as “It’s 
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such a stark contrast compared to originally telling you about it. It seems a little abstract at 
the moment” and “I mean I remember it but it’s like watching a movie that has nothing to do 
with me”, respectively. As with Morphine, the emotional tone of the re-experienced 
memories generally lacked negative affect and most participants described feeling removed 
or distanced from their memories. 
On all the psychological probes data together, that is, ‘directed probes’, ‘memories of 
loss’ and ‘free association’, there were three notable differences between the group’s 
affective responses. On Naltrexone, five participants in the High-Anxiety group felt 
‘detached ‘compared to two in the Low-Anxiety group. On Morphine, five participants in the 
Low-Anxiety group felt ‘muted pain/detachment ‘compared to two in the High Anxiety 
group. On Morphine, three participants in the High-Anxiety group reported feeling more 
‘connected’ compared to zero in the Low-Anxiety group. The groups did not differ with 
respect to feeling ‘relaxed’ on Morphine or ‘low drive’ on Naltrexone. 
Summary of results for the split ECR-Anxiety sample. Opioid Medications: 
Morphine and Naltrexone did not account for any significant differences between the groups 
for PANIC/GRIEF, affect or mood. There was a trend towards significance in the Low- 
Anxiety group for Morphine, which accounted for the largest decrease in PANIC/GRIEF on 
the ANPS. There were no significant association between changes in PANIC/GRIEF and the 
opioid-based medications on ‘directed probes’, but there was a trend towards significance in 
the High-Anxiety group on Morphine. There were no significant associations between the 
‘directed probes’ and the ANPS measures for Naltrexone or Morphine. There were no 
statistically significant associations between change in emotional intensity during ‘memories 
of loss’ recall and medication. Lastly, the groups did differ with respect to their prominent 
affects. More participants in the High-Anxiety group reported feeling ‘detached’ compared to 
the Low-Anxiety group on Naltrexone; more participants reported feeling ‘muted 
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pain/detachment’ on Morphine in the Low-Anxiety group compared to the High-Anxiety 
group and more participants in the High-Anxiety group reported feeling ‘connected’ on 
Morphine compared to zero in the Low-Anxiety group. 
Overall Summary of Results for Psychometric and Psychological Probes data 
Whole sample (see Table 19): 
Hypothesis One: Madopar will increase SEEKING, PA and significantly improve 
mood, relative to baseline, on the psychometric measures and psychological probes data. 
Madopar significantly reduced SEEKING and PA and had no significant effect on mood. 
There was a trend towards significance on the ‘directed probes’, indicating that a majority of 
participants qualitatively reported an increase in SEEKING. There was no significant 
association between the psychometric (ANPS) and qualitative (‘directed probes’) measures 
of increased SEEKING, indicating that psychometrically participants reported reduced 
SEEKING whereas qualitatively, they reported increased SEEKING. Two prominent affects 
were identified: ‘feeling positively stimulated’ and ‘feeling negatively stimulated’; in other 
words, a majority of participants felt ‘stimulated’ but they valenced the experience 
differently. Change in emotional intensity for ‘memories of loss’ was significantly associated 
with Placebo, but not to any other medication. 
Hypothesis Two: Haloperidol will significantly decrease SEEKING, increase NA and 
significantly worsen mood, relative to baseline, on the psychometric measures and 
psychological probes data. Haloperidol significantly reduced SEEKING but did not 
significantly worsen mood or NA. There was a trend towards significance on the ‘directed 
probes’, indicating that a majority of participants qualitatively reported a decrease in 
SEEKING. There was a trend towards significance between the psychometric (ANPS) and 
qualitative (‘directed probes’) measures of reduced SEEKING, indicating that a majority of 
participants reported reduced SEEKING on both measures. Three prominent affects were 
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identified: ‘low drive’, ‘detached’ and ‘relaxed’. There were no statistically significant 
differences in change in emotional intensity for ‘memories of loss’. 
Hypothesis Three: Morphine will significantly decrease PANIC/GRIEF, increase PA 
and significantly improve mood, relative to baseline, on the psychometric measures and 
psychological probes data. Morphine significantly reduced PANIC/GRIEF but did not 
improve PA or mood. There was no significant association on the ‘directed probes’. There 
was no significant association between the psychometric (ANPS) and qualitative (‘directed 
probes’) measures of reduced PANIC/GRIEF, indicating that psychometrically participants 
reported reduced PANIC/GRIEF whereas qualitatively, eight reported no change in 
PANIC/GRIEF. Three prominent affects were identified: ‘relaxed’, ‘muted pain/detachment’ 
and ‘connected’. Change in emotional intensity for ‘memories of loss’ was significantly 
associated with Placebo, but not to any other medication. 
Hypothesis Four: Naltrexone will significantly increase PANIC/GRIEF and NA and 
significantly worsen mood, relative to baseline, on the psychometric measures and 
psychological probes data. Naltrexone significantly reduced PANIC/GRIEF and did not 
significantly increase NA or worsen mood. There was a trend towards Naltrexone worsening 
mood. There was no significant association on the ‘directed probes’, indicating that most 
participants did not qualitatively report any change in the increase of PANIC/GRIEF. There 
was no significant association between the psychometric (ANPS) and qualitative (‘directed 
probes’) measures of increased PANIC/GRIEF, indicating that psychometrically most 
participants reported reduced PANIC/GRIEF whereas qualitatively, most of the participants 
reported no change in PANIC/GRIEF. Two prominent affects were identified: ‘detached’ and 
‘low drive’. Change in emotional intensity for ‘memories of loss’ was significantly associated 
with Placebo, but not to any other medication. 
Although no specific predictions were made for Placebo, it significantly reduced 
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SEEKING, but had no effect on affect or mood. No prominent affects were identified. 
 
Split MDI sample (see Table 19): 
 
Hypothesis Five: The magnitude of change for SEEKING, PANAS and MDI on the 
dopamine-based medications will be significantly different between the low and high 
baseline-MDI groups (i.e. high and low baseline ‘despair’) on the psychometric measures 
and psychological probes data. Madopar did not account for any significant differences 
between the Low and High-MDI groups on SEEKING, affect or mood. Haloperidol 
accounted for significant differences between the Low and High-MDI groups on SEEKING, 
PA and mood. Haloperidol reduced SEEKING and PA and worsened mood to a greater 
extent in the Low-MDI group. Haloperidol did not have a differential effect on NA. 
There was a significant association on the ‘directed probes’ in the Low-MDI group, 
indicating that most participants in this group, but not the High-MDI group, qualitatively 
reported an increase in SEEKING on Madopar and a decrease in SEEKING on Haloperidol, 
in keeping with expected medication effects. There was no significant association between 
the psychometric (ANPS) and qualitative (‘directed probes’) measures of increased 
SEEKING in both groups on Madopar. This result indicated that in both groups, most 
participants reported a decrease in SEEKING on the ANPS, but several participants 
qualitatively reported an increase in SEEKING on the ‘directed probes’ on Madopar. But on 
Haloperidol, there was a significant association between the two measures in the Low-MDI 
group. Participants in this group, but not the High-MDI group, reported a decrease in 
SEEKING on the ANPS and on the ‘directed probes’. In the high-MDI group, more 
participants reported a decrease in SEEKING on the ANPS compared to the ‘directed 
probes’. The Low-MDI group was relatively more ‘positively stimulated’ on Madopar 
compared to the High-MDI group who felt ‘negatively stimulated’. The High-MDI group felt 
relatively more ‘detached’ on Haloperidol compared to the Low-MDI group. There was a 
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significance in change in emotional intensity for ‘memories of loss’ on Madopar, compared to 
Placebo, in the Low-MDI group, but not the High-MDI group. 
Split ECR-Avoidance sample (see Table 19): 
 
Hypothesis Six: The magnitude of change for PANIC/GRIEF, PANAS and MDI on 
the opioid-based medications will be significantly different between the low and high 
baseline-ECR ‘anxious’ and ‘avoidant’ attachment groups (i.e., high and low baseline 
‘protest’) on the psychometric measures and psychological probes data. Morphine and 
Naltrexone did not account for any significant differences between the Avoidance groups on 
PANIC/GRIEF, PA or mood. Morphine and Naltrexone significantly reduced NA in the 
Low-Avoidance group. There was no significant association on the ‘directed probes’ on 
Morphine or Naltrexone in both groups. This result indicated that the same number of 
participants in both groups qualitatively reported decreases in PANIC/GRIEF on Morphine 
and very few participants in both groups qualitatively reported increases in PANIC/GRIEF on 
Naltrexone. There was no significant association between the psychometric (ANPS) and 
qualitative (‘directed probes’) measures of PANIC/GRIEF in the High-Avoidance group for 
Morphine or Naltrexone. This result indicated that participants in this group reported a 
decrease in PANIC/GRIEF on the ANPS, but often reported ‘no change’ on the ‘directed 
probes’ on Morphine and Naltrexone. Furthermore, there was no significant association 
between the psychometric (ANPS) and qualitative (‘directed probes’) measures of 
PANIC/GRIEF in the Low-Avoidance group for Naltrexone, indicating that most participants 
in this group reported a decrease in PANIC/GRIEF on the ANPS compared to the ‘directed 
probes’, where ‘no change’ was mostly reported. No correlation between the two measures 
could be run for Morphine in the Low-Avoidance group because all participants in this group 
reported a decrease in PANIC/GRIEF on the ANPS. There was no statistically significant 
change in emotional intensity for the ‘memories of loss’ in either group on Morphine or 
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Naltrexone. There were no noteworthy differences between the group’s affective responses to 
Morphine. On Naltrexone, three participants experienced a reduction in drive in the High- 
Avoidance group compared to one in the Low-Avoidance group. 
Split ECR-Anxiety sample (see Table 19): 
 
Morphine and Naltrexone did not account for any significant differences between the 
groups on PANIC/GRIEF, affect or mood. There was a trend towards significance for 
Morphine to decrease PANIC/GRIEF on the ANPS in the Low-Anxiety group. There was a 
trend towards a significant association on the ‘directed probes’ in the High-Anxiety group, 
indicating that most participants in this group, but not the Low-Anxiety group, qualitatively 
reported a decrease in PANIC/GRIEF on Morphine. On Naltrexone, there was no significant 
association in both groups on the ‘directed probes’, since very few participants in either 
group qualitatively reported an increase in PANIC/GRIEF. There was no significant 
association between the psychometric (ANPS) and qualitative (‘directed probes’) measures of 
PANIC/GRIEF in the High-Anxiety group for Morphine or Naltrexone. This result indicated 
that most participants in this group reported a decrease in PANIC/GRIEF on the ANPS 
compared to the ‘directed probes’, where mostly no change was reported. Furthermore, there 
was no significant association between the psychometric (ANPS) and qualitative (‘directed 
probes’) measures of PANIC/GRIEF in the Low-Anxiety group for Naltrexone, indicating 
that most participants in this group reported a decrease in PANIC/GRIEF on the ANPS 
compared to the ‘directed probes’, where no change was mostly reported. No correlation 
between the two measures could be run for Morphine in the Low-Anxiety group because all 
participants in this group reported a decrease in PANIC/GRIEF on the ANPS. There was no 
statistically significant association between change in emotional intensity when recalling 
‘memories of loss’ and the opioid-based medications between the groups. More participants 
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in the High-Anxiety group reported feeling ‘detached’ on Naltrexone and more participants 
reported feeling ‘muted pain/detachment’ on Morphine in the Low-Anxiety group. 
 
Table 19 
Summary of Results 
 Madopar Haloperidol Morphine Naltrexone Placebo 
Whole Sample      
SEEKING reduced reduced   reduced 
PANIC/GRIEF   reduced reduced  
PA reduced  reduced  trend towards 
significance 
to reduce 
NA  no effect  no effect  














no effect no effect  
ANPS vs Directed 
Probes 
no association trend towards 
significant 
association 





























































Split MDI Sample      
SEEKING no effect reduced for 
Low-MDI 
group 
   
PANIC/GRIEF      
PA no effect reduced for 
Low-MDI 
group 
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 Madopar Haloperidol Morphine Naltrexone Placebo 
NA no effect no effect    
MDI no effect increased for 
Low-MDI 
group 
   










   
ANPS vs Directed 
Probes 




   
Change in 
emotional intensity 












no effect for 
either group 
   

















   
Split ECR- 
Avoidance Sample 
     
SEEKING      
PANIC/GRIEF   no effect no effect  
PA   no effect no effect  








MDI   no effect no effect  
Directed Probes   no effect no effect  
ANPS vs Directed 
Probes 





  no effect no effect  
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on memories of 
loss 
 Madopar Haloperidol Morphine Naltrexone Placebo 
Prominent Affects   N=4 ‘relaxed’ 




N=3 ‘relaxed’  





















     
SEEKING      




no effect  
PA   no effect no effect  
NA   no effect no effect  
MDI   no effect no effect  






no effect  
ANPS vs Directed 
Probes 





on memories of 
loss 
  no effect no effect  

























Canonically, the separation-distress response to social loss manifests firstly as PANIC, 
expressed as ‘protest’, followed by GRIEF, expressed as ‘despair’, if the ‘protest’ behaviour 
does not lead to the desired reunion. Panksepp’s (1998) claim is that the despair phase of the 
separation-distress response is the normal prototype of depression, that is, sadness, 
hopelessness, anergia and anhedonia (Solms & Panksepp, 2010). Within the theoretical 
framework of affective neuroscience, major depression is thus characterised by an 
overactivated PANIC/GRIEF system and an underactivated SEEKING system (Panksepp, 
2004). Empirical support for this view is well established in the preclinical literature but the 
evidence in humans is limited, at best. In light of this, the PANIC/GRIEF and SEEKING 
systems were artificially stimulated in 16 healthy volunteers. Both psychometric questionnaires 
and psychological probes were used to identify, measure and qualitatively characterise the 
anticipated effects of these manipulations. The aims of the study were to, firstly, establish 
whether a stimulated PANIC/GRIEF system and a dampened SEEKING system would lead to 
depressive affects that are homologous to the mammalian ‘protest’ and ‘despair’ behaviours 
and, secondly, explore the influence of attachment traits and separation/loss events in relation 
to the role of the SEEKING and PANIC/GRIEF systems in separation distress. To my 
knowledge, this study is the first to attempt to pharmacologically induce in human subjects the 
‘despair’ and ‘protest’ behaviours seen in various other mammal species. The sample 
comprised participants who had personal experience of psychoanalysis or psychotherapy, were 
not clinically depressed, and did not display higher than normal PA and NA, SEEKING and 
PANIC/GRIEF scores at baseline, compared to published norms. There was some indication 
that participants displayed higher avoidant and anxious scores on the ECR at baseline, but this 
was in comparison to one unmatched sample. 
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Several important issues to remember in relation to the discussion of the results is that 
this was an exploratory study, the psychological effects that I sought to identify were very 
subtle (since minimal once-off dosages were used), and the sample size was small. Moreover, 
given that the study lacked statistical power, no definitive conclusions could be drawn from 
psychometric results in isolation; the results were therefore interpreted with corroborating 
evidence from the qualitative data. 
Essentially, the results of this study were mixed. Although the effects of the medications 
on dopaminergic- and opioidergic-related affects in participants was similar to those 
documented in other mammals, these effects were not demonstrated consistently across the 
whole sample. Some results were significant in the direction of predicted effects, with 
corroborating qualitative evidence, some were significant in the opposite direction to predicted 
effects, while other predictions failed to reach significance. In some instances, there was only 
limited qualitative support (from the psychological probes data) for predicted outcomes. 
The results of each hypothesis will be discussed in relation to confirmatory evidence - 
where there was any at all - in support of the central claims of the study, along with various 
methodological, pharmacological and psychological factors that could have accounted for non- 
significant and inconsistent findings. 
Increased SEEKING. In the preclinical literature, an activated SEEKING system 
produces an increase in exploratory activity characterised by heightened motor behaviour, 
motivation, energy and curiosity (Panksepp, 1998) and is generally thought to be experienced 
as rewarding (Alcaro & Panksepp, 2011). Therefore, the first hypothesis of the study was that 
administering Madopar (a D1/D2 agonist) would produce such increased SEEKING 
behaviours and improve PA and mood in a human sample. Results of the psychometric analyses 
showed that all predictions about Madopar were not met. Contrary to predictions, Madopar 
significantly reduced SEEKING and PA and had no significant effect on mood. However,   in 
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contrast to the quantitative psychometric results, the qualitative psychological probes revealed 
some patterns of response that were in keeping with the anticipated effects of a stimulated 
SEEKING system. Half of the participants reported feeling ‘positively stimulated’ -- described 
variously as ‘euphoric’, ‘upbeat’, ‘optimistic’, ‘happy’ and ‘high’ -- and both groups of coders 
were in complete agreement in this respect. Madopar had a significantly positive effect on how 
participants felt when recalling their ‘memories of loss’, compared to Placebo, reporting feeling 
less sadness and pain associated with their loss. Nine participants reported that they felt an 
increase in SEEKING when asked about this during the ‘directed probes’. I was thus able to 
qualitatively demonstrate that a stimulated SEEKING system triggered positive feelings and 
that it was able to reduce the sadness associated with experiences of loss, but this only happened 
in half the sample. In sharp contrast, the other half experienced psychobehavioural effects 
contrary to expectations. These participants reported feeling ‘negatively stimulated’ -- 
described variously as ‘anxious’, ‘detached’, ‘isolated’ and ‘sad’ -- and found the experience 
of a stimulated SEEKING system stimulating in an unpleasant and distressing way. These 
participants also frequently reported experiencing side-effects on Madopar, such as elevated 
heart rate, feeling jittery, shaky and nausea. The cumulative effect of negative 
psychobehavioural and physical effects could have contributed towards reduced SEEKING and 
PA scores. Moreover, the descriptive data showed that SEEKING and PA were in fact reduced 
by all medications, not only Madopar. This trend will be discussed in greater detail in a later 
section. 
Decreased SEEKING. A pharmacologically deactivated or damaged SEEKING 
system leads to reduced motivation in animals, who express no eagerness to engage in any 
activity (Stellar & Stellar, 1985). Thus, the second hypothesis of the study was that Haloperidol 
(a D2 antagonist) would decrease SEEKING and worsen NA and mood in a human sample. 
Unlike Madopar which produced contradictory results, both the psychometric data and the 
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psychological probes yielded confirmatory results, more in keeping with predictions. 
Haloperidol significantly reduced SEEKING as reflected by reduced SEEKING scores on the 
ANPS. Although not significant, Haloperidol worsened mood as reflected by increased MDI 
scores in eight of the 16 participants. Haloperidol did not increase NA as expected, but it 
significantly reduced PA from baseline (t (13) = 2.47, p = .028, d = 0.84) in 11 participants. 
Many of the positive items on the PANAS scale, such as, ‘interested’, ‘excited’, ‘enthusiastic’, 
‘alert’, ‘attentive’ and ‘active’ are typically descriptive of the construct of SEEKING. Since 
Haloperidol significantly reduced SEEKING, it is reasonable that PA would also be 
significantly reduced. The psychological probes provided support for the findings from the 
psychometric analysis. Specifically, on the ‘directed probes’, eight participants reported that 
they felt a decrease in SEEKING, in keeping with the statistically significant reduction in 
SEEKING on the ANPS. Two commonly reported affective responses to Haloperidol were 
lowered drive (loss of motivation, energy and interest) and detachment, which are highly 
typical of decreased SEEKING and low mood. On the ‘memories of loss’, although there was 
no statistically significant change in emotional intensity when participants were recalling their 
episodes of loss on Haloperidol, the majority of participants qualitatively described that they 
felt emotionally numb when thinking about their losses, which is not incompatible with feelings 
of low drive and detachment. I was thus able to demonstrate that a dampened SEEKING system 
did produce several depressive affects in humans akin to mammalian ‘despair’ behaviours - 
such as anergia, amotivation and low mood and that PA was significantly reduced. 
Decreased PANIC. Being close to others generally feels good and it is a need we are 
said to share with other animals. The PANIC/GRIEF system promotes positive social bonding 
and it has been demonstrated repeatedly that opioids reduce separation-distress in other 
mammals (Panksepp & Biven, 2012). Therefore, the third hypothesis of the study was that 
Morphine (a µ-opioid agonist) would reduce PANIC/GRIEF and improve affective valence 
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and mood in a human sample. The results were somewhat mixed. In keeping with predictions, 
Morphine significantly reduced PANIC/GRIEF on the ANPS and even though the following 
association did not reach statistical significance, mood was improved in 10 participants, as 
reflected by reduced MDI scores on Morphine. There was evidence from the psychological 
probes data in support of the psychometrically significant reduction in PANIC/GRIEF and of 
the descriptive improvement in mood. Specifically, on ‘directed probes’, eight participants 
reported a decrease in PANIC/GRIEF. One of the prominent affects that were identified on 
Morphine was feeling ‘relaxed’. Participants reported feeling calm, subdued, mellow etc., in 
keeping with findings from other researchers such as O'Neill et al. (2000), who showed that 
their healthy subjects experienced increases in ‘subjective calmness’ on doses of Morphine 
equivalent to those used in the present study. Another prominent affect was a ‘muted sense of 
pain/detachment’. Here participants described feeling detached from their memories, but more 
importantly, that the pain associated with their loss was reduced or muted. Both affects are 
consistent with reduced PANIC/GRIEF and indicative of some improvement in mood. 
Furthermore, Morphine was shown to have a significant effect on change in emotional intensity 
when participants recalled their ‘memories of loss’, compared to Placebo, and the nature of this 
change was in keeping with the predicted effects of Morphine in that participants generally 
described feeling removed from the memory or emotion connected to it. In this sense, their 
PANIC/GRIEF on the Morphine recall was reduced compared to their baseline recall in that 
they found it difficult to access the pain associated with the loss. I was thus able to discern 
some evidence that a dampened PANIC/GRIEF system lead to an increase in the expression of 
feelings of contentment, relaxation, happiness and reduced concern and that the mental pain 
associated with previous loss was reduced. 
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With respect to PA, results were inconsistent with predictions. Morphine significantly 
reduced PA5. Three possible reasons could have contributed towards this finding. Firstly, as 
previously mentioned, the euphoric effects of μ-opioid agonists, especially in subjects with 
limited previous exposure to exogenous opioids, are not consistently reported in the literature. 
According to Ribeiro, Kennedy, Smith, Stohler, and Zubieta (2005), it is not typical for opioid 
users to experience euphoric effects initially, reporting instead predominantly negative 
experiences often accompanied by nausea. It is generally only after continual use that the 
euphoric effects are experienced. Furthermore, Zacny, Lichtor, Zaragoza, and de Wit (1992) 
argue that μ-opioid agonists have a biphasic effect on mood. They found that even though their 
subjects initially reported increases in ‘liking’ at time of dosing, fentanyl (a μ-opioid agonist), 
did not increase ratings on psychometric measures of drug-induced euphoria several hours later. 
Other properties of the drugs such as its μ-receptor affinity, how it was administered, the dose 
and genetic variations of the opioid system, could also have played a role (Levran, Yuferov, & 
Kreek, 2012). For instance, intravenous opioid administration produces greater euphoric effects 
than oral administration (Marsch et al., 2001). Nummenmaa and Tuominen (2017) conclude 
that although opioid agonists may produce pleasurable effects, further research is needed to 
establish the particular conditions under which opioid agonists actually elicit subjectively felt 
pleasure or euphoria. Secondly, as previously mentioned, the positive items on the PANAS 
scale correspond quite strongly with the construct of SEEKING. A post- hoc analysis revealed 
that there was a significant difference between baseline SEEKING and SEEKING after 
Morphine, t(15) =4.95, p < .001, d = 1.82. This significant reduction in SEEKING on Morphine 
could have accounted for the significant reduction in PA. Thirdly, it is not unusual for patients 
on chronic opioid medication to be less emotionally responsive. 
 
 
5 Morphine did reduce NA from the baseline mean of 13.19 to a post-Morphine mean of 
11.88, which is keeping with its predicted effects. 
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Johnson and Mosri (2016) describe these patient’s thinking and feelings as ‘autistic’ (p.3) to 
the extent that their relatedness to and need for human interaction is reduced. This is consistent 
with findings in the pre-clinical literature that Morphine reduces the need to seek out social 
contact (Nelson & Panksepp, 1998). Although participants in the current study only received a 
once-off dose of Morphine, it is still noteworthy that there was poor agreement between coders 
A and B with respect to feeling ‘Connected’, one of the prominent affects initially identified 
on Morphine. Coders A had originally identified this affect in eight participants, but coders B 
only identified it in five of the eight identified by coders A. The following description from a 
participant on Morphine is illustrative and points to a decrease in the desire to relate/interact 
with others: “Towards evening I was struck by a feeling of being very unenthused. Surprising 
in the circumstances because there was interesting live music, but I had no interest or wish to 
participate. I was noticeably bland.” 
Lastly, a more general point on the role of opioids in social behaviour is that although 
there are numerous studies confirming this association (Nelson & Panksepp, 1998), negative 
reports are not uncommon, and the discrepancy of results could be due to several factors, one 
of them being that the administration of agonists and antagonists affects multiple opioid 
systems and peptides (Mansour, Watson, & Akil, 1995). 
Increased PANIC/GRIEF. A decrease in µ-opioids is thought to lead to feelings of 
anhedonia, sadness, reduced PA, decreased feelings of social connection and intensified 
responses to social stress (Zellner et al., 2011). The fourth hypothesis of this study thus 
predicted that Naltrexone, (a µ-opioid antagonist) would increase PANIC/GRIEF and worsen 
affective valence and mood. Few of the predictions about Naltrexone were confirmed. 
PANIC/GRIEF was significantly reduced, and not increased as predicted, and NA was also 
not significantly worsened. Naltrexone increased PANIC/GRIEF in just five participants and 
increased NA in six participants. The only finding in keeping with predictions was that there 
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was a trend towards significance for Naltrexone to worsen mood as measured by the MDI. 
The psychological probes data mirrored the psychometric findings, confirming that 
Naltrexone did not increase PANIC/GRIEF as expected. Throughout the psychological 
probes for Naltrexone, there was little indication of increased feelings of sadness relating to 
loneliness, social isolation, longing for significant others or rejection; the essence of what 
comprises an increase in PANIC/GRIEF. Only for ‘memories of loss’ did two participants 
report an increase in sadness, but mostly participants described difficulty connecting with 
their memories. Moreover, the only prominent affect that both coders A and B agreed upon 
was that of feeling ‘detached’; participants described feeling detached from the affect 
associated with their memories of loss and of feeling removed. An increase in PANIC/GRIEF 
as measured by the ANPS is strongly centred on increases in feelings of sadness relating to 
intimate others and social loss or isolation. If participants felt affectively disconnected, it is 
not likely that they would have readily agreed to statements affirming any increase in 
psychological pain relating to separation from or loss of intimate relationships. To confirm 
this, I re-examined each participant’s response to the seven statements on the ANPS 
indicating an increase in PANIC/GRIEF. Of the total 112 responses to statements indicating 
an increase in PANIC/GRIEF, only 17 responses indicated ‘agree’; the majority of responses 
indicated ‘disagree’ or ‘strongly disagree’ to statements describing an increase in 
PANIC/GRIEF. To illustrate: only three participants agreed with the statement “I often feel 
sad”; no participants agreed with the statement “I often have the feeling that I am going to 
cry”; two participants agreed with the statement “I often think about people I have loved who 
are no longer with me”; three participants agreed with the statement “I tend to think about 
losing loved ones often” and so forth. This not only explains the lack of increase in 
PANIC/GRIEF but also explains the significant decrease in PANIC/GRIEF on the ANPS. 
This pattern of response on the ANPS was likewise reflected in the psychological probes 
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data. On ‘directed probes’ nine participants indicated ‘no change’ in increased feelings of 
PANIC/GRIEF. Feelings of disconnection on Naltrexone are commonly reported. For 
instance, Inagaki and colleagues (2016) and Inagaki (2018) found that subjects felt socially 
disconnected on Naltrexone. Chelnokova et al. (2016) reported that Naltrexone reduced the 
time that their participants spent fixating on facial images, indicating that opioid antagonism 
led to people paying less attention to the face and eyes and thereby gathering less socially 
relevant information. Jamner and Leigh (1999) found that female participants who were 
administered Naltrexone felt a decrease in pleasure in relation to social interactions and spent 
a greater time alone. My finding that participants felt affectively disconnected is thus in 
keeping with this research. Disconnectedness is not synonymous with loss, but it is of course 
the opposite of feeling connected. 
Furthermore, the question of whether dysphoric or depressive symptoms are 
associated with the use of Naltrexone remains controversial. Several studies have reported 
such side-effects (Crowley et al., 1985; Hollister et al., 1981; Mendelson et al., 1978). For 
instance, Depue and Morrone-Strupinsky (2005) found that blocking opioids diminishes 
warmth and affection in women who were shown an affiliative type of film clip. Schweiger et 
al. (2014) showed that women reported a decrease in feelings such as cosiness and being 
liked in a game of trust after taking Naltrexone. Other studies however (Dean et al., 2006; 
Miotto et al., 2002) have not confirmed these claims. For instance, in the Van Steenbergen, 
Weissman, Stein, Malcolm-Smith, and van Honk (2017) study, a dose of 50mg Naltrexone (a 
dose equivalent to the one used in the present study) found no significant effects on negative 
or positive affect as measured by the PANAS. The results of this study, it would seem, are 
more in keeping with the former view, for two reasons. Firstly, there was a trend towards 
significance between Naltrexone and mood as reflected by higher MDI scores in half of the 
participants. Secondly, although Naltrexone did not significantly increase NA as expected, 
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this finding was more understandable when I re-examined each participant’s responses to the 
ten NA items on the PANAS. No participants felt ‘ashamed’ and for the following affects 
‘upset’, ‘guilty’, ‘scared’, and ‘afraid’, only two participants in each case indicated feeling ‘a 
little’ of this type of affect. This is reasonable, given that these types of affects are not 
typically associated with Naltrexone. In light of this, I performed a post-hoc analysis of 
Naltrexone’s effects on PA and found a statistically significant result, z = -3.53, p <.001, r 
=0.883; Naltrexone reduced PA in all 16 subjects. Therefore, although Naltrexone did not 
increase PANIC/GRIEF, there was evidence to show that a stimulated PANIC/GRIEF system 
produced depressive affects, as reflected in increased depression scores, significant 
reductions in PA and feelings of social/affective disconnection. 
Other factors to consider which could have impacted these results are that although 
Naltrexone has the highest sensitivity for mu-opioids, the possibility of kappa antagonism, 
which is known to produce dysphoric responses in humans could not be excluded 
(Ranganathan et al., 2012); Naltrexone’s effects could be specific to certain types of stimuli 
and varying effects depending on dosing regiments, that is, chronic versus once-off (Wardle, 
Bershad, & de Wit, 2016). 
Attachment and opioids. With regard to the relative effects of Morphine versus 
Naltrexone on the SAAM attachment measure, I found that avoidance on Morphine was 
significantly lower than avoidance on Naltrexone. This result was in keeping with 
Naltrexone’s general effects in that feeling ‘detached’ was a prominent affect which could 
have made participants feel more avoidant. Although there was no significant difference on 
security between the opioid-related medications, security scores on Morphine were greater 
compared to Naltrexone in 10 participants. This too was consistent with the emotional 
effects of Morphine. Participants felt ‘relaxed’ and had ‘a muted sense of pain/sadness’, 
which could have contributed towards a stronger sense of security. Lastly, there was no 
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significant difference on anxiety between the opioid-based medications; anxiety was only 
lower on Morphine compared to Naltrexone in six of the 16 participants. One possible 
reason for this could be that the study sample was found to be significantly more anxious 
when compared to an unmatched data set. 
Despair as the normal prototype for depression. A shutdown of the SEEKING 
system is said to constitute the despair phase of the separation distress response and since the 
despair phase is hypothesised to be the normal prototype for depression, I investigated 
whether SEEKING, mood and affective valence would be differentially affected in 
participants with high depression scores vs those with low depression scores. The sample was 
split into High and Low depression groups based on MDI scores, with the two groups 
representing High and Low ‘despair’ respectively. The fifth hypothesis of the study predicted 
that the two groups would differ in their responses to the psychometric measures and 
psychological probes on the Dopamine-related medications. Even though there were no 
statistically significant differences between the groups on Madopar, descriptively, the 
reduction in PA and the increase in NA and MDI scores from baseline was in each instance 
comparatively greater in the High ‘despair’ group. This is probably due to the interesting 
trend that the majority of participants in the High ‘despair’ group described their experience 
on Madopar as ‘negatively stimulating’, while the majority of participants in the Low 
‘despair’ group described their experience as ‘positively stimulating’. On Haloperidol, 
however, the Low ‘despair’ group had significantly reduced SEEKING and PA and higher 
depression scores, compared to the High ‘despair’ group. Taken together, these two findings 
may suggest that Low ‘despair’ participants are less familiar with depressive feelings and 
therefore show greater sensitivity to the up and down regulating effects of Madopar and 
Haloperidol. The psychological probes data provided some corroborating evidence for these 
findings. The most notable difference between the group’s responses to Haloperidol was that 
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considerably more participants in the High ‘despair’ group felt ‘detached’ (six participants in 
this group compared to two in the Low ‘despair’ group), which could explain why they 
would not necessarily indicate any significant alterations in their affect. Furthermore, twice 
as many participants in the Low ‘despair’ group compared to the High ‘despair’ group 
experienced a ‘low drive’ on Haloperidol which could account for the reduced SEEKING 
and PA and the higher MDI scores in this group. A more compelling finding was that there 
was a significant association on the ‘directed probes’ between SEEKING and both DA 
medications in the Low ‘despair ‘group; a higher proportion of participants in this group 
reported an increase in SEEKING when on Madopar and a decrease in SEEKING when on 
Haloperidol. With respect to ‘memories of loss’, there was a significant association between 
change in emotional intensity and Madopar, when compared to Placebo in the Low ‘despair’ 
group. Of the six participants who experienced a change, five described feeling either less 
emotional pain or more positive when re-experiencing their memories of loss, which was in 
keeping with five participants in this group feeling ‘positively stimulated’ on Madopar. Thus, 
the Low ‘despair’ group confirmed predictions that high vs low depression scores would 
differentially influence SEEKING, affect and mood, albeit for Haloperidol only. More 
importantly, the nature and direction of this change was not only in keeping with the study’s 
hypothesis about the anticipated effects of a dopamine antagonist, but for the first time, I was 
also able to demonstrate, with significance, in a subset of participants with Low ‘despair’, a 
subjective increase in SEEKING, and an improvement in PA and mood (that is, feeling 
‘positively stimulated’ and experiencing less emotional pain) on Madopar, which was more 
in line with the predictions of the study’s first hypothesis. In short, participants with lower 
depression scores had opioid systems that behaved as expected and those with higher 
depression scores did not. This broadly suggests that depressed affect is associated with 
opioid dysregulation. 
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Although the effects of the opioid medications on the split MDI groups were not 
included in the study’s original predictions, an interesting descriptive finding mentioned 
previously was that the High-Despair group appeared relatively more responsive to the 
opioid antagonist compared to the Low-Despair group. What stood out in particular was the 
effect of Naltrexone on SEEKING. A post-hoc analysis revealed that the difference in 
SEEKING between the groups was significant, t(14) = 2.16, p = .049, d = 1.08. What these 
results tentatively illustrate is the mechanism of pathological depression – as conceptualised 
in this thesis – in action. To reiterate, in affective terms, major depression is understood as a 
disorder characterised by an overactive PANIC/GRIEF system and underactive SEEKING 
system (Panksepp, 2004). I was able to show that the stimulation of PANIC/GRIEF in 
participants with higher depression scores, led to a comparatively larger reduction in 
SEEKING, compared to those participants with lower depression scores. Thus, prolonged 
social loss, as reflected by a stimulated PANIC/GRIEF system, diminished SEEKING to a 
greater extent in those with higher despair. 
Protest and avoidant attachment. An overactive PANIC/GRIEF system putatively 
constitutes the protest phase of the separation distress model, and since protest is in response 
to separation from an attachment figure, I investigated whether PANIC/GRIEF, mood and 
affective valence would be differentially affected in participants who were more or less 
avoidant or more or less anxious in their attachment styles to romantic partners. The sample 
was split into High and Low avoidance/anxiety groups based on ECR scores, with the two 
groups representing High and Low ‘protest’ respectively. The sixth hypothesis of the study 
predicted that the two groups would differ in their responses to the psychometric measures 
and psychological probes on the Opioid-based medications. Although the Low and High- 
Avoidance groups did not show any statistically significant differences for PANIC/GRIEF, 
PA or mood on the opioid-based medications, there was a significant difference for NA, with 
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the Low-Avoidance group experiencing a significantly larger reduction in NA on Morphine 
and Naltrexone. Moreover, descriptively, PANIC/GRIEF scores were reduced to a greater 
extent from baseline in the Low-Avoidance group compared to the High-Avoidance group 
and MDI scores were reduced for the Low-Avoidance group but increased for the High- 
Avoidance on Morphine. There was some support for these psychometric findings in the 
psychological probes data. The following are statements from participants in the Low- 
Avoidance group on Morphine: “I feel less negative emotion than when I last described”, “I 
feel much more a sense of pleasure in relatedness to others”, “It turned into a slight…don’t 
want to say euphoria because that is too strong, but maybe a slight happiness”, “I do feel 
relaxed and comfortable in terms of people that are close to me and people that I, you know, 
interacting with people”, “What is coming to mind is enjoyable events I had with her, not the 
actual split. This is unusual” and “The mental imagery is more positive that what it would 
normally be”. Taken together, these results provide some evidence that participants with 
lower avoidance scores, and hence a more secure sense of dependence on others, experienced 
less PANIC/GRIEF and NA and an improvement in mood on Morphine, compared to 
participants with higher avoidance scores. This is in keeping with the earlier finding that 
avoidance on Morphine was significantly less than avoidance on Naltrexone on the SAAM 
questionnaire for the whole sample, which highlights a degree of consistency between the 
two measures of attachment. Moreover, the Low-Avoidance group had significantly higher 
SEEKING scores at baseline compared to the High-Avoidance group which is also consistent 
with the overall positive experience of this group on Morphine. Maccallum and Bryant 
(2018) argue that high avoidance attachment essentially results in a shutdown of attachment 
and social withdrawal, which could have contributed to the comparatively lower baseline 
SEEKING scores for the High-Avoidance group. High attachment avoidance has also been 
associated with lower responsivity of brain circuits involved in emotional processing and low 
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MOR availability in regions linked to social distress and social interaction (Nummenmaa et 
al., 2015). This study’s findings are consistent with this view in that I found that participants 
who were relatively more avoidant, that is, those with High ‘protest’, were comparatively less 
responsive to the associated feelings of a Morphine-related decrease in PANIC/GRIEF such 
as feeling bonded and attached. Several statements from the psychological probes data of 
participants who were relatively more avoidant point to this kind of emotional detachment 
and an unwillingness/inability to engage with memories of personal loss: “It feels peripheral 
at the moment; I’m unable to intensely experience that now”, “I can acknowledge the feelings 
but not experience the feelings”, “My recollection of it now is a feeling of loneliness; 
different than usual”, “I can remember the feeling, but I’m not feeling the feeling”, “It’s less 
of an intense emotional experience” , “I don’t feel emotionally attached to that event, or I 
don’t feel a link to the emotions I would have felt” and “I was feeling unconfident, a little 
socially embarrassed, which is unusual for me”. Therefore, there was some qualitative and 
descriptive evidence to show that those participants with higher avoidance/higher protest 
were less responsive to the associated feelings of a dampened PANIC/GRIEF system, 
reflected in comparatively higher PANIC/GRIEF and MDI scores and a smaller reduction in 
NA. 
Protest and anxious attachment. There were no significant differences between the 
Low and High-Anxiety groups for PANIC/GRIEF, affect or mood on the opioid-based 
medications. There were however two trends towards significance. Firstly, the Low-Anxiety 
group reported a comparatively greater decrease in PANIC/GRIEF on the ANPS on 
Morphine. There was evidence of this psychometric trend in the psychological probes data 
also, as reflected in the statements of participants from the Low-Anxiety group: “I have an 
overall positive affect; I feel happy”, “I’m feeling strangely calm”, “It was easier to engage 
with how I felt; I felt calm and relaxed”, “Definitely just more content”, and “I feel content 
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and energised.” The second trend was for the High-Anxiety group, who on ‘directed probes’, 
reported a comparatively greater decrease in PANIC/GRIEF on Morphine. There was once 
again support for this trend in the psychological probes data in the statements of participants 
from the High-Anxiety group: “It’s kind of a warm comfort, almost a slightly numb 
sensation”, “I don’t feel worried or panicky at all”, “There is no sense of panic”, “I’m not 
feeling any stress”, “I’m feeling pretty calm” and “Feeling quite sort of mellow”. Although 
both groups experienced a reduction in PANIC/GRIEF on Morphine, as expected, these 
trends were at odds. On ‘directed probes’, the High-Anxiety group were clearly experiencing 
the anxiety-alleviating effects of Morphine to a greater extent than the Low-Anxiety group, 
but this pattern was reversed on the ANPS; here the Low-Anxiety group experienced the 
greater reduction in PANIC/GREIF. One reason could be the lack of significant association 
between the two measures of PANIC/GRIEF (ANPS and ‘directed probes’), to be discussed 
in greater detail in a later section. Another possible explanation as to why these trends were 
antithetical and why I did not find any clear significant differences between the two anxiety 
groups on both opioid-based medications is that Nummenmaa et al. (2015) reported that 
individual differences in attachment anxiety, unlike attachment avoidance, were not 
influenced by endogenous MOR availability and that avoidant and anxious attachment may 
be supported by distinct pathways. Along these lines, this study’s results showed that unlike 
avoidant attachment, where differential patterns of response between low vs high avoidance 
were discernible, both opioid medications had comparatively little differential between-group 
effects on depressive affect and NA in relation to Low vs High- anxiety. The Low and High- 
Anxiety groups mean MDI and NA scores post Morphine were almost identical. The same 
applied to Naltrexone. Furthermore, the mean MDI scores for both groups on Morphine were 
very close to their respective baseline means, pointing to a possible lack of association 
between a dampened PANIC/GRIEF system, Low vs High-anxiety and depression scores. 
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The only notable difference between the groups was for PA. The mean PA score post 
Morphine was greater for the High-Anxiety group compared to the Low-Anxiety group, 
indicating that a dampened PANIC/GRIEF system was possibly associated with a greater 
increase in PA for those with higher anxiety, which is a reasonable outcome. 
These findings on avoidant and anxious attachment, although tentative and exploratory 
and from a small subset of participants, begin to shed some insight into the largely unexplored 
relationship between depressive affect, attachment and loss. Although lacking psychometric 
significance, qualitatively and descriptively, there was some evidence to show that dampening 
the PANIC/GRIEF system led to those participants with higher avoidance to experience less 
reduction in their PANIC/GRIEF and NA, and an increase in depressive affect. There were thus 
some identifiable differences between Low and High ‘protest’, as measured by the avoidance 
subscale, and depressive and NA. The results for anxious attachment were mixed. There were 
no recognizable differences between Low and High ‘protest’, as measured by the anxiety 
subscale, and depressive affect and NA, but there were descriptive differences between Low and 
High-Anxiety for PA. In light of these results, an interesting theoretical consideration is that the 
role of the PANIC/GRIEF system in depression could relate more to avoidance and social 
withdrawal rather than anxiety, and possibly even to a certain subtype of depression. In his 
paper ‘Affective neuroscience of the emotional BrainMind’, Panksepp (2010) introduced the 
idea of relating various subtypes of depression to the different basic emotion systems. 
Furthermore, since a relationship between attachment style and the opioid system has 
previously been established (Nummenmaa et al., 2015) and is suggested by this study’s 
findings, the use of opioid medications as a ‘fill-in’ for secure attachment in avoidant 
individuals would be an interesting area for future research. 
Two general trends in the results. Firstly, and as previously mentioned, SEEKING 
and PA were reduced from baseline by all the medications in the whole sample. Possible 
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reasons why this occurred in the case of Madopar have already been discussed. In the case of 
Haloperidol, a reduction in SEEKING was in keeping with its predicted effects as a DA 
antagonist. Its effect on PA has previously been addressed, but in addition, Haloperidol has 
been shown to have a negative impact on contentment in healthy subjects (Saeedi et al., 2006), 
which would also contribute to the decrease in PA and worsening of mood. 
With regards to Naltrexone, as previously discussed, the existing evidence is 
inconsistent. There are studies that have shown that dysphoria can be a side effect of Naltrexone 
(Hollister et al., 1981), which could explain why Naltrexone reduced SEEKING and PA. There 
is some degree of support for this view from the current study in that some participants 
experienced negative psychobehavioural effects on Naltrexone akin to dysphoria, such as 
disconnected, reluctant to engage, feeling subdued, difficultly concentrating, reduced interest 
and anxiety. Although evidence is once again limited, there is another view that normal subjects 
may be at greater risk of having dysphoric reactions (Miotto et al., 2002) or that subjects who 
are under substantial physical or psychological stress may experience dysphoric symptoms on 
Naltrexone (Malcolm, O'Neil, Von, & Dickerson, 1987). Both possibilities could have played 
a role in the current study to explain Naltrexone’s effects on SEEKING and PA, since the 
study’s sample was normal and found to be significantly more anxious on the ECR. The latter 
statement, however, must be interpreted with caution since this finding was based on a 
comparison to one unmatched data set. 
In the case of Morphine, the interaction of opioids with other neurotransmitters is 
complex. Opioid agonists are known to effect DA release, reuptake and metabolism in the 
striatum and substantia nigra (Kream, Stefano, & Ptáček, 2010). Morphine is associated with 
increased DA neuronal firing in the VTA, activation of mesolimbic pathways, and an increase 
in extracellular DA in the NAc (DiChiara, Acquas, & Carboni, 1990). These interactions could 
possibly account for Morphine’s effect on SEEKING. Moreover, and as previously discussed, 
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although studies on opioid-naïve subjects have reported increases in euphoria and pleasure 
following administration of μ-receptor agonists (Riley et al., 2010; Zacny & Gutierrez, 2009), 
several studies have failed to corroborate such findings. Ipser et al. (2013) found that although 
the partial µ-opioid agonist, buprenorphine, decreased fear recognition in normal subjects, it 
had no effect on mood. Tedeschi, Smith, and Richens (1984) also reported no mood effects on 
the partial µ-opioid receptor agonist, Meptazinol. In the classic study of Lasagana, Felsinger, 
and Beecher (1955), the authors reported that former addicts were more likely to experience 
the positive effects of opioids compared to subjects who were administered opioids for the first 
time, and of the 20 non-users in their study, only two indicated that they would be willing to 
repeat the study. Those subjects who were naïve to opioid use reported that they felt sedated, 
mentally clouded and ill. In the current study, there were several participants who similarly 
reported feeling tired and fuzzy/foggy on Morphine. It is possible that the sedative effects of 
Morphine, coupled with one of its prominent affects, namely, feeling ‘detached’, would not 
likely have engendered increased feelings of SEEKING. A possible explanation as to why 
Morphine decreased PA could, as previously discussed, lie in the items that constitute PA in 
the PANAS. Specifically, items such as ‘interested’, ‘excited’, ‘strong’, ‘enthusiastic’, ‘proud’, 
‘alert’, ‘inspired’, ‘determined’, ‘attentive’, and ‘active’ are strongly aligned with the construct 
of SEEKING. I re-examined each participant’s PA questionnaire on Morphine and noted that 
11 participants indicated a lower score (compared to baseline) on the following items: 
‘interested’, ‘excited’, ‘enthusiastic’, ‘alert’, ‘inspired’, ‘determined’, ‘attentive’, and ‘active’. 
Thus, the significant decrease in SEEKING together with the observed sedatory effects of 
Morphine, could have accounted for the significant reduction in PA. 
Lastly, SEEKING was also significantly reduced by Placebo, which is not an entirely 
unexpected finding since placebo effects are thought to rely on the release of endogenous 
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opioids (Zubieta et al., 2005), and these effects have been shown to be associated with opposite 
responses of DA and opioid activity (Scott et al., 2008). 
Secondly, except in the case of Haloperidol, where there was a trend towards 
significance, a result that was common to the other three medications was that there was no 
statistically significant relationship between the psychometric definitions of SEEKING and 
PANIC/GRIEF, as measured by the ANPS, and their ‘directed probes’ counterparts. On 
Madopar, 14 participants reported a decrease in SEEKING on the ANPS, whereas on ‘directed 
probes’, nine reported an increase in SEEKING, resulting in the lack of correlation between 
the two measures. The formal psychometric nature of the one measure compared to the 
qualitative nature of the other could have contributed towards the differential responses from 
participants. On the ‘directed probes’, increased SEEKING was explained to participants to 
mean: ‘Wanting to find or discover something; searching or looking for something; feeling 
inquisitive about or interested in something; actively looking forward to or anticipating 
something; being positive; being hopeful.’ On the ANPS, high SEEKING was measured by 7 
statements: “Almost any little problem or puzzle stimulates my interest”, “Seeking an answer 
is as enjoyable as finding the solution”, “I enjoy anticipating and working towards a goal almost 
as much as achieving it”, “ I really enjoy looking forward to new experiences”, “My curiosity 
sometimes drives me to do things that others might consider a waste of time ”, “Whenever I 
am in a new place I always like to explore the area and get a better feel for my surroundings” 
and “I often feel I could accomplish almost anything” (Davis & Panksepp, 2011). The ‘directed 
probes’ version was relatively more expansive and sanguine, especially with the inclusion of 
feeling ‘positive’ and ‘hopeful’, compared to the ANPS with its stronger focus on concrete and 
practical examples of activities. During the ‘directed probes’, participants were encouraged to 
explore the construct of SEEKING more widely and some of the qualitative descriptives that 
they used were: ‘happy’, ‘euphoric’, ‘upbeat’, ‘optimistic’, ‘confident’, ‘bold’, and ‘engaged’. 
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These nuanced affects would not necessarily be captured by the SEEKING questions on the 
ANPS. Also, specific references to increased curiosity, anticipation or interest were rarely 
made in relation to the positive feelings experienced on Madopar, which could possibly explain 
why participants were less likely to report an increase in SEEKING on the ANPS compared to 
‘directed probes’. 
The two measures of PANIC/GRIEF were likewise not consistent with one another. On 
Morphine, more participants reported a decrease in PANIC/GRIEF on the ANPS compared to 
the ‘directed probes’, where eight participants reported no change in PANIC/GRIEF. A 
decrease in PANIC/GRIEF on ‘directed probes’ was described to participants as: “Feelings of 
safety and security; warm fuzzy feelings, like being loved and cared about; the feeling of being 
bonded or attached; and the associated feelings of being confident about the reliability of 
intimate others and durability of relationships.” On the ANPS, a decrease in PANIC/GRIEF 
was measured by the following seven questions: “I seem to be affected very little by personal 
rejection”; “I rarely become sad”; “I never become homesick”; “It does not particularly sadden 
me when friends or family members are disapproving of me”; “I rarely have the feeling that I 
am close to tears”; “I rarely think about people or relationships I have lost” and “It would not 
bother me to spend the holidays away from family and friends” (Davis & Panksepp, 2011). The 
‘directed probes’ definition of decreased PANIC/GRIEF had a relatively stronger emphasis on 
feelings of being loved by and bonded to intimate others. As previously mentioned, feeling 
‘connected’, which specifically referred to an increased desire to be with loved ones, was the 
third prominent affect identified by coders A. However, coders B were not in strong agreement 
with coders A (only 62.5%) as to the prominence of this affect, identifying it in only six 
participants. This could possibly explain why half of the participants reported no change in 
PANIC/GRIEF on ‘directed probes’, with its stronger emphasis on feelings of attachment, 
because those feelings were not as prominent as originally thought. For Naltrexone, 
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although the direction of change in PANIC/GRIEF reported by participants was contrary to 
predictions, the two measures were once again inconsistent. Eleven participants reported a 
decrease in PANIC/GRIEF on the ANPS, while nine participants reported no change in 
PANIC/GRIEF on ‘directed probes’. This issue has previously been discussed in an earlier 
section but is reiterated now for contextuality. On the ANPS, an increase in PANIC/GRIEF 
was measured by the following seven questions: “I often feel sad”; “I often have the feeling 
that I am going to cry”; “I often feel lonely”; “I often think about people I have loved who are 
no longer with me”; “I tend to think about losing loved ones often”; “I frequently feel 
downhearted when I cannot be with my friends or loved ones”; “I am a person who strongly 
feels the pain from my personal losses”. The prominent affect for Naltrexone was that 
participants felt emotionally detached/disconnected and this led to responses of ‘disagree’ or 
‘strongly disagree’ to many of the above ANPS statements, given their strong emphasis on 
feelings about intimate relationships and connections. As mentioned already, this is potentially 
important for the simple reason that ‘detachment’ is the opposite of ‘attachment’. Participants 
in general rarely made references to feelings of increased psychological pain as expected. What 
was more commonly described was an absence of feeling – an emotional numbness. These 
reasons would have accounted for the decrease in PANIC/GRIEF scores on the ANPS. On the 
‘directed probes’, an increase in PANIC/GRIEF was described as an increase in the following 
types of feelings: ‘Mental suffering or mental pain of the kind caused by the prospect or 
experience of separation, loss, or rejection; or the ensuing mental anguish, torment or distress 
caused by separation, loss, or rejection.’ The emotional detachment/numbness and the absence 
of NA would similarly have accounted for participants reporting no change in PANIC/GRIEF 
on ‘directed probes’, with its strong emphasis on increases in mental anguish/suffering. 
Two further points about the lack of correlation between the two measures is that on 
the ‘directed probes’, participants had an option of indicating that they felt no change in 
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SEEKING or PANIC/GRIEF, whereas this was not an option on the ANPS. Secondly, the 
ANPS is a personality scale and to my knowledge has not been used previously to measure 
changes in state. Thus, the extent to which the ANPS was in fact measuring changes in 
personality, or whether changes in traits can occur following once-off pharmacological 
manipulation, is questionable. 
Either way, over and above the lack of correlation between the two measures, the results 
of either measure independently were variable and not always consistent with predictions. To 
illustrate: The results of the ‘directed probes’ were consistent with the predictions about the 
dopamine-based medications, but not the opioid-based medications. The results of the ANPS 
were consistent with the dopamine antagonist and opioid agonist, but not the dopamine agonist 
and opioid antagonist. 
Aims of the study revisited. The critical question is thus: to what extent do these results 
provide confirmatory evidence for the central aims of this study? 
The first aim was to explore whether a stimulated PANIC/GRIEF system and a 
dampened SEEKING system would lead to depressive affects that were homologous to the 
mammalian separation distress behaviours of ‘protest’ and ‘despair’. Although I was unable to 
demonstrate that a PANIC/GRIEF system stimulated by Naltrexone led to an increase in the 
feelings typically associated with ‘protest’, such as the panicky mental distress of separation 
anxiety, I was able to provide some evidence that (qualitatively and descriptively) it led to the 
worsening of mood, a significant reduction in PA and feelings of social and affective 
disconnection. There was some evidence to show that a PANIC/GRIEF system dampened by 
Morphine lead to an increase in the expression of feelings of contentment, relaxation, happiness 
and reduced concern and that the psychological pain associated with loss was reduced. 
Likewise, there was some evidence to show that, qualitatively, a SEEKING system dampened 
by Haloperidol led to a worsening of mood and PA and produced depressive affects such as 
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low drive, low energy, loss of motivation and interest and detachment – affects typically 
associated with the ‘despair’ phase of separation distress. Furthermore, when the SEEKING 
system was dampened in this way, participants with lower ‘despair’ had significantly reduced 
SEEKING and PA and higher depression scores, compared to participants with higher 
‘despair’. I was also able to provide some qualitative evidence that a SEEKING system 
stimulated by Madopar generated positive affects and that participants re-experienced their 
‘memories of loss’ in a more positive light. Moreover, a SEEKING system stimulated in this 
way produced a greater improvement in PA and mood in the subset of participants with lower 
‘despair’ compared to those with higher ‘despair’. Lastly, I was able to show that the 
stimulation of PANIC/GRIEF by Naltrexone in a subset of participants with high ‘despair’ led 
to a comparatively larger and significant reduction in SEEKING, demonstrating that prolonged 
social loss diminishes SEEKING. 
The second aim of this study was to investigate the role of attachment style in relation 
to depressive feelings and loss. The study’s findings suggested that measures of avoidant 
attachment rather than anxious attachment were comparatively more effective in differentiating 
between Low and High ‘protest’, when the PANIC/GRIEF system was dampened, and that 
those with higher ‘protest’ experienced comparatively more PANIC GRIEF, negative and 
depressive affect. 
The data thus provided suggestive rather than strongly confirmatory evidence for the 
central aims of this study. Various factors and limitations have been considered previously as 
to why this would be the case. One factor however remains to be addressed which I believe 
greatly impacted upon results and could have accounted for much of the inconsistency in 
observed participant responses. I refer here to the ‘human’ element – the specific target of this 
study. Obtaining subjective self-reports from human beings was a unique strength of this study, 
but it also acted as a significant confound. In humans, unlike animals, there is much more 
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cortical elaboration of primary affective responses. Human consciousness is not only raw 
affect; human consciousness includes the cognitive elaboration of the affect to an unusually 
high degree. How one interprets one’s feelings at any given moment is a combination of one’s 
whole cognitive development in relation to the raw affect. A core affect can be 
interpreted/elaborated in completely different ways by different people. Imagine, for example, 
the different ways in which a celibate priest and an aspirant ‘jock’ might experience sexual 
arousal. This sort of thing was observed consistently throughout this study and illustrated 
particularly well by Madopar. All the participants described feeling stimulated, which was the 
core affect, but half experienced this arousal as positively stimulating and the other half as 
negatively stimulating. Morphine did not reduce the psychological pain of all participants. 
Some felt relaxed, described variously as ‘calm’, ‘warm’, ‘content’ and ‘happy’ while others 
felt detached. Likewise, some participants experienced the feeling of low drive on Haloperidol 
as lowered energy, motivation and interest and feeling withdrawn, while others experienced it 
as relaxing, comfortable, and calm. A few participants experienced feeling severely depressed 
on Naltrexone, while a few -- in sharp contrast -- had very pleasurable responses to Naltrexone. 
Administering medications to change the quality of participant’s experience often had 
opposite effects on their experience of well-being via the same fundamental mechanism. The 
implication here is that if these opposite effects were observed with these particular 
medications in this study, could this not apply to all psychoactive medications? In fact, what 
was observed is not inconsistent with what a substantial body of literature shows. There are 
widely varying results about the efficacy of antidepressants. Studies have reported that only 
half of patients taking them respond positively and 55% will experience at least one adverse 
side effect (Papakostas, 2009). In a recent review of SSRIs versus placebo in patients with 
major depressive disorder, involving the analysis of 131 trials, Jakobsen et al. (2017) reported 
that although most studies did show a small benefit from this antidepressant treatment, the 
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‘benefit’ translated to a mere 1.29 points on the Hamilton Depression Rating Scale in the case 
of mild to moderate depression and 2.69 points in the case of severe depression. A 3-point 
difference on the HDRS has been reported as “no clinical change”, that is, it is undetectable by 
patient and clinician alike (Leucht et al., 2013; Moncrieff & Kirsch, 2015). Moreover, the 
authors found an increase in the risk of serious and several non-serious adverse events related 
to the use of SSRIs. A meta-analysis by Fournier et al. (2010) found that the benefit of SSRIs 
compared to placebo was related to the severity of depressive symptoms, that is, minimal or 
non-existent in mild to moderate depression and substantial in the case of severe depression. 
Similarly, Kirsch et al. (2008) reported that clinically significant differences between 
antidepressants and placebo could only be demonstrated for patients who scored more than 28 
on the HDRS, that is, for those patients who were severely depressed. Additional analyses 
indicated that the perceived clinical efficacy among those severely depressed patients was due 
to them being less responsive to placebo rather than more responsive to antidepressants. Even 
more recently, Cipriani et al. (2018) published results from a meta-analysis of 522 trials of 21 
antidepressants and placebo and found that antidepressants were more effective than placebo 
for the short-term treatment of depression only in patients diagnosed with moderate to severe 
depression. 
Personalized medication has been one response to the variability of reported 
antidepressant effectiveness. The argument here is that different people need different types of 
medications based on their genotype and other biomarkers. For example, there is some evidence 
that polymorphisms in genes regulating the HPA axis can influence responses to antidepressant 
medications (Binder & Holsboer, 2006) and specific blood tests have been designed to detect 
elevated levels of inflammation that have been associated with poor antidepressant response 
(Cattaneo et al., 2016), to cite but a few. Another response from psychiatry has been to re-visit 
the diagnostic categories for depression.  Dowrick (2009) 
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identifies three intellectual ‘border disputes’ about the category of depression. There are those 
who argue there is considerable overlap in the symptomology of depression and other mood 
disorders, and consequently other diagnoses are in danger of being obliterated. Some view the 
category as being too narrowly defined, proposing a fusion with other diagnoses and, lastly, 
there are those who consider the category as too broadly defined, arguing for different sub- 
types of depression. Considering my findings, a possible alternative account could be that the 
drugs only influence one aspect of the mind, namely raw affect. The other aspect of the patient, 
that is, their cognition, their cortex, is not fundamentally – and certainly not only -- governed 
by neuromodulators. The cortex – which is very much larger in humans than the animals 
typically studied in preclinical trials, namely rodents – differs substantially in this respect from 
limbic and especially upper brainstem structures. It is a highly individualised memory-based 
structure made up of one’s individual lifetime experiences. This accounts for the way in which 
we interpret our feelings, and links directly to psychodynamic concepts of internal working 
models (Bowlby, 1969) and self-referential processing, discussed in the introduction. 
These interpersonal interpretive mechanisms that process the self in relation to 
significant others remain pivotal to understanding depressive states. Psychodynamically, all 
types of distress, including separation distress, lead to the enlisting of cognitive-affective 
schemas which mediate the distress (Blatt & Luyten, 2009). 
No drug can alter the structure of one’s memory or personality or cognition, and 
therefore drug therapy alone will probably never be sufficient to assist the totality of the 
depressive mind. In Freudian terms: one cannot treat the id alone; the ego too must be treated. 
The defensive structure of the mind must be taken into account. 
197  
Limitations and Future Considerations 
 
Small sample size and insufficient power. As previously acknowledged, the small 
sample size was a serious limitation of the current study, generating a statistical power of 
only 0.59 for the whole sample analysis. The small and selective sample used in the current 
study prevents findings from being extrapolated, and possibly undermines the internal and 
external validity of this study. Furthermore, many analyses were run in relation to the small 
sample size and were not Bonferroni corrected. Since this was an exploratory study - an 
introductory and novel investigation - it was important not to miss any potential effects and 
findings, which could inform further research in this area. However, it is acknowledged that 
low-powered studies produce more false negatives and the probability that an observed effect 
that reaches statistical significance actually reflects a true effect, is also lowered (Button et 
al., 2013; Faber & Fonseca, 2014). The current small sample size is explicable to some extent 
for a few reasons, the first being the highly specific selection criteria. Participants had to be 
selected from psychological-related professions or they had to have undergone some kind of 
long-term psychotherapy and they had to be known to the study's consultant psychoanalyst. 
They had to commit to six interview sessions over an extended period of time, disclose 
potentially painful experiences from their past and most importantly, agree to ingest four 
psychoactive medications. Thus, the level of commitment required from participants was 
substantial. Under these circumstances, the recruitment process was highly challenging, and I 
was ultimately fortunate to be able to recruit 16 motivated and scientifically curious 
participants who remained committed throughout. Secondly, the small sample size afforded 
me the opportunity to investigate each participant's responses in great depth (both 
quantitatively and psychologically). The qualitative in-depth investigation of participant 
responses was an essential aspect of this study, if I was going to succeed in identifying subtle 
mood effects. The qualitative data that was gathered proved to be invaluable. It is based on 
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this data that many subtle affective responses to the medications were identified; affects that 
would not have been identified had I relied solely on purely psychometric measures derived 
from broadly defined concepts. The aforementioned points underscore the complex issue of 
sample size in studies of this nature. For instance, replicating this study would require that the 
sample size be set at N = 47 in order to achieve statistically significant power > .90. This 
would entail enormous recruitment challenges and data collection could prove to be 
significantly onerous. These are factors that would need to be addressed when considering 
future replication studies. 
Quasi-experiment limitations. The most significant limitation of this type of design 
is the lack of randomization, which challenges the validity of the study. Another limitation is 
that subjects in quasi-experimental studies typically undergo interventions in the same order, 
which precludes blinding (Thompson & Panacek, 2006). The reader is reminded that the 
study’s psychoanalyst and participants were blind to the medications and the order of 
medications and the order in which the measures were administered were counterbalanced. 
Measures. There were various methodological issues relating to the measures used in 
the study. Two different attachment questionnaires were administered - the ECR-R at 
baseline and the SAAM post-intervention - which excluded pre and post comparisons. An 
attachment measure that can be adapted to measure both trait and state changes would be 
better suited for future research. There are some shortcomings of the ANPS which could have 
impacted results. It has been reported that people do not differentiate well between feelings of 
distress and loneliness with regard to the PANIC/GRIEF system (Davis et al., 2003). Others 
have found the full scale to be overly long, to have a poorly defined factor structure, for some 
items to be poorly worded, and an overlap to exist between the FEAR and PANIC/GRIEF 
subscales (Barret et al., 2013; Geir, Selsbakk, Theresa, & Sigmund, 2014). Gender 
differences on the ANPS have been identified, with women scoring higher on the CARING, 
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FEAR and PANIC/GRIEF subscales (Pingault, Pouga, Grèzes, & Berthoz, 2012). 
Furthermore, the ANPS is a personality measure and although it has been used in several 
neurobiological studies, I am not aware of the scale being used previously to measure state 
changes. Thus, the effectiveness of the ANPS to measure subtle changes in core affects 
following psychopharmacological manipulation is unknown. Furthermore, unlike ‘directed 
probes’ where participants had the option to indicate if they felt no change in affect, post 
medication, there was no equivalent option on the ANPS to indicate no effect, which was one 
of the reasons that these two measures lacked statistical association. In general, given the 
wide range of emotions elicited by the medications in this study, the use of more 
discriminable measures of affect is recommended for future research. For instance, positive 
and negative affect on the PANAS are broadly defined constructs and this measure was 
possibly ineffective in measuring the more subtle emotional affects produced by the 
medications. The design of new measures of affect specifically based on current results is 
worthy of future consideration. 
Medications. Neurochemical interactions could also have impacted the study’s 
results. For instance, μ‐opioid agonists affect DA release (Passarelli et al., 1999; Spanagel, 
Herz, & Shippenberg, 1990). Even a single dose of morphine has been shown to have 
prolonged effects on dopaminergic activity (Zhang, Zhang, Jin, Zhang, & Zhen, 2008). Most 
medications used to manipulate the opioid system also affect opioid receptors throughout the 
rest of the body (Inagaki, 2018). Moreover, even though the inclusion of a placebo is standard 
practice in this kind of research, the full extent of placebo effects on opioidergic activity in 
the present study could not be measured. Sex differences in relation to the opioid systems 
have been reported, with higher µ-opioid binding in women (Zubieta et al., 1999) and more 
severe adverse subjective effects to Naltrexone being reported by women in the luteal phase 
of their cycle (Roche & King, 2015). I did not record the menstrual cycle phases of female 
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participants and this could have had implications for the opioid-related findings, given that 
the majority of participants were female. 
Sample. Considering the gender differences in both depression and opioid-related 
activity, a better approach for future research would be to include only one gender or to 






The separation-distress model of depression attempts to account for the way in which 
depression makes people feel by seeking to identify the specific changes from ‘protest’ to 
‘despair’ that lead to the psychological pain of depression. The transition from ‘protest’ to 
‘despair’ is associated with very particular feeling states; a hyperactive PANIC/GRIEF 
system leads to feelings of distress associated with social loss, whereas a hypoactive 
SEEKING system leads to feelings of having lost interest in life. Depression is about affect, 
and yet the underlying mechanisms of the subjective experience of the psychological pain 
and despair of depression remain largely unexplored. The human data that is currently 
available is minimal and not directly focused on the affective systems of SEEKING and 
PANIC/GRIEF. This pioneering and complicated study sought to identify these particular 
feeling states in human subjects, which were previously mainly established in lower 
mammals. Although no definitive conclusions can be drawn from this study, the data did 
reveal patterns of response that are at the very least in keeping with the claim that the 
‘despair’ phase of the mammalian separation distress response produces subjective affective 
changes in humans akin to depression, corroborating the many observations in the animal 
literature regarding the dopaminergic hypothesis of depression. Dampening the SEEKING 
system led to lack of interest, energy, motivation, emotional detachment, a desire to withdraw 
from the world and a significant reduction in PA. Stimulating the PANIC/GRIEF system led 
to a worsening of mood, a decrease in PA and feelings of social and affective disconnection. 
Participants with higher depression scores, that is, higher ‘despair’, experienced the 
stimulation of their SEEKING systems negatively, and stimulation of their PANIC/GRIEF 
systems diminished SEEKING to a greater extent compared to those with lower ‘despair’, 
suggesting that depressed affect is associated with opioid dysregulation. Similarly, 
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participants with higher avoidance scores, that is, higher ‘protest’, experienced a relatively 
smaller reduction in PANIC/GRIEF, when this system was dampened, providing some 
insights into the dynamics of attachment style and opioid regulation. Taken together, these 
results provide some ‘proof of concept’ for the conceptualization of depression as 
pathological ‘despair’ and that depression feels bad because a dampened SEEKING system 
and a stimulated PANIC/GRIEF system produce the type of feelings that are characteristic of 
depression. One of the strengths of this model and by extension, this study, is that it extends 
the scope of research on depression from a predominantly neurobiological focus to include 
the subjective interpretation of feelings generated by the core affective systems implicated in 
depression. For this reason, I contend, once again, that this conceptualization of the brain 
basis of depression aligns with the clinical realities of the condition more closely than most. 
Of equal import is that the highly variable responses of participants to the medications in this 
study evinces a possible reason why the efficacy of drug intervention alone in depression 
remains debatable, and underscores the importance of the self, with its individualised 
experiences, complexities and memories, as a crucial mediator of raw affects. The current 
study has contributed some observations – whilst tentative and exploratory - into the 
dynamics of the affectively conceptualised depressed mind by elucidating the primary 
process emotions upon which they are based, and the data generated from this study has 
added to our understanding of the subjective experience of psychoactive intervention. There 
is a pressing need for more data that describes succinctly these human subjective 
experiences. Lastly, the results of this study shed some insight into the possible limitations of 
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Health Screening Questionnaire 
 




Name:    
 
Surname:    
 
Date of birth:    
 
Gender:    
 
Email address:       
 
Phone number:      
 
Cell phone:    
 
Weight:   _ (kg) 
 
Height:    
 
 
Do you suffer from coronary artery disease or a circulatory or peripheral vascular disease? yes no 
If yes, please provide details: 
Do you suffer from any other form of heart disease or defect? yes no 
If yes, please provide details: 
Do you suffer from any metabolic or hormonal disease or condition, such as diabetes or thyroid 
gland disorder? 
yes no 
If yes, please provide details:   







 If yes, please provide details: 
Do you suffer from any allergies, or have a history of allergic reactions to any medication? yes no 
If yes, please provide details: 
Do you suffer from any gastrointestinal disease or have a history of liver or gallbladder 
disease? 
yes no 
If yes, please provide details: 
Do you suffer from any disease or symptom(s) of the central nervous system such as epilepsy 
or migraine, including psychiatric disorders such as depression or panic attacks? 
yes no 
If yes, please provide details: 
Do you suffer from any disease or symptom(s) of the kidney or bladder, such as kidney stones 
or frequent urination? 
yes no 
If yes, please provide details: 
Do you suffer from any disease of the blood or immune system, such as anaemia or HIV/AIDS? yes no 
If yes, please provide details: 
Do you have a history of cancer? yes no 
If yes, please provide details: 
Do you suffer from any other medical condition(s), or experience any other significant 
symptoms? 
yes no 
If yes, please provide details: 
MEDICATION USE  
 




Participant Information Sheet 
 
 
‘Human subjective homologues of established basic emotion correlations in lower 
mammals: A neuro-psychoanalytic study’ 
(1) You are invited to participate in a neuro-psychoanalytical study to be conducted in 
the Psychology Department at the University of Cape Town. Please read this 
information sheet carefully and do not hesitate to ask the researcher for any 
additional information. 
(2) The purpose of this study is to explore the effects that certain psychoactive medicines 
have on brain emotion systems. The aims of this study are (1) to begin to 
systematically explore the subjective components of some basic emotion command 
systems that animal models have suggested may be relevant to the phenomena of 
separation, loss and attachment, and (2) to lay the groundwork for clinical 
exploitation of this knowledge for the treatment of emotional disorders. 
(3) Prior to commencing participation in the study, you will be required to complete a 
medical screening questionnaire. The purpose of this is to ensure that you are 
medically fit to participate in this study. 
(4) Should you agree to participate in this study, you will be required to attend six 
sessions in total: one ‘induction’ session and five ‘experimental’ sessions. During the 
‘induction’ session, you will be asked to (a) read this Participant Information Sheet, 
(b) sign a consent form, (c) complete a set of psychological questionnaires, and (d) 
record three memorable episodes of personal loss that you have experienced. During 
this session, you will also be informed of the specific types of medications that you 
will be taking. During the ‘experimental’ session, you will be required to (a) 
complete a set of psychological questionnaires, and (b) undergo an analytic interview 
with an experienced psychoanalyst. The interviews will be audio recorded. The 
confidentiality of your interview and your identity will be protected. The recordings 
will only be viewed by an independent rater and by the researcher for the purposes of 
qualitative analysis. The recordings will not be viewed in any other context. Your 
name will not appear in any part of the dissertation or in any subsequent publications. 
(5) One of four psychoactive medicines and one placebo will be administered in minimal 
effective dosages before each interview. All medications may cause side-effects in 
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some people, but the medications used in this study have been shown in previous 
clinical studies to be safe and well tolerated in human subjects. 
(6) There are no anticipated risks involved in this research, but if you should experience 
any form of physical or psychological distress, please inform the researcher 
immediately. Also, should you feel that you need to consult a doctor, you will be 
referred for medical treatment, and the costs will be covered by the administrators of 
this study. 
(7) This study forms part of a Ph.D. degree at the University of Cape Town (UCT). 
(8) The study has been reviewed by the UCT Psychology Department’s ethics 
committee. 
(9) If you decide to take part, this information sheet will be given to you to keep and you 
will be asked to sign a consent form. 
(11) You can withdraw from the study at any time, without having to provide a reason 
and all costs reimbursed. 
(12) If you have any questions regarding this study, or concerns regarding the 
manner in which the study was conducted, please contact Eleni Pantelis on (021) 650 









I, (name of participant)    
 
of (address)    
 




‘Human subjective homologues of established basic emotion correlations in lower 
mammals: A neuro-psychoanalytic study’ 
 
 
I fully understand the aims of this study, which has been thoroughly explained to me. 
I understand that I will ingest either a psychoactive medicine and/or placebo. 
I fully understand and accept that I will be expected to divulge personal information regarding my 
thoughts and feelings. I do so on the understanding that all identifying information revealing the 
link between me and my data will be erased. 
I understand that my consent is entirely voluntary and that I may withdraw from the research study 
at any time and for any reason. 
 
 
Print Name: Signature:     
 
Date: |    | |/|    | | |/|    | | | | Time: |    | |: |    | | (24 hours) 
